PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
Compounds modulating PPARδ activity address the need for effective treatment of PPARδ-related diseases by enhancing mitochondrial function and reducing disease symptoms in conditions like Duchenne Muscular Dystrophy and kidney injury.
Patent Information
- Application Number
- CA3000431
- Authority / Receiving Office
- CA · CA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-06-20
- Filing Date
- 2016-10-05
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2036-10-05
AI Technical Summary
There is a need for novel compounds capable of effectively and reliably activating PPARδ in vitro and in vivo, with improved pharmacokinetic properties and metabolic stability, to treat PPARδ-related diseases such as mitochondrial, muscular, demyelinating, vascular, and metabolic diseases.
Development of compounds and compositions that modulate PPARδ activity, including specific structures of Formula (I), (II), and (III), or their pharmaceutically acceptable salts, administered in therapeutic amounts to treat PPARδ-related diseases.
The compounds increase PPARδ activity, improving mitochondrial biogenesis and function, reducing disease symptoms, and enhancing endurance exercise capacity in models of Duchenne Muscular Dystrophy, and reducing injury in kidney and muscle tissues.
Abstract
Description
PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62 / 238,629, filed October 7, 2015; U.S. Provisional Application No. 62 / 243,263, filed October 19, 2015; and U.S. Provisional Application No. 62 / 352,348, filed June 20, 2016. FIELD This application concerns agonists of peroxisome proliferator-activated receptors (PPAR), particularly PPAR delta (PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>), and methods for their use, such as to treat or prevent one or more PPARδ-related diseases. BACKGROUND Peroxisome proliferator-activated receptor delta (PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>) is a nuclear receptor that is capable of regulating mitochondria biosynthesis. As shown in PCT / 2014 / 033088, modulating the activity of PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> is useful for the treatment of diseases, developmental delays, and symptoms related to mitochondrial dysfunction, such as Alpers''s Disease, MERRF-Myoclonic epilepsy and ragged-red fiber disease, Pearson Syndrome, and the like. Modulation PPARδ activity is effective in the treatment of other conditions, such as muscular diseases, demyelinating diseases, vascular diseases, and metabolic diseases. Indeed, PPARδ is an important biological target for compounds used to help treat and prevent mitochondrial diseases, muscle-related diseases and disorders, and other related conditions. Accordingly, there remains a need in the art for novel compounds capable of effectively and reliably activating PPARδ in vitro and in vivo. There is also a need for PPARδ activating compounds with improved pharmacokinetic properties and improved metabolic stability. The present invention addresses these and other such needs. SUMMARY Provided herein, inter alia, are compounds and compositions comprising such compounds that are useful for increasing PPARS activity. In particular, disclosed herein are methods modulating the activity of PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> for the treatment of diseases, developmental delays, and symptoms related to mitochondrial dysfunction (see, e.g., Example 1). For example, the disclosed compounds and compositions are useful in the treatment of mitochondrial diseases, such as Alpers's Disease, CPEO-Chronic progressive external ophthalmoplegia, Kearns-Sayra Syndrome (KSS), Leber Hereditary Optic Neuropathy (LHON), MELAS-Mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke- like episodes, MERRF-Myoclonic epilepsy and ragged-red fiber disease, NARP-neurogenic muscle weakness, ataxia, and retinitis pigmentosa, and Pearson Syndrome. Alternatively, the disclosed compounds and compositions are useful in the treatment of other PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related diseases, such as renal diseases, muscular diseases, demyelinating diseases, vascular diseases, and metabolic diseases. For example, example 3 describes the use of Compound 2d to improve mitochondrial biogenesis and function in Duchenne Muscular Dystrophy (DMD) muscle cells. Example 4 describes the use of Compound 2d to increase capacity for endurance exercise in mouse model of Duchenne Muscular Dystrophy. Example 5 describes the use of Compound 2d to reduce dystrophic muscle phenotype in mouse model of Duchenne Muscular Dystrophy. Example 6 describes oral administration of Compounds 2a, 2d, and 2n to reduce ischemia-reperfusion induced kidney injury in rats. In one embodiment, provided herein is a compound of Formula (I), (II), or (III): [Image disponible dans le document PDF, Image available in the PDF document] (I); [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(II)<annotation encoding="application / x-tex">(II)< / annotation>< / semantics>< / com:Math>; or [Image disponible dans le document PDF, Image available in the PDF document] (III), or a pharmaceutically acceptable salt thereof, wherein: R<com:Sup>1< / com:Sup> is hydrogen, halogen, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-haloalkyl, -CN, C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkoxy, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>- haloalkoxy, or <com:Math><semantics>−C3−C6<annotation encoding="application / x-tex">-C_3-C_6< / annotation>< / semantics>< / com:Math>-cycloalkyl; Q<com:Sup>1< / com:Sup> is CH or N; R<com:Sup>2< / com:Sup> is hydrogen, halogen, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-haloalkyl, -C<com:Sub>3< / com:Sub>-C<com:Sub>6< / com:Sub>-cycloalkyl, - <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-alkoxy, <com:Math><semantics>−C1<annotation encoding="application / x-tex">-C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-haloalkoxy, <com:Math><semantics>−S(C1<annotation encoding="application / x-tex">-S(C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-alkyl), <com:Math><semantics>−SO2(C1<annotation encoding="application / x-tex">-SO_2(C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-alkyl), 5- or 6-membered heterocycle, aryl, 5-membered heteroaryl, <com:Math><semantics>−≡−R2A<annotation encoding="application / x-tex">- \equiv -R^{2A}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−O(CH2)mR2B<annotation encoding="application / x-tex">-O(CH_2)_m R^{2B}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH(C1−C4−alkyl)<annotation encoding="application / x-tex">-NH(C_1-C_4-alkyl)< / annotation>< / semantics>< / com:Math>, - <com:Math><semantics>N(C1−C4−alkyl)2<annotation encoding="application / x-tex">N(C_1-C_4-alkyl)_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−C(O)(C1−C4−alkyl)<annotation encoding="application / x-tex">-C(O)(C_1-C_4-alkyl)< / annotation>< / semantics>< / com:Math>, wherein aryl and heteroaryl are optionally substituted with halogen, -OH, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkyl, formyl, acetyl, acetoxy, or carboxy, and wherein m is an integer having value of 1, 2, or 3; x is an integer having a value of 1 or 2; R<com:Sup>2A< / com:Sup> and R<com:Sup>2B< / com:Sup> are each independently -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-haloalkyl, or -C<com:Sub>3< / com:Sub>-C<com:Sub>6< / com:Sub>- cycloalkyl; each R<com:Sup>20< / com:Sup> is independently hydrogen, halogen, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkyl, -CN, or -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkoxy; and [Image disponible dans le document PDF, Image available in the PDF document] Pharmaceutical compositions of compounds of Formula (I), (II), and (III) also are disclosed herein. Particular embodiments comprise a pharmaceutically acceptable carrier or excipient and one or more of the disclosed compounds, or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions of the invention can be used in therapy, e.g., for treating a PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease or condition in a subject. Another embodiment comprises treating a PPARδ-related disease or condition in a subject by administering to the subject a therapeutically effective amount of one or more disclosed compounds, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound(s). Also provided herein is the use of one or more of the disclosed compounds, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising one or more of the disclosed compounds, for the preparation of a medicament for the treatment of a PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease or condition. In another embodiment, provided herein the disclosed compounds, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising one or more of the disclosed compounds are for use in treating a PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease or condition. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing fatty acid oxidation increases with Compound 2d administration in Duchenne Muscular Dystrophy (DMD) patient cells. FIG. 2 is a graph showing mitochondrial biogenesis increases with Compound 2d treatment in DMD patient cells. FIG. 3 is a graph showing treadmill running distance of DMD model mouse (mdx) increases with Compound 2d. FIG. 4 is a plot showing pathology scored necrosis is reduced in mdx quadriceps with Compound 2d treatment. FIG. 5 is a graph showing necrotic region size is decreased with Compound 2d administration in mdx mice. FIG. 6 is a plot showing inflammation is reduced in mdx quadriceps muscle with Compound 2d administration. FIG. 7 is a plot showing quadriceps muscle regeneration is increased with Compound 2d administration in mdx mice. FIG. 8 is a graph showing diaphragm muscle necrosis is reduced with Compound 2d administration in mdx mice. FIG. 9 is a graph showing mdx diaphragm muscles are more fibrotic than healthy, non-dystropic control mouse diaphragms. FIG. 10 is a graph showing Compound 2d administration reduces mdx mouse diaphragm fibrosis. FIG. 11 is a graph showing the therapeutic effect of oral administration of Compound 2a (FIG. 11A), Compound 2d (FIG. 11B), and Compound 2n (FIG. 11C) in a rat model of acute kidney injury. DETAILED DESCRIPTION Peroxisome proliferator-activated receptor delta (PPAR-<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>), also known as peroxisome proliferator-activated receptor beta (PPAR-β) or as NR1C2 (nuclear receptor subfamily 1, group C, member 2), refers to a nuclear receptor protein that function as a transcription factor regulating the expression of genes. Ligands of PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> can promote myoblast proliferation after injury, such as injury to skeletal muscle. PPARδ (OMIM 600409) sequences are publically available, for example from GenBank® sequence database (e.g., accession numbers NP_001165289.1 (human, protein) NP_035275 (mouse, protein), NM_001171818 (human, nucleic acid) and NM_011145 (mouse, nucleic acid)). Herein, the phrase "PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> agonist" refers to substances that increase the activity of PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>. Substances can be tested for their PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> agonist activity by contacting the substance with cells expressing PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>, detecting their binding with PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> and then detecting signals that serve as the indicator of the activation of PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>. Definitions The term "alkyl" used alone or as part of a larger moiety, such as "alkoxy", "haloalkyl", "haloalkoxy", "cycloalkyl", and the like, means saturated aliphatic straight-chain or branched monovalent hydrocarbon radical. Unless otherwise specified, an alkyl group typically has 1 to 4 carbon atoms, i.e., <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>–<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-alkyl. As used herein, a “<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>–<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-alkyl” group means a radical having from 1 to 4 carbon atoms in a linear or branched arrangement, and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl. "Alkoxy" means an alkyl radical attached through an oxygen linking atom, represented by <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-alkyl. For example, “<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-alkoxy” includes methoxy, ethoxy, propoxy, isopropoxy and butoxy. The terms "haloalkyl" and "haloalkoxy" mean alkyl or alkoxy, as the case may be, substituted with one or more halogen atoms. For example, "<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-haloalkyl" includes fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, bromomethyl, fluoroethyl, difluoroethyl, dichloroethyl and chloropropyl, and "C<com:Sub>1< / com:Sub>–C<com:Sub>4< / com:Sub>-haloalkoxy" includes fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, bromomethoxy, fluoroethoxy, difluoroethoxy, dichloroethoxy and chloropropoxy. The term "halogen" means fluorine or fluoro (F), chlorine or chloro (Cl), bromine or bromo (Br), or iodine or iodo (I). Examples of "aryl" include phenyl, naphthyl, anthracenyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, fluorenyl, indanyl and indenyl. "Cycloalkyl" means a 3–12 membered saturated aliphatic cyclic hydrocarbon radical. It can be monocyclic, bicyclic (e.g., a bridged or fused bicyclic ring), or tricyclic. For example, monocyclic <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math>-cycloalkyl means a radical having from 3 to 6 carbon atoms arranged in a monocyclic ring. For example, "C<com:Sub>3< / com:Sub>–C<com:Sub>6< / com:Sub>-cycloalkyl" includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. "5- or 6-membered heterocycle" means a radical having from 5 or 6 ring atoms (including 1 to 3 ring heteroatoms) arranged in a monocyclic ring. Examples of "5- or 6- membered heterocycle" include, but are not limited to, morpholinyl, thiomorpholinyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, dihydroimidazole, dihydrofuranyl, dihydropyranyl, dihydropyridinyl, dihydropyrimidinyl, dihydrothienyl, dihydrothiophenyl, dihydrothiopyranyl, tetrahydroimidazole, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothienyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, and tetrahydrothiopyranyl. "5-membered heteroaryl" means a monocyclic aromatic ring system having five ring atoms selected from carbon and at least one (typically 1 to 3, more typically 1 or 2) heteroatoms (e.g., oxygen, nitrogen or sulfur). Typical examples are 5-membered heteroaryl containing 1 or 2 atoms selected independently from nitrogen atoms, sulfur atoms and oxygen atoms such as pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, and the like. If a group is described as being "substituted", a non-hydrogen substituent is in the place of hydrogen on a carbon, sulfur or nitrogen of the substituent. Thus, for example, a substituted alkyl is an alkyl wherein at least one non-hydrogen substituent is in the place of hydrogen on the alkyl substituent. To illustrate, monofluoroalkyl is alkyl substituted with a fluoro substituent, and difluoroalkyl is alkyl substituted with two fluoro substituents. It should be recognized that if there is more than one substitution on a substituent, each non- hydrogen substituent can be identical or different (unless otherwise stated). A person of ordinary skill in the art will recognize that the compounds and definitions provided do not include impermissible substituent patterns (e.g., methyl substituted with 5 different groups, and the like) Such impermissible substitution patterns are clearly recognized by a person of ordinary skill in the art. Compounds having one or more chiral centers can exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Stereoisomers include all diastereomeric, enantiomeric, and epimeric forms as well as racemates and mixtures thereof. The term "geometric isomer" refers to compounds having at least one double bond, wherein the double bond(s) may exist in cis, trans syn, anti, entgegen (E), and zusammen (Z) forms as well as mixtures thereof. When a disclosed compound is named or depicted by structure without indicating stereochemistry, it is understood that the name or the structure encompasses one or more of the possible stereoisomers, or geometric isomers, or a mixture of the encompassed stereoisomers or geometric isomers. When a geometric isomer is depicted by name or structure, it is to be understood that the geometric isomeric purity of the named or depicted geometric isomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by weight. Geometric isomeric purity is determined by dividing the weight of the named or depicted geometric isomer in the mixture by the total weight of all of the geomeric isomers in the mixture. Racemic mixture means 50% of one enantiomer and 50% of is corresponding enantiomer. When a compound with one chiral center is named or depicted without indicating the stereochemistry of the chiral center, it is understood that the name or structure encompasses both possible enantiomeric forms (e.g., both enantiomerically-pure, enantiomerically-enriched or racemic) of the compound. When a compound with two or more chiral centers is named or depicted without indicating the stereochemistry of the chiral centers, it is understood that the name or structure encompasses all possible diasteriomeric forms (e.g., diastereomerically pure, diastereomerically enriched and equimolar mixtures of one or more diastereomers (e.g., racemic mixtures) of the compound. Enantiomeric and diastereomeric mixtures can be resolved into their component enantiomers or stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Enantiomers and diastereomers also can be obtained from diastereomerically- or enantiomerically-pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods. When a compound is designated by a name or structure that indicates a single enantiomer, unless indicated otherwise, the compound is at least 60%, 70%, 80%, 90%, 99%, or 99.9% optically pure (also referred to as "enantiomerically pure"). Optical purity is the weight in the mixture of the named or depicted enantiomer divided by the total weight in the mixture of both enantiomers. When the stereochemistry of a disclosed compound is named or depicted by structure, and the named or depicted structure encompasses more than one stereoisomer (e.g., as in a diastereomeric pair), it is to be understood that one of the encompassed stereoisomers or any mixture of the encompassed stereoisomers are included. It is to be further understood that the stereoisomeric purity of the named or depicted stereoisomers is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight. The stereoisomeric purity in this case is determined by dividing the total weight in the mixture of the stereoisomers encompassed by the name or structure by the total weight in the mixture of all of the stereoisomers. Included in the present teachings are pharmaceutically acceptable salts of the compounds disclosed herein. The disclosed compounds have basic amine groups and therefore can form pharmaceutically acceptable salts with pharmaceutically acceptable acid(s). Suitable pharmaceutically acceptable acid addition salts of the compounds described herein include salts of inorganic acids (such as hydrochloric acid, hydrobromic, phosphoric, nitric, and sulfuric acids) and of organic acids (such as, e.g., acetic acid, benzenesulfonic, benzoic, methanesulfonic, and p-toluenesulfonic acids). For example, in one embodiment the acid addition salt is a hemisulfate salt. Compounds of the present teachings with acidic groups such as carboxylic acids can form pharmaceutically acceptable salts with pharmaceutically acceptable base(s). Suitable pharmaceutically acceptable basic salts include ammonium salts, alkali metal salts (such as sodium and potassium salts), alkaline earth metal salts (such as magnesium and calcium salts) and organic base salts (such as meglumine salt). As used herein, the term "pharmaceutically-acceptable salt" refers to pharmaceutical salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, and allergic response, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically-acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmacologically acceptable salts in J. Pharm. Sci., 1977, 66:1-19. The neutral forms of the compounds of the invention are regenerated from their corresponding salts by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents. The neutral forms of compounds disclosed herein also are included in the invention. The terms "administer", "administering", "administration", and the like, as used herein, refer to methods that may be used to enable delivery of compositions to the desired site of biological action. These methods include, but are not limited to, intraarticular (in the joints), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, subcutaneous, orally, topically, intrathecally, inhalationally, transdermally, rectally, and the like. Administration techniques that can be employed with the agents and methods described in the art. As used herein, the terms "co-administration", "administered in combination with", and their grammatical equivalents, are meant to encompass administration of two or more therapeutic agents to a single subject, and are intended to include treatment regimens in which the agents are administered by the same or different route of administration or at the same or different times. In some embodiments the one or more compounds described herein will be co- administered with other agents. These terms encompass administration of two or more agents to the subject so that both agents and / or their metabolites are present in the subject at the same time. They include simultaneous administration in separate compositions, administration at different times in separate compositions, and / or administration in a composition in which both agents are present. Thus, in some embodiments, the compounds described herein and the other agent(s) are administered in a single composition. In some embodiments, the compounds described herein and the other agent(s) are admixed in the composition. Generally, an effective amount of a compound taught herein varies depending upon various factors, such as the given drug or compound, the pharmaceutical formulation, the route of administration, the type of disease or disorder, the identity of the subject or host being treated, and the like, but can nevertheless be routinely determined by one skilled in the art. An effective amount of a compound of the present teachings may be readily determined by one of ordinary skill by routine methods known in the art. The term "effective amount" or "therapeutically effective amount" means an amount when administered to the subject which results in beneficial or desired results, including clinical results, e.g., inhibits, suppresses or reduces the symptoms of the condition being treated in the subject as compared to a control. For example, a therapeutically effective amount can be given in unit dosage form (e.g., from 1 mg to about 50 g per day, e.g., from 1 mg to about 5 grams per day). The particular mode of administration and the dosage regimen will be selected by the attending clinician, taking into account the particulars of the case (e.g., the subject, the disease, the disease state involved, the particular treatment, and whether the treatment is prophylactic). Treatment can involve daily or multi-daily or less than daily (such as weekly or monthly etc.) doses over a period of a few days to months, or even years. However, a person of ordinary skill in the art would immediately recognize appropriate and / or equivalent doses looking at dosages of approved compositions for treating a PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> related disease using the disclosed PPAR agonists for guidance. A "subject" is a mammal, preferably a human, but can also be an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like). "Pharmaceutically acceptable excipient" and "pharmaceutically acceptable carrier" refer to a substance that aids the formulation and / or administration of an active agent to and / or absorption by a subject and can be included in the compositions of the present disclosure without causing a significant adverse toxicological effect on the subject. Non-limiting examples of pharmaceutically acceptable carriers and excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and / or aromatic substances and the like that do not deleteriously react with or interfere with the activity of the compounds provided herein. One of ordinary skill in the art will recognize that other pharmaceutical carriers and excipients are suitable for use with disclosed compounds. Compounds of the Invention Disclosed herein are embodiments of a compound having general Formula (I), (II), or (III): [Image disponible dans le document PDF, Image available in the PDF document] (I); [Image disponible dans le document PDF, Image available in the PDF document] (II); or [Image disponible dans le document PDF, Image available in the PDF document] (III), or a pharmaceutically acceptable salt thereof, wherein: R<com:Sup>1< / com:Sup> is hydrogen, halogen, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-haloalkyl, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkoxy, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>- haloalkoxy, or -C<com:Sub>3< / com:Sub>-C<com:Sub>6< / com:Sub>-cycloalkyl; Q<com:Sup>1< / com:Sup> is CH or N; R<com:Sup>2< / com:Sup> is hydrogen, halogen, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-haloalkyl, -C<com:Sub>3< / com:Sub>-C<com:Sub>6< / com:Sub>-cycloalkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>- alkoxy, <com:Math><semantics>−C1−C4<annotation encoding="application / x-tex">-C_1-C_4< / annotation>< / semantics>< / com:Math>-haloalkoxy, <com:Math><semantics>−S(C1−C4<annotation encoding="application / x-tex">-S(C_1-C_4< / annotation>< / semantics>< / com:Math>-alkyl), <com:Math><semantics>−SO2(C1−C4<annotation encoding="application / x-tex">-SO_2(C_1-C_4< / annotation>< / semantics>< / com:Math>-alkyl), 5- or 6-membered heterocycle, aryl, 5-membered heteroaryl, <com:Math><semantics>−≡−R2A<annotation encoding="application / x-tex">- \equiv -R^{2A}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−O(CH2)mR2B<annotation encoding="application / x-tex">-O(CH_2)_mR^{2B}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH(C1−C4−alkyl)<annotation encoding="application / x-tex">-NH(C_1-C_4-alkyl)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−<annotation encoding="application / x-tex">-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>N(C1−C4−alkyl)2<annotation encoding="application / x-tex">N(C_1-C_4-alkyl)_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−−C(O)(C1−C4−alkyl)<annotation encoding="application / x-tex">--C(O)(C_1-C_4-alkyl)< / annotation>< / semantics>< / com:Math>, wherein aryl and heteroaryl are optionally substituted with halogen, -OH, -CN, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkyl, formyl, acetyl, acetoxy, or carboxy, and wherein m is an integer having value of 1, 2, or 3; x is an integer having a value of 1 or 2; R<com:Sup>2A< / com:Sup> and R<com:Sup>2B< / com:Sup> are each independently -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkyl, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-haloalkyl, or -C<com:Sub>3< / com:Sub>-C<com:Sub>6< / com:Sub>-cycloalkyl; each R<com:Sup>20< / com:Sup> is independently hydrogen, halogen, -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkyl, -CN, or -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkoxy; and <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>CH3<annotation encoding="application / x-tex">CH_3< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>CD3<annotation encoding="application / x-tex">CD_3< / annotation>< / semantics>< / com:Math>. In a 1<com:Sup>st< / com:Sup> embodiment, the compound has the structure of Formula (I), (II), or (III), wherein <com:Math><semantics>R3<annotation encoding="application / x-tex">R^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>CH3<annotation encoding="application / x-tex">CH_3< / annotation>< / semantics>< / com:Math>, and the remaining variables are the same as defined above. In a 2<com:Sup>nd< / com:Sup> embodiment, the compound has the structure of Formula (Ia), (IIa), or (IIIa): [Image disponible dans le document PDF, Image available in the PDF document] , (IIIa); or a pharmaceutically acceptable salt thereof, wherein the variables are as defined for Formulas (I), (II), and (III). In a 3<com:Sup>rd< / com:Sup> embodiment, the compound the compound has the structure of Formula (Iaa): [Image disponible dans le document PDF, Image available in the PDF document] (Iaa); or, alternatively, the structure of Formula (Iaa'): [Image disponible dans le document PDF, Image available in the PDF document] (Iaa'); or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in the 1<com:Sup>st< / com:Sup> embodiment. In a 4<com:Sup>th< / com:Sup> embodiment, the compound has the structure of Formula (Ib), (IIb) or (IIIb): [Image disponible dans le document PDF, Image available in the PDF document] (Ib); [Image disponible dans le document PDF, Image available in the PDF document] (IIb); or [Image disponible dans le document PDF, Image available in the PDF document] (IIIb); or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in the 1<com:Sup>st< / com:Sup> embodiment. In a 5<com:Sup>th< / com:Sup> embodiment, the compound the compound has the structure of Formula (Ibb): [Image disponible dans le document PDF, Image available in the PDF document] (Ibb); or, alternatively, the structure of Formula (Ibb'): [Image disponible dans le document PDF, Image available in the PDF document] (Ibb'); or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in the 1<com:Sup>st< / com:Sup> embodiment. In a 6<com:Sup>th< / com:Sup> embodiment, the compound has the structure of any one of Formulas (I)–(III), (Ia)–(IIIa), (Iaa), (Ib)–(IIIb), or (Ibb), wherein R<com:Sup>2< / com:Sup> is halogen, -C<com:Sub>1< / com:Sub>–C<com:Sub>4< / com:Sub>-alkyl, -C<com:Sub>1< / com:Sub>–C<com:Sub>4< / com:Sub>-haloalkyl, -<com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-haloalkoxy, -<com:Math><semantics>S(C1<annotation encoding="application / x-tex">S(C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-alkyl), or furanyl, wherein the furanyl can be optionally substituted with -C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>-alkyl; and the remainder of the variables are as defined in the 1<com:Sup>st< / com:Sup> embodiment. In a 7<com:Sup>th< / com:Sup> embodiment, the compound has the structure of any one of Formulas (I)–(III), (Ia)–(IIIa), (Iaa), (Ib)–(IIIb), or (Ibb), wherein R<com:Sup>2< / com:Sup> is halogen, -CH<com:Sub>3< / com:Sub>, -C<com:Sub>1< / com:Sub>-haloalkyl, -C<com:Sub>1< / com:Sub>- haloalkoxy, -SCH<com:Sub>3< / com:Sub>, or furanyl, wherein the furanyl can be optionally substituted with -CH<com:Sub>3< / com:Sub>; and the remainder of the variables are as defined in the 1<com:Sup>st< / com:Sup> embodiment. In a 8<com:Sup>th< / com:Sup> embodiment, the compound has the structure of any one of Formulas (I)–(III), (Ia)-(IIIa), (Iaa), (Ib)-(IIIb), or (Ibb), wherein R<com:Sup>2< / com:Sup> is halogen, CH<com:Sub>3< / com:Sub>, -C<com:Sub>1< / com:Sub>-haloalkyl, -C<com:Sub>1< / com:Sub>- haloalkoxy, or -SCH<com:Sub>3< / com:Sub>, and the remainder of the variables are as defined in the 1<com:Sup>st< / com:Sup> embodiment. In an 9<com:Sup>th< / com:Sup> embodiment, the compound has the structure of any one of Formulas (I)– (III), (Ia)-(IIIa), (Iaa), (Ib)-(IIIb), or (Ibb), wherein R<com:Sup>2< / com:Sup> is chloro, unsubstituted furanyl, -CH<com:Sub>3< / com:Sub>, -CF<com:Sub>3< / com:Sub>, -OCF<com:Sub>3< / com:Sub>, -OCHF<com:Sub>2< / com:Sub>, or -SCH<com:Sub>3< / com:Sub>, and the remainder of the variables are as defined in the 1<com:Sup>st< / com:Sup> embodiment. In a 10<com:Sup>th< / com:Sup> embodiment, the compound has the structure of any one of Formulas (I)–(III), (Ia)-(IIIa), (Iaa), (Ib)-(IIIb), or (Ibb), wherein R<com:Sup>2< / com:Sup> is -CF<com:Sub>3< / com:Sub> or -OCF<com:Sub>3< / com:Sub>, and the remainder of the variables are as defined in the 1<com:Sup>st< / com:Sup> embodiment. In an 11<com:Sup>th< / com:Sup> embodiment, the compound has the structure of any one of Formulas (I)— (III), (Ia)-(IIIa), (Iaa), (Ib)-(IIIb), or (Ibb), wherein R<com:Sup>2< / com:Sup> is -CF<com:Sub>3< / com:Sub>, and the remainder of the variables are as defined in the 1st embodiment. In a 12<com:Sup>th< / com:Sup> embodiment, the compound has the structure of any one of Formulas (I)– (III), (Ia)–(IIIa), (Iaa), (Ib)–(IIIb), or (Ibb), wherein R<com:Sup>1< / com:Sup> is hydrogen or halogen; and the remainder of the variables are as defined in the 1<com:Sup>st< / com:Sup>, 6<com:Sup>th< / com:Sup>, 7<com:Sup>th< / com:Sup>, 8<com:Sup>th< / com:Sup>, 9<com:Sup>th< / com:Sup>, 10<com:Sup>th< / com:Sup>, or 11<com:Sup>th< / com:Sup> embodiment. In a 13<com:Sup>th< / com:Sup> embodiment, the compound has the structure of any one of Formulas (I)– (III), (Ia)–(IIIa), (Iaa), (Ib)–(IIIb), or (Ibb), wherein R<com:Sup>1< / com:Sup> is hydrogen or fluoro; and the remainder of the variables are as defined in the 1<com:Sup>st< / com:Sup>, 6<com:Sup>th< / com:Sup>, 7<com:Sup>th< / com:Sup>, 8<com:Sup>th< / com:Sup>, 9<com:Sup>th< / com:Sup>, 10<com:Sup>th< / com:Sup>, or 11<com:Sup>th< / com:Sup> embodiment. In a 14<com:Sup>th< / com:Sup> embodiment, the compound has the structure of any one of Formulas (I)– (III), (Ia)–(IIIa), (Iaa), (Ib)–(IIIb), or (Ibb), wherein each R<com:Sup>20< / com:Sup> is independently hydrogen or halogen; and the remainder of the variables are as defined in the 1<com:Sup>st< / com:Sup>, 6<com:Sup>th< / com:Sup>, 7<com:Sup>th< / com:Sup>, 8<com:Sup>th< / com:Sup>, 9<com:Sup>th< / com:Sup>, 10<com:Sup>th< / com:Sup>, 11<com:Sup>th< / com:Sup>, 12<com:Sup>th< / com:Sup>, or 13<com:Sup>th< / com:Sup> embodiment. In a 15<com:Sup>th< / com:Sup> embodiment, the compound has the structure of any one of Formulas (I)— (III), (Ia)–(IIIa), (Iaa), (Ib)–(IIIb), or (Ibb), wherein R<com:Sup>20< / com:Sup> is hydrogen or fluoro; and the remainder of the variables are as defined in the 1<com:Sup>st< / com:Sup>, 6<com:Sup>th< / com:Sup>, 7<com:Sup>th< / com:Sup>, 8<com:Sup>th< / com:Sup>, 9<com:Sup>th< / com:Sup>, 10<com:Sup>th< / com:Sup>, 11<com:Sup>th< / com:Sup>, 12<com:Sup>th< / com:Sup>, or 13<com:Sup>th< / com:Sup> embodiment. In a 16<com:Sup>th< / com:Sup> embodiment, the compound has the structure of any one of Formula (Iaa) or (Ibb), wherein <com:Math><semantics>R1<annotation encoding="application / x-tex">R^1< / annotation>< / semantics>< / com:Math> is hydrogen or fluoro, <com:Math><semantics>R2<annotation encoding="application / x-tex">R^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>–<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-haloalkyl or <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>–<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>-haloalkoxy, <com:Math><semantics>R20<annotation encoding="application / x-tex">R^{20}< / annotation>< / semantics>< / com:Math> is hydrogen, and x is an integer having a value of 1. In a 17<com:Sup>th< / com:Sup> embodiment, the compound has the structure of any one of Formula (Iaa) or (Ibb), wherein R<com:Sup>1< / com:Sup> is hydrogen, R<com:Sup>2< / com:Sup> is trifluoromethyl or trifluoromethoxy, R<com:Sup>20< / com:Sup> is hydrogen, and x is an integer having a value of 1. In certain embodiments, the invention is any one of the compounds depicted in the exemplification section of the instant application; pharmaceutically acceptable salts as well as the neutral forms of these compounds also are included in the invention. Specifically, disclosed embodiments concern is any one of the compounds depicted in Examples 2a–2u; pharmaceutically acceptable salts as well as the neutral forms of these compounds also are included in the disclosed embodiments. In preferred embodiments, disclosed embodiments concern any one of Compounds 2a–2u; pharmaceutically acceptable salts as well as the neutral forms of these compounds also are included in the disclosed embodiments. Another embodiment of the invention is hydrates or other solvates of the compounds disclosed herein, such as ethanolates, and crystal polymorph substances of any one of the compound of the formula (I), (II) and (III) or a pharmaceutically acceptable salt thereof. Methods of Preparing Compounds of the Invention Methods of preparing compounds of Formula (I), (II), and (III) are disclosed. In general, a compound of Formula (I), wherein R<com:Sup>3< / com:Sup> is -CH<com:Sub>3< / com:Sub>, may be prepared by reacting a compound of Formula (IV) [Image disponible dans le document PDF, Image available in the PDF document] (IV) with prop-2-yn-1amine to afford a compound of Formula (V): [Image disponible dans le document PDF, Image available in the PDF document] (V). The compound of Formula (V) can be subsequently reacted with 2-methoxybenzylamine to afford a compound of Formula (VI): [Image disponible dans le document PDF, Image available in the PDF document] (VI). The compound of Formula (IV) then can be subjected to demethylation conditions to afford a compound of Formula (VII): [Image disponible dans le document PDF, Image available in the PDF document] (VII). The compound of Formula (VII) can be reacted with (R)-ethyl 6-bromo-3-methylhexanoate to afford a compound of formula (VIII): [Image disponible dans le document PDF, Image available in the PDF document] (VIII). Subsequently, the compound of Formula (VII) may be subjected to hydrolysis conditions to afford the compound of Formula (I). Similarly, a compound of Formula (II) may be prepared by reacting a compound of Formula (VII) with (E)-ethyl 6-bromo-4-methylhex-4-enoate to afford a compound of Formula (IX): [Image disponible dans le document PDF, Image available in the PDF document] (IX). Subsequent hydrolysis of the compound of Formula (IX) affords the compound of Formula (II). Likewise, a compound of Formula (III) may be prepared by reacting a compound of Formula (VII) with (E)-ethyl 6-bromo-2,2-dimethylhex-4-enoate to afford a compound of Formula (X): [Image disponible dans le document PDF, Image available in the PDF document] (X). Subsequent hydrolysis of the compound of Formula (X) affords the compound of Formula (III). Detailed synthetic protocols for preparing exemplary compounds of Formula (I), (II), and (III) are presented in Examples 2a–2u. Methods of Treatment Methods of treating a PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease or condition in a subject are disclosed. The methods can include administering to the subject a therapeutically effective amount of one or more compounds or compositions provided herein. In one embodiment, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is a mitochondrial disease. Examples of mitochondrial diseases include, but are not limited to, Alpers's Disease, CPEO-Chronic progressive external ophthalmoplegia, Kearns-Sayra Syndrome (KSS), Leber Hereditary Optic Neuropathy (LHON), MELAS-Mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes, MERRF-Myoclonic epilepsy and ragged-red fiber disease, NARP-neurogenic muscle weakness, ataxia, and retinitis pigmentosa, and Pearson Syndrome. In other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is a vascular disease (such as a cardiovascular disease or any disease that would benefit from increasing vascularization in tissues exhibiting impaired or inadequate blood flow). In other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>- related disease is a muscular disease, such as a muscular dystrophy. Examples of muscular dystrophy include but are not limited to Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy. In some embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease or condition is a demyelinating disease, such as multiple sclerosis, Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease, encephalomyelitis, neuromyelitis optica, adrenoleukodystrophy, or Guillian-Barre syndrome. In other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is a metabolic disease. Examples of metabolic diseases include but are not limited to obesity, hypertriglyceridemia, hyperlipidemia, hypoalphalipoproteinemia, hypercholesterolemia, dyslipidemia, Syndrome X, and Type II diabetes mellitus. In yet other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is a muscle structure disorder. Examples of a muscle structure disorders include, but are not limited to, Bethlem myopathy, central core disease, congenital fiber type disproportion, distal muscular dystrophy (MD), Duchenne & Becker MD, Emery-Dreifuss MD, facioscapulohumeral MD, hyaline body myopathy, limb-girdle MD, a muscle sodium channel disorders, myotonic chondrodystrophy, myotonic dystrophy, myotubular myopathy, nemaline body disease, oculopharyngeal MD, and stress urinary incontinence. In still other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is a neuronal activation disorder, Examples of neuronal activation disorders include, but are not limited to, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, Guillain-Barre syndrome, Lambert-Eaton syndrome, multiple sclerosis, myasthenia gravis, nerve lesion, peripheral neuropathy, spinal muscular atrophy, tardy ulnar nerve palsy, and toxic myoneural disorder. In other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is a muscle fatigue disorder. Examples of muscle fatigue disorders include, but are not limited to chronic fatigue syndrome, diabetes (type I or II), glycogen storage disease, fibromyalgia, Friedreich's ataxia, intermittent claudication, lipid storage myopathy, MELAS, mucopolysaccharidosis, Pompe disease, and thyrotoxic myopathy. In some embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is a muscle mass disorder. Examples of muscle mass disorders include, but are not limited to, cachexia, cartilage degeneration, cerebral palsy, compartment syndrome, critical illness myopathy, inclusion body myositis, muscular atrophy (disuse), sarcopenia, steroid myopathy, and systemic lupus erythematosus. In other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is a beta oxidation disease. Examples of beta oxidation diseases include, but are not limited to, systemic carnitine transporter, carnitine palmitoyltransferase (CPT) II deficiency, very long-chain acyl-CoA dehydrogenase (LCHAD or VLCAD) deficiency, trifunctional enzyme deficiency, medium - chain acyl - CoA dehydrogenase (MCAD) deficiency, short - chain acyl- CoA dehydrogenase (SCAD) deficiency, and riboflavin - responsive disorders of <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-oxidation (RR -MADD). In some embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is a vascular disease. Examples of vascular diseases include, but are not limited to, peripheral vascular insufficiency, peripheral vascular disease, intermittent claudication, peripheral vascular disease (PVD), peripheral artery disease (PAD), peripheral artery occlusive disease (PAOD), and peripheral obliterative arteriopathy. In other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is an ocular vascular disease. Examples of ocular vascular diseases include, but are not limited to, age-related macular degeneration (AMD), stargardt disease, hypertensive retinopathy, diabetic retinopathy, retinopathy, macular degeneration, retinal haemorrhage, and glaucoma. In yet other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is a muscular eye disease. Examples of muscular eye diseases include, but are not limited to, strabismus (crossed eye / wandering eye / walleye ophthalmoparesis), progressive external ophthalmoplegia, esotropia, exotropia, a disorder of refraction and accommodation, hypermetropia, myopia, astigmatism, anisometropia, presbyopia, a disorders of accommodation, or internal ophthalmoplegia. In yet other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is a metabolic disease. Examples of metabolic disorders include, but are not limited to, hyperlipidemia, dyslipidemia, hyperchlolesterolemia, hypertriglyceridemia, HDL hypocholesterolemia, LDL hypercholesterolemia and / or HLD non-cholesterolemia, VLDL hyperproteinemia, dyslipoproteinemia, apolipoprotein A-I hypoproteinemia, atherosclerosis, disease of arterial sclerosis, disease of cardiovascular systems, cerebrovascular disease, peripheral circulatory disease, metabolic syndrome, syndrome X, obesity, diabetes (type I or II), hyperglycemia, insulin resistance, impaired glucose tolerance, hyperinsulinism, diabetic complication, cardiac insufficiency, cardiac infarction, cardiomyopathy, hypertension, non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), thrombus, Alzheimer disease, neurodegenerative disease, demyelinating disease, multiple sclerosis, adrenal leukodystrophy, dermatitis, psoriasis, acne, skin aging, trichosis, inflammation, arthritis, asthma, hypersensitive intestine syndrome, ulcerative colitis, Crohn's disease, and pancreatitis. In still other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is cancer. Examples of cancer include, but are not limited to, cancers of the colon, large intestine, skin, breast, prostate, ovary, and / or lung. In other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is an ischemic injury. Examples of ischemic injuries include, but are not limited to, cardiac ischemia, such as myocardial infarction; brain ischemia (e.g., acute ischemic stroke; chronic ischemic of the brain, such as vascular dementia; and transient ischemic attack (TIA); bowel ischemia, such as ischemic colitis; limb ischemia, such as acute arm or leg ischemia; subcutaneous ischemia, such as cyanosis or gangrene; and ischemic organ injury, such as ischemic renal injury (IRI). In still other embodiments, the PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>-related disease is a renal disease. Examples of renal diseases include, but are not limited to, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, acute nephritis, recurrent hematuria, persistent hematuria, chronic nephritis, rapidly progressive nephritis, acute kidney injury (also known as acute renal failure), chronic renal failure, diabetic nephropathy, or Bartter's syndrome. PCT / US2014 / 033088 demonstrates genetic and pharmacological activation of PPARδ promotes muscle regeneration in an acute thermal injury mouse model. Accordingly, use of PPAR<com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> as a therapeutic target to enhance regenerative efficiency of skeletal muscle is also provided. Pharmaceutical Compositions and Administration Thereof Additional Therapeutic Agents Pharmaceutical compositions are disclosed that include one or more compounds provided herein (such as 1, 2, 3, 4, or 5 of such compounds), and typically at least one additional substance, such as an excipient, a known therapeutic other than those of the present disclosure, and combinations thereof. In some embodiments, the disclosed PPAR agonists can be used in combination with other agents known to have beneficial activity with the disclosed PPAR agonists. For example, disclosed compounds can be administered alone or in combination with one or more other PPAR agonists, such as a thiazolidinedione, including rosiglitazone, pioglitazone, troglitazone, and combinations thereof, or a sulfonylurea agent or a pharmaceutically acceptable salt thereof, such as tolbutamide, tolazamide, glipizide, carbutamide, glisoxepide, glisentide, glibornuride, glibenclamide, gliquidone glimepiride, gliclazide and the pharmaceutically acceptable salts of these compounds, or muraglitazar, farglitazar, naveglitazar, netoglitazone, rivoglitazone, K-111, GW-677954, (-)-Halofenate, acid, arachidonic acid, clofbrate, gemfibrozil, fenofibrate, ciprofibrate, bezafibrate, lovastatin, pravastatin, simvastatin, mevastatin, fluvastatin, indomethacin, fenoprofen, ibuprofen, and the pharmaceutically acceptable salts of these compounds. In one embodiment, disclosed compounds may be administered in combination with dexamphetamine, amphetamine, mazindole or phentermine; and administered in combination with medicaments having an anti-inflammatory effect. Further, when used for the treatment of a metabolic condition, the pharmaceutical compositions provided herein can be administered as a combination therapy with one or more pharmacologically active substances having favorable effects on metabolic disturbances or disorders. For example, the disclosed pharmaceutical compositions may be administered in combination with RXR agonists for treating metabolic and cardiovascular diseases medicaments, which lower blood glucose; antidiabetics, such as insulins and insulin derivatives, including Lantus, Apidra, and other fast-acting insulins, and GLP-1 receptor modulators; active ingredients for treating dyslipidemias; anti-atherosclerotic medicaments; anti-obesity agents; anti-inflammatory active ingredients; active ingredients for treating malignant tumors; anti-thrombotic active ingredients; active ingredients for treating high blood pressure; active ingredients for treating heart failure, and combinations thereof. Methods of Administration The precise amount of compound administered to provide a therapeutically effective amount to the subject will depend on the mode of administration, the type, and severity of the the disease and / or condition and on the characteristics of the subject, such as general health, age, sex, body weight, and tolerance to drugs. One of ordinary skill in the art will be able to determine appropriate dosages depending on these and other factors. When administered in combination with other therapeutic agents, a "therapeutically effective amount" of any additional therapeutic agent(s) will depend on the type of drug used. Suitable dosages are known for approved therapeutic agents and can be adjusted by one of ordinary skill in the art according to the condition of the subject, the type of condition(s) being treated and the amount of a compound of the invention being used by following, for example, dosages reported in the literature and recommended in the Physician's Desk Reference (57th ed., 2003). For example, a therapeutically effective amount can be given in unit dosage form (e.g., 0.1 mg to about 50 g per day). The disclosed PPARδ agonists can be administered to a subject by routes known to one of skill in the art. Examples of routes of administration include, but are not limited to, parenteral, e.g., intravenous, intradermal, subcutaneous, oral, intranasal (e.g., inhalation), transdermal, topical, transmucosal, and rectal administration. An exemplary method for oral administration of the compounds of the invention is shown for Compound 2a, Compound 2d, and Compound 2n herein (see Example 6). Exemplary methods for intravenous administration of the compounds of the invention is described in U.S. Provisional Application No. 62 / 404,390. Administration of the agents by intravenous formulation is well known in the pharmaceutical industry. Intravenous formulations comprise the pharmaceutically active agent dissolved in a pharmaceutically acceptable solvent or solution, such as sterile water, normal saline solutions, lactated Ringer's, or other salt solutions such as Ringer's solution. An oral formulation typically is prepared as a compressed preparation in, for example, the form of a tablet or pill. A tablet may contain, for example, about 5–10% of the active ingredient (e.g., a salt of Formula (I), (II), or (III)); about 80% of fillers, disintegrants, lubricants, glidants, and binders; and 10% of compounds which ensure easy disintegration, disaggregation, and dissolution of the tablet in the stomach or the intestine. Pills can be coated with sugar, varnish, or wax to disguise the taste. EXEMPLIFICATION Example 1a PPARδ activity screen Cell Culture and Transfection: CV-1 cells were grown in DMEM+10% charcoal stripped FCS. Cells were seeded into 384-well plates the day before transfection to give a confluency of 50-80% at transfection. A total of 0.8 g DNA containing 0.64 micrograms pCMX-PPARDelta LBD, 0.1 micrograms pCMX.beta.Gal, 0.08 micrograms pGLMH2004 reporter and 0.02 micrograms pCMX empty vector was transfected per well using FuGene transfection reagent according to the manufacturer's instructions (Roche). Cells were allowed to express protein for 48 h followed by addition of compound. Plasmids: Human PPARδ was used to PCR amplify the PPARδ LBD. The amplified cDNA ligand binding domain (LBD) of PPARδ isoform was (PPARδ amino acid 128 to C- terminus) and fused to the DNA binding domain (DBD) of the yeast transcription factor GAL4 by subcloning fragments in frame into the vector pCMX GAL (Sadowski et al. (1992), Gene 118, 137) generating the plasmids pCMX-PPARDelta LBD. Ensuing fusions were verified by sequencing. The pCMXMH2004 luciferase reporter contains multiple copies of the GAL4 DNA response element under a minimal eukaryotic promoter. pCMX\(\beta\)Gal was generated. Compounds: All compounds were dissolved in DMSO and diluted 1:1000 upon addition to the cells. Compounds were tested in quadruple in concentrations ranging from 0.001 to 100 µM. Cells were treated with compound for 24 h followed by luciferase assay. Each compound was tested in at least two separate experiments. Luciferase assay: Medium including test compound was aspirated and washed with PBS. 50µl PBS including 1 mM Mg++ and Ca++ were then added to each well. The luciferase assay was performed using the LucLite kit according to the manufacturer's instructions (Packard Instruments). Light emission was quantified by counting on a Perkin Elmer Envision reader. To measure 3-galactosidase activity 25 µl supernatant from each transfection lysate was transferred to a new 384 microplate. Beta-galactosidase assays were performed in the microwell plates using a kit from Promega and read in a Perkin Elmer Envision reader. The beta-galactosidase data were used to normalize (transfection efficiency, cell growth etc.) the luciferase data. Statistical Methods: The activity of a compound is calculated as fold induction compared to an untreated sample. For each compound the efficacy (maximal activity) is given as a relative activity compared to GW501516, a PPARδ agonist. The EC<com:Sub>50< / com:Sub> is the concentration giving 50% of maximal observed activity. EC<com:Sub>50< / com:Sub> values were calculated via non-linear regression using GraphPad PRISM (GraphPad Software, San Diego, Calif.). Table 1. PPARdelta Activity Screen [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Certain compounds of this invention show agonistic activity of PPAR and selectivity for PPARδ. In addition, certain compounds of this invention show improved clearance compared to comparator compounds. Also, certain compounds of this invention showlow hERG inhibition compared to comparator compounds. Example 1b Pharmacokinetic (PK) Screening (I.V.) In this example, the intravenous PK profile of several PPARδ agonists disclosed herein in male CD1 mice was determined. Similar methods can be used to analyze other compounds provided herein. All compounds were administered separately to CD1 mice at 1 mg / kg (i.v.), except the comparator compound to 2cwas administered at 3 mg / kg (i.v.), as noted below. [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] * smg / kg 1.v. dose High or low clearance (CL) values were assigned based on the reported value for hepatic blood flow in mice (CL= 85 mL / min / kg). Plasma CL values were obtained from i.v. pharmacokinetic profiles of the compounds in CD-1 mice after administration of either 1 mg / kg or 3 mg / kg doses. See Boxenbaum H. (1980) Interspecies variation in liver weight, hepatic blood flow and antipyrine intrinsic clearance in extrapolation of Benzodiazepines and phenytoin. J. Pharmacokinet Biopharm 8: 165-176. The compounds of the invention have desirable clearance profiles, improved exposure and / or improved half-life characteristics over their respective comparator compounds. Example 2 Synthetic Preparation of Compound Embodiments [Image disponible dans le document PDF, Image available in the PDF document] . . . . . . . . . . . . . . . . . . . . [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Synthesis of (R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethoxy)phenyl)-1H-imidazol- 1-yl)methyl)phenoxy)hexanoic acid (Compound 2a) [Image disponible dans le document PDF, Image available in the PDF document] Scheme-1: [Image disponible dans le document PDF, Image available in the PDF document] Scheme-2: [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of (R)-3,7-dimethyloct-6-enoic acid: [Image disponible dans le document PDF, Image available in the PDF document] In a 5 L three neck round bottom flask, (R)-pulegone (150.0 g, 986.84 mmol) was purged with HCl gas for 3h at -30°C. The reaction mixture was transferred to re-sealable reaction tube and mixture allowed to stand at RT for 12 h. The mixture was treated with NaOH solution (4N, 3L) and resulting mixture was stirred at RT for further 12 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water (1000 mL) and washed with diethyl ether (3 x 1000 mL). The aqueous layer was acidified (pH 4) with dilute HCl before extracting with diethyl ether (3 x 1000 mL). The combined organic layer was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to get the title compound (125 g, 74.8 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 12.01 (s, 1H), 5.07 (t, <com:Math><semantics>J=6.9<annotation encoding="application / x-tex">J = 6.9< / annotation>< / semantics>< / com:Math> Hz, 1H), 2.22 (dd, <com:Math><semantics>J=15.0<annotation encoding="application / x-tex">J = 15.0< / annotation>< / semantics>< / com:Math>, 6.0 Hz, 1H), 2.03-1.78 (m, 4H), 1.64 (s, 3H), 1.56 (s, 3H), 1.36-1.17 (m, 2H), 0.88 (d, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> <com:Math><semantics>Hz<annotation encoding="application / x-tex">Hz< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>3H<annotation encoding="application / x-tex">3H< / annotation>< / semantics>< / com:Math>). Step-2: Synthesis of ethyl (R)-3,7-dimethyloct-6-enoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 5 L round bottom flask, a suspension of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3,7-dimethyloct-6-enoic acid (100.0) g, 587.41 mmol) and K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (243.59 g, 1762.23 mmol) in DMF (1000 mL) was treated with ethyl bromide (95.94 g, 881.12 mmol) at RT. The reaction mixture was stirred at RT for 2 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water (1000 mL) and extracted with diethyl ether (3 x 1000 mL). The combined organic extracts were dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to get the title compound (101.1 g (86.7 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 5.08 (t, <com:Math><semantics>J=6.9<annotation encoding="application / x-tex">J = 6.9< / annotation>< / semantics>< / com:Math> Hz, 1H), 4.12 (q, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.29 (dd, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.29 (dd, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.29 (dd, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.29 (dd, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.29 (dd, <com:Math><semantics>J=7<annotation encoding="application / x-tex">J = 7< / annotation>< / semantics>< / com:Math> <com:Math><semantics>=14.7,6.0 Hz,1H,2.12−2.05 (m, 1H),1.99−1.94 (m, 3H),1.66 (s, 3H),1.58 (s, 3H),1.39−1.94 (m, 3H)<annotation encoding="application / x-tex">= 14.7, 6.0 \text{ Hz}, 1\text{H}, 2.12-2.05 \text{ (m, 1H)}, 1.99-1.94 \text{ (m, 3H)}, 1.66 \text{ (s, 3H)}, 1.58 \text{ (s, 3H)}, 1.39-1.94 \text{ (m, 3H)}< / annotation>< / semantics>< / com:Math> 1.16 (m, 2H), 1.24 (t, <com:Math><semantics>J=6.9<annotation encoding="application / x-tex">J = 6.9< / annotation>< / semantics>< / com:Math> Hz, 3H), 0.93 (d, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> Hz, 3H). Step-3: Synthesis of ethyl <com:Math><semantics>(3R)<annotation encoding="application / x-tex">(3R)< / annotation>< / semantics>< / com:Math>-5-<com:Math><semantics>(3,3<annotation encoding="application / x-tex">(3,3< / annotation>< / semantics>< / com:Math>-dimethyloxiran-2-yl)-3-methylpentanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 5 L round bottom flask, to a solution of ethyl (R)-3,7-dimethyloct-6-enoate (100.0) g, 504.51 mmol) in diethyl ether (1 L) was added a solution of 65% mCPBA (267.51 g, 1.01 mol) in diethyl ether (1 L) dropwise at -30°C. Once the addition was complete, the mixture was warmed to 0°C and stirred at same temperature for 6 h, before allowing it to stand overnight (~ 14 h) at 0-3°C. After completion of the reaction (monitored by TLC), the reaction mixture was diluted with diethyl ether (1 L) and washed with 1N NaOH (2 x 1 L), followed by water (1 L). The organic layer was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to afford the title compound (99.5 g, 92.0%). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 4.12 (q, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.2 Hz, 2H), 2.69 (t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 5.4 Hz, 1H), 2.30 (dd, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> <com:Math><semantics>=8.7,1.5 Hz 1H<annotation encoding="application / x-tex">= 8.7, 1.5 \text{ Hz } 1\text{H}< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.17−2.09 (m, 1H)<annotation encoding="application / x-tex">2.17-2.09 \text{ (m, 1H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2.04−1.97 (m, 1H)<annotation encoding="application / x-tex">2.04-1.97 \text{ (m, 1H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1.55−1.42 (m, 4H)<annotation encoding="application / x-tex">1.55-1.42 \text{ (m, 4H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1.30 (s, 3H)<annotation encoding="application / x-tex">1.30 \text{ (s, 3H)}< / annotation>< / semantics>< / com:Math>, 1.27 (s, 3H), 1.25 (t, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 3H), 0.95 (d, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> Hz, 3H). Step-4: Synthesis of ethyl (R)-3-methyl-6-oxohexanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 5 L round bottom flask, a solution of ethyl (3R)-5-(3,3-dimethyloxiran-2-yl)-3- methylpentanoate (99.0 g, 462.07 mmol) in 1, 4 - dioxane (1 L) was treated with a solution of NaIO<com:Sub>4< / com:Sub> (296.49 g, 1.386 mol) in water (1L) at RT. The reaction mixture was stirred at same temperature for 12 h. Upon completion of reaction (monitored by TLC), the inorganic salts were filtered through Celite® pad and filtrate was extracted with EtOAc (3 x 1 L). The combined organic extract was washed with water, brine and dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>. The solution was concentrated under reduced pressure to afford the title compound (79.56 g, 99.3 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.79 (s, 1H), 4.11 (q, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.48-2.43 (m, 2H), 2.27 <com:Math><semantics>(dd,J=15,6.6Hz,1H),2.17−2.10(m,1H),2.02−1.96(m,1H),1.72−1.66(m,1H),1.54−1.50<annotation encoding="application / x-tex">(dd, J = 15, 6.6 Hz, 1H), 2.17-2.10 (m, 1H), 2.02-1.96 (m, 1H), 1.72-1.66 (m, 1H), 1.54-1.50< / annotation>< / semantics>< / com:Math> (m, 1H), 1.25 (t, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 3H), 0.96 (d, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> Hz, 3H). Step 5: Synthesis of ethyl (R)-6-hydroxy-3-methylhexanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 1 L round bottom flask, a solution of ethyl (R)-3-methyl-6-oxohexanoate (79.0 g, 458.76 mmol) in methanol (400 mL) was treated with NaBH<com:Sub>4< / com:Sub> (27.75 g, 734.02 mmol) at RT. The reaction mixture was stirred at RT for 2 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water (500 mL) and extracted with EtOAc (3 x 500 mL). The combined organic extract was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to get the title compound (70.0 g). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 4.12 (q, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.2 Hz, 2H), 3.64 (t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 6.3 Hz, 2H), 2.30 (dd, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> <com:Math><semantics>=14.7,6.6 Hz,1H,2.17−2.09 (m, 1H),2.02−1.96 (m, 1H),1.67−1.56 (m, 5H),1.26 (t, J=7.2 (m, 5H),1.26 (t, J=7.2 (m, 5H),1.26 (m, 5H),1.26 (m, 5H),1.26 (m, 5H),<annotation encoding="application / x-tex">= 14.7, 6.6 \text{ Hz}, 1\text{H}, 2.17-2.09 \text{ (m, 1H)}, 2.02-1.96 \text{ (m, 1H)}, 1.67-1.56 \text{ (m, 5H)}, 1.26 \text{ (t, } J = 7.2 \text{ (m, 5H)}, 1.26 \text{ (t, } J = 7.2 \text{ (m, 5H)}, 1.26 \text{ (m, 5H)}, 1.26 \text{ (m, 5H)}, 1.26 \text{ (m, 5H)},< / annotation>< / semantics>< / com:Math> Hz, 3H), <com:Math><semantics>0.95<annotation encoding="application / x-tex">0.95< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> Hz, 3H). Step-6: Synthesis of ethyl (R)-6-bromo-3-methylhexanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 1 L round bottom flask, a solution of ethyl <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-hydroxy-3-methylhexanoate (65.0 g, 373.56 mmol) in DCM (650 mL) was treated with PBr<com:Sub>3< / com:Sub> (101.0 g, 373.56 mmol) at RT. The reaction mixture was stirred at RT for 3 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water (500 mL) and extracted with diethyl ether (3 x 500 mL). The organic extract was separated and dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>. The solvent was removed under reduced pressure. The desired product was obtained (57.12) g) was used directly in the next step without further purifications. Step-7: Synthesis of N-(prop-2-yn-1-yl)-4-(trifluoromethoxy)benzamide: [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL round bottom flask, a stirred solution of 4-(trifluoromethoxy)benzoic acid (20.0 g, 97.08 mmol) and prop-2-yn-1-amine (6.44 g, 116.49 mmol) in DMF (200 mL) was treated sequentially with EDCI.HCl (22.24 g, 116.49 mmol), HOBt (16.01 g, 116.49 mmol) and Et<com:Sub>3< / com:Sub>N (20.4 mL, 145.62 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 12 h under nitrogen atmosphere. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with ice cold water and solid precipitated out. The solid was filtered and dried under reduced pressure to yield the title compound (22.0 g, 95.4%). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.08 (brs, 1H), 7.99 (d, <com:Math><semantics>J=8.7<annotation encoding="application / x-tex">J = 8.7< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.48 (d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>4.05−4.03<annotation encoding="application / x-tex">4.05-4.03< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>3.14<annotation encoding="application / x-tex">3.14< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=2.4<annotation encoding="application / x-tex">J = 2.4< / annotation>< / semantics>< / com:Math> Hz, 1H). LCMS (ESI<com:Sub>+< / com:Sub>, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 244.2 (M+H)<com:Sup>+< / com:Sup>. Step-8: Synthesis of 1-(2-methoxybenzyl)-5-methyl-2-(4-(trifluoromethoxy)phenyl)-1H- imidazole: [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL resealable tube, a solution of N-(prop-2-yn-1-yl)-4- (trifluoromethoxy)benzamide (15.0 g, 61.73 mmol) and 2-methoxybenzyl amine (21.10 g, 154.32 mmol) in toluene (150 mL) was treated with Zn(OTf)<com:Sub>2< / com:Sub> (2.30 g, 6.17 mmol) at RT under nitrogen atmosphere. The reaction mixture was heated at 120°C for 12 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc (3 x 100 mL). The organic extract was washed with saturated NaHCO<com:Sub>3< / com:Sub>, brine and dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>. The solution was concentrated under reduced pressure and residue obtained was purified by silica gel column chromatography (elution, 25% EtOAc in hexanes) to yield the title compound (15.2 g, 67.8%). <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.55 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 2H), 7.39 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 2H), 7.28 (m, 1H), <com:Math><semantics>7.05<annotation encoding="application / x-tex">7.05< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>6.91−6.86<annotation encoding="application / x-tex">6.91-6.86< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>6.37<annotation encoding="application / x-tex">6.37< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=7.5<annotation encoding="application / x-tex">J = 7.5< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>5.14<annotation encoding="application / x-tex">5.14< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>3.80<annotation encoding="application / x-tex">3.80< / annotation>< / semantics>< / com:Math> (s, 3H), 2.08 (s, 3H). <com:Sup>19< / com:Sup>F NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> - 52.03. LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 363.6 (M+H)<com:Sup>+< / com:Sup>. Step-9: Synthesis of 2-((5-methyl-2-(4-(trifluoromethoxy)phenyl)-1H-imidazol-1- yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL round bottom flask, a solution of 1-(2-methoxybenzyl)-5-methyl-2-(4- (trifluoromethoxy)phenyl)-1H-imidazole (30.0 g, 82.64 mmol) in dichloromethane (300 mL) was treated with BBr<com:Sub>3< / com:Sub> (30.0 mL, 82.64 mmol) drop wise at 0°C. The reaction mixture was stirred at RT for 2 h. Upon completion of reaction (monitored by TLC), the reaction mixture was basified (pH ~ 9) with aqueous NaHCO<com:Sub>3< / com:Sub> and extracted with EtOAc. The organic extract was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to afford the title compound (27.1 g, 94.4%). <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.93 (s, 1H), 7.55 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 9.0 Hz, 2H), 7.39 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.1 Hz, 2H), <com:Math><semantics>7.11−7.06<annotation encoding="application / x-tex">7.11-7.06< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>6.91−6.82<annotation encoding="application / x-tex">6.91-6.82< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>6.70<annotation encoding="application / x-tex">6.70< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=6.9<annotation encoding="application / x-tex">J = 6.9< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>6.27<annotation encoding="application / x-tex">6.27< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=7.8<annotation encoding="application / x-tex">J = 7.8< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.09 (s, 2H), 2.06 (s, 3H). <com:Sup>19< / com:Sup>F NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ -56.76. LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 349.3 (M+H)<com:Sup>+< / com:Sup>. Step-10: Synthesis of ethyl <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2<annotation encoding="application / x-tex">(2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>((5<annotation encoding="application / x-tex">((5< / annotation>< / semantics>< / com:Math>-methyl-2-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(trifluoromethoxy)phenyl)−1H−<annotation encoding="application / x-tex">(trifluoromethoxy)phenyl)-1H-< / annotation>< / semantics>< / com:Math> imidazol-1-yl)methyl)phenoxy)hexanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 250 mL round bottom flask, a stirred solution of 2-((5-methyl-2-(4- (trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenol (10.0 g, 28.71 mmol) in DMF (100 mL) was treated with KO<com:Sup>t< / com:Sup>Bu (9.66 g, 86.13 mmol) and ethyl (R)-6-bromo-3- methylhexanoate (20.33 g, 86.13 mmol) at RT under nitrogen atmosphere. The resulting reaction mixture was stirred at RT for 2 h. Upon completion of the reaction (monitored by TLC), the reaction mixture quenched with ice cold water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (gradient elution, 15-30% EtOAc in hexanes) to afford the title compound <com:Math><semantics>(7.5g,52.1%)<annotation encoding="application / x-tex">(7.5 g, 52.1\%)< / annotation>< / semantics>< / com:Math>. LCMS (ESI<com:Sub>+< / com:Sub>, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 505.4 (M+H)<com:Sup>+< / com:Sup>. Step-11: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2<annotation encoding="application / x-tex">(2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>((5<annotation encoding="application / x-tex">((5< / annotation>< / semantics>< / com:Math>-methyl-2-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(trifluoromethoxy)phenyl)−1H−<annotation encoding="application / x-tex">(trifluoromethoxy)phenyl)-1H-< / annotation>< / semantics>< / com:Math> imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound 2a): [Image disponible dans le document PDF, Image available in the PDF document] In a 250 mL round bottom flask, a stirred solution of ethyl (R)-3-methyl-6-(2-((5- methyl-2-(4-(trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate (7.5 g, 14.86 mmol) in THF (75 mL), ethanol (32 mL) and water (32 mL) was treated with lithium hydroxide monohydrate (3.12 g, 74.33 mmol) at RT. The reaction mixture was stirred at RT for 12 h. Upon completion of reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The residue obtained was washed with EtOAc, diluted with cold water and acidified (pH ~5) with 1N HCl. The solid was filtered and dried under reduced pressure to give the title compound (5.3 g, 75.7 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>, 80 °C): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 11.70 (brs, 1H), 7.57 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.32 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.32 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.32 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.32 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.32 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>=8.4 Hz,2H),7.24 (t, J=7.2 Hz,1H),7.01 (d, J=8.4 Hz,1H),6.89 (s, 1H),6.85 (t, J=7.2 Hz,1Hz)<annotation encoding="application / x-tex">= 8.4 \text{ Hz}, 2\text{H}), 7.24 \text{ (t, } J = 7.2 \text{ Hz}, 1\text{H}), 7.01 \text{ (d, } J = 8.4 \text{ Hz}, 1\text{H}), 6.89 \text{ (s, } 1\text{H}), 6.85 \text{ (t, } J = 7.2 \text{ Hz}, 1\text{Hz})< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.40 (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.16 (s, 2H), 4.02 (t, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.20 (dd, <com:Math><semantics>J=14.8<annotation encoding="application / x-tex">J = 14.8< / annotation>< / semantics>< / com:Math>, 6.0 Hz, 1H), 2.11 (s, 3H), 2.06-2.00 (m, 1H), 1.90-1.88 (m, 1H), 1.75-1.71 (m, 2H), 1.48-1.45 (m, 1H), <com:Math><semantics>1.33−1.29<annotation encoding="application / x-tex">1.33-1.29< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>0.91(d,J=6.8Hz,3H)<annotation encoding="application / x-tex">0.91(d, J = 6.8 Hz, 3H)< / annotation>< / semantics>< / com:Math>. <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ -56.80 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 477.8 (M+H)<com:Sup>+< / com:Sup>. 5 HPLC: 98.19 % (210 nm). Example-2b: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-<com:Math><semantics>(2−((2−(4−chlorophenyl)−5−methyl−1H−imidazol−1−yl)methyl)phenoxy)−<annotation encoding="application / x-tex">(2-((2-(4-chlorophenyl)-5-methyl-1H-imidazol-1-yl)methyl)phenoxy)-< / annotation>< / semantics>< / com:Math> 3-methylhexanoic acid (Compound 2b) [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of 4-chloro-N-(prop-2-yn-1-yl)benzamide: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-chlorobenzoic acid (5.0 g, 31.94 mmol) and prop-2-yn-1-amine (1.75 g, 31.94 mmol) following the experimental procedure described in step-7 of Example-2a. Yield: 4.52 g (73.0%). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.21 (brs, 1H), 7.85 (d, <com:Math><semantics>J=8.8<annotation encoding="application / x-tex">J = 8.8< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.53 (d, <com:Math><semantics>J=8.8<annotation encoding="application / x-tex">J = 8.8< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>4.04−4.02<annotation encoding="application / x-tex">4.04-4.02< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>3.12<annotation encoding="application / x-tex">3.12< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=2.8<annotation encoding="application / x-tex">J = 2.8< / annotation>< / semantics>< / com:Math> Hz, 1H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 194.0, 196.0 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of 2-(4-chlorophenyl)-1-(2-methoxybenzyl)-5-methyl-1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-chloro-N-(prop-2-yn-1-yl)benzamide (1.0 g, 5.16 mmol) and 2-methoxybenzyl amine (1.06 g, 7.74 mmol) following the experimental procedure described in step-8 of Example-2a. Yield: 0.81 g (51.1%). <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.41 (d, <com:Math><semantics>J=8.8<annotation encoding="application / x-tex">J = 8.8< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.30-725 (m, 3H), 6.98 (s, 1H), <com:Math><semantics>6.93−6.88<annotation encoding="application / x-tex">6.93-6.88< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>6.58<annotation encoding="application / x-tex">6.58< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>5.09<annotation encoding="application / x-tex">5.09< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>3.86<annotation encoding="application / x-tex">3.86< / annotation>< / semantics>< / com:Math> (s, 3H), <com:Math><semantics>2.11<annotation encoding="application / x-tex">2.11< / annotation>< / semantics>< / com:Math> (s, 3H), LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 313.1, 315.1 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of 2-((2-(4-chlorophenyl)-5-methyl-1H-imidazol-1-yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-(4-chlorophenyl)-1-(2-methoxybenzyl)-5- methyl-1H-imidazole (0.8 g, 2.56 mmol) following the experimental procedure described in step-9 of Example-2a. Yield: 0.62 g (81.15%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 299.3, 301.3 (M+H)<com:Sup>+< / com:Sup>. Step-4: Synthesis of ethyl (R)-6-(2-((2-(4-chlorophenyl)-5-methyl-1H-imidazol-1- yl)methyl)phenoxy)-3-methylhexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-((2-(4-chlorophenyl)-5-methyl-1H- imidazol-1-yl)methyl)phenol (0.6 g, 2.01 mmol) and ethyl (R)-6-bromo-3-methylhexanoate (0.186 g, 1.48 mmol) following the experimental procedure described in step-10 of Example- 2a. Yield: 0.321 g (35.1%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 454.5, 456.5 (M+H)<com:Sup>+< / com:Sup>. Step-5: Synthesis (R)-6-(2-((2-(4-chlorophenyl)-5-methyl-1H-imidazol-1-yl)methyl) phenoxy)-3-methylhexanoic acid (Compound 2b): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from ethyl (<com:Math><semantics>R<annotation encoding="application / x-tex">R< / annotation>< / semantics>< / com:Math>)-6-(2-((2-(4-chlorophenyl)-5- methyl-1H-imidazol-1-yl)methyl)phenoxy)-3-methylhexanoate (0.3 g, 0.66 mmol) following the experimental procedure described in step-11 of Example-2a and purified by preparative silica gel thin layer chromatography (elution, 4% MeOH-CH<com:Sub>2< / com:Sub>Cl<com:Sub>2< / com:Sub>). Yield: 0.05 g (18%). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>, 80°C): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.48 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 2H), 7.40 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 2H), 7.24 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.00 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.88 (s, 1H), 6.84 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.51 <com:Math><semantics>(d,J=7.2 Hz,1H),5.14 (s, 2H),3.99 (t, J=5.6 Hz,2H),2.19−2.16 (m, 1H),2.09 (s, 3H),<annotation encoding="application / x-tex">(d, J = 7.2 \text{ Hz}, 1\text{H}), 5.14 \text{ (s, 2H)}, 3.99 \text{ (t, } J = 5.6 \text{ Hz}, 2\text{H}), 2.19-2.16 \text{ (m, 1H)}, 2.09 \text{ (s, 3H)},< / annotation>< / semantics>< / com:Math> 2.06-2.00 (m, 1H), 1.93-1.86 (m, 1H), 1.72-1.67 (m, 2H), 1.45-1.42 (m, 1H), 1.32-1.26 (m, 1H), <com:Math><semantics>0.91<annotation encoding="application / x-tex">0.91< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 427.2, 429.2 (M+H)<com:Sup>+< / com:Sup>. HPLC: 95.84% (210 nm). Example-2c: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-<com:Math><semantics>(2−((2−(4−(furan−2−yl)phenyl)−5−methyl−1H−imidazol−1−yl)methyl)<annotation encoding="application / x-tex">(2-((2-(4-(furan-2-yl)phenyl)-5-methyl-1H-imidazol-1-yl)methyl)< / annotation>< / semantics>< / com:Math> phenoxy)-3-methylhexanoic acid (Compound 2c): [Image disponible dans le document PDF, Image available in the PDF document] Scheme: [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of ethyl (R)-6-<com:Math><semantics>(2−((2−(4−(furan−2−yl)phenyl)−5−methyl−1H−imidazol−1−<annotation encoding="application / x-tex">(2-((2-(4-(furan-2-yl)phenyl)-5-methyl-1H-imidazol-1-< / annotation>< / semantics>< / com:Math> yl)methyl)phenoxy)-3-methylhexanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 50 mL round bottom flask, a stirred solution of 2-((2-(4-(furan-2-yl)phenyl)-5- methyl-1H-imidazol-1-yl)methyl)phenol (0.2 g, 0.60 mmol) (a procedure for the preparation of which is disclosed in U.S. Application No. 62 / 061,483) in DMF (5 mL) was treated with <com:Math><semantics>K2CO3<annotation encoding="application / x-tex">K_2CO_3< / annotation>< / semantics>< / com:Math> (0.25 g, 1.81 mmol) and ethyl (R)-6-bromo-3-methylhexanoate (0.42 g, 1.81 mmol) at RT under nitrogen atmosphere. The resulting reaction mixture was heated 60°C for 12 h. Upon completion of the reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and extracted with ethyl acetate (25 mL X 3). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (gradient elution, 15-30% EtOAc in hexanes) to afford the title compound (0.181 g, 61.2%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 487.3 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-<com:Math><semantics>(2−((2−(4−(furan−2−yl)phenyl)−5−methyl−1H−imidazol−1−yl)<annotation encoding="application / x-tex">(2-((2-(4-(furan-2-yl)phenyl)-5-methyl-1H-imidazol-1-yl)< / annotation>< / semantics>< / com:Math> methyl)phenoxy)-3-methylhexanoic acid (Compound 2c): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from ethyl (R)-6-(2-((2-(4-(furan-2-yl)phenyl)-5- methyl-1H-imidazol-1-yl)methyl)phenoxy)-3-methylhexanoate (0.180 g, 0.37 mmol) following the experimental procedure described in step-11 of Example-2a and purified by preparative HPLC [Luna (250 mm x 21.20 mm, 5 µ); flow: 18.0 ml / min; mobile phase: A / B <com:Math><semantics>=0.1%<annotation encoding="application / x-tex">=0.1\%< / annotation>< / semantics>< / com:Math> TFA in water / MeCN; T / %B = 0 / 20, 2 / 20 / 8 / 70]. Yield: 0.04g (23.6%). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>, 80 °C): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.68 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.8 Hz, 2H), 7.65 (s, 1H), 7.50 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.8 Hz, 2H), 7.24 (t, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz 1H), 7.02 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.90-6.84 (m, 3H), 6.57-6.56 (m, 1H), <com:Math><semantics>6.48<annotation encoding="application / x-tex">6.48< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>5.18<annotation encoding="application / x-tex">5.18< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>4.02<annotation encoding="application / x-tex">4.02< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>2.19−2.15<annotation encoding="application / x-tex">2.19-2.15< / annotation>< / semantics>< / com:Math> (m, 1H), 2.10 (s, 3H), 2.04-1.98 (m, 1H), 1.91-1.86 (m, 1H), 1.72-1.70 (m, 2H), 1.47-1.42 (m, 1H), 1.31-1.29 (m, 1H), 0.89 (d, <com:Math><semantics>J=6.8<annotation encoding="application / x-tex">J = 6.8< / annotation>< / semantics>< / com:Math> Hz, 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 459.2 (M+H)<com:Sup>+< / com:Sup>. HPLC: 97.50 % (210 nm). Example-2d: <com:Math><semantics>Synthesisof(𝑅)-3-𝑚𝑒𝑡ℎ𝑦𝑙-6-(2-((5-𝑚𝑒𝑡ℎ𝑦𝑙-2-(4-(𝑡𝑟𝑖𝑓𝑙𝑢𝑜𝑟𝑜𝑚𝑒𝑡ℎ𝑦𝑙)𝑝ℎ𝑒𝑛𝑦𝑙)-1H−imidazol−1−<annotation encoding="application / x-tex">Synthesis of \textit{(R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1} H-imidazol-1-< / annotation>< / semantics>< / com:Math> yl)methyl)phenoxy)hexanoic acid (Compound 2d) [Image disponible dans le document PDF, Image available in the PDF document] 5 Scheme: [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of N-(prop-2-yn-1-yl)-4-(trifluoromethyl)benzamide: [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL round bottom flask, a stirred solution of 4-(trifluoromethyl)benzoic acid (10 g, 52.63 mmol) and prop-2-yn-1-amine (3.47 g, 63.15 mmol) in DMF (200 mL) was treated sequentially with EDCI.HCl (20.09 g, 105.2 mmol), HOBt (14.2 g, 105.2 mmol) and Et<com:Sub>3< / com:Sub>N (14.6 mL, 105.2 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 12 h under nitrogen atmosphere. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with ice cold water and solid precipitated out. The solid was filtered and dried under reduced pressure to yield the title compound (8.42 g, 70.5%). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.90 (d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.71 (d, <com:Math><semantics>J=8.8<annotation encoding="application / x-tex">J = 8.8< / annotation>< / semantics>< / com:Math> Hz, 2H), 6.47 (brs, 1H), <com:Math><semantics>4.28−4.62<annotation encoding="application / x-tex">4.28-4.62< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>3.12<annotation encoding="application / x-tex">3.12< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=2.4<annotation encoding="application / x-tex">J = 2.4< / annotation>< / semantics>< / com:Math> Hz, 1H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 228.2 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of 1-(2-methoxybenzyl)-5-methyl-2-(4-(trifluoromethyl)phenyl)-1H- imidazole: [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL resealable reaction tube, a solution of N-(prop-2-yn-1-yl)-4- (trifluoromethyl)benzamide (13.3 g, 58.59 mmol) and 2-methoxybenzyl amine (12.0 g, 87.84 mmol) in toluene (150 mL) was treated with Zn(OTf)<com:Sub>2< / com:Sub> (6.67 g, 17.5 mmol) at RT under nitrogen atmosphere. The reaction mixture was heated at 110°C for 12 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc (3 x 100 mL). The combined organic extract was washed with saturated NaHCO<com:Sub>3< / com:Sub>, brine and dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>. The solution was concentrated under reduced pressure and the residue obtained was purified by silica gel column chromatography (elution, 25% EtOAc in hexanes) to afford the title compound (17.3 g, 85.3%). <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>): δ 7.59-7.54 (m, 4H), 7.30-7.23 (m, 1H), 7.00 (s, 1H), 6.91-6.86 (m, 2H), <com:Math><semantics>6.57<annotation encoding="application / x-tex">6.57< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>5.11<annotation encoding="application / x-tex">5.11< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>3.84<annotation encoding="application / x-tex">3.84< / annotation>< / semantics>< / com:Math> (s, 3H), <com:Math><semantics>2.11<annotation encoding="application / x-tex">2.11< / annotation>< / semantics>< / com:Math> (s, 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 347.3 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of 2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1- yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL round bottom flask, a solution of 1-(2-methoxybenzyl)-5-methyl-2-(4- (trifluoromethyl)phenyl)-1H-imidazole (17.3 g, 49.94 mmol) in DCM (150 mL) was treated with BBr<com:Sub>3< / com:Sub> (1.0 M, 90.0 mL) drop wise at 0°C. The reaction mixture was stirred at RT for 4 h. Upon completion of reaction (monitored by TLC), the reaction mixture was basified (pH ~ 9) with aqueous NaHCO<com:Sub>3< / com:Sub> and extracted with EtOAc (3 x 500 mL). The combined organic extract was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to afford the title compound (19.2 g, crude). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.99 (s, 1H), 7.88 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 2H), 7.77 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 2H), 7.33 (s, 1H), 7.14-7.10 (m, 1H), 6.83 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.74-6.70 (m, 1H), 6.55 (d, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 6.8 Hz, 1H), 5.21 (s, 2H), 2.16 (s, 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 333.3 (M+H)<com:Sup>+< / com:Sup>. Step-4: Synthesis of ethyl <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(4−(trifluoromethyl)phenyl)−1H−<annotation encoding="application / x-tex">(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-< / annotation>< / semantics>< / com:Math> imidazol-1-yl)methyl)phenoxy)hexanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 250 mL round bottom flask, a stirred solution of 2-((5-methyl-2-(4- (trifluoromethyl) phenyl)-1H-imidazol-1-yl)methyl)phenol (4.0 g, 12.0 mmol) in DMF (100 mL) was treated with KO<com:Sup>t< / com:Sup>Bu (4.03 g, 36.1 mmol) and ethyl (R)-6-bromo-3-methylhexanoate (8.52 g, 36.10 mmol) at RT under nitrogen atmosphere. The resulting reaction mixture was stirred at RT for 12 h. Upon completion of the reaction (monitored by TLC), the reaction mixture quenched with ice cold water and extracted with EtOAc (3 x 100 mL). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (gradient elution, 15-30% EtOAc in hexanes) to afford the title compound (3.31 g, 56.3%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 489.3 (M+H)<com:Sup>+< / com:Sup>. Step-5: Synthesis of (R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol- 1-yl)methyl)phenoxy)hexanoic acid (Compound 2d): [Image disponible dans le document PDF, Image available in the PDF document] In a 250 mL round bottom flask, a stirred solution of ethyl (R)-3-methyl-6-(2-((5- methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate (3.3 g, 6.75 mmol) in THF (30 mL), ethanol (10 mL) and water (10 mL) was treated with lithium hydroxide monohydrate (1.42 g, 33.8 mmol) at RT. The reaction mixture was stirred at RT for 12 h. Upon completion of reaction (monitored by TLC), the reaction mixture was concentrated under reduced pressure. The residue obtained was washed with EtOAc, diluted with cold water and acidified (pH ~5) with 1N HCl. The solid obtained was filtered and dried under reduced pressure to give the title compound (1.12 g, 36.0 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 12.00 (brs, 1H), 7.71 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.62 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>7.26−7.21<annotation encoding="application / x-tex">7.26-7.21< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>7.01<annotation encoding="application / x-tex">7.01< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>6.93<annotation encoding="application / x-tex">6.93< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>6.86−6.83<annotation encoding="application / x-tex">6.86-6.83< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>6.38<annotation encoding="application / x-tex">6.38< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.8<annotation encoding="application / x-tex">J = 6.8< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.16 (s, 2H), 3.98 (t, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.19-2.14 (m, 1H), 2.08 (s, 3H), 1.99-1.93 (m, 1H), 1.84-1.76 (m, 1H), 1.67-1.65 (m, 2H), 1.45-1.42 (m, 1H), 1.28-1.18 (m, 1H), 0.83 (d, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 3H)<com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> -56.4 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 460.8 (M+H)<com:Sup>+< / com:Sup>. HPLC: 98.89 % (210 nm). Preparation of Polymorphs and Salts of Compound 2d Various forms of compound 2d can be formed from different crystallization experiments, as detailed below. Compound 2d Form B New Form B of Compound 2d was obtained by slurrying Compound 2d in ethyl acetate at 50 °C, 2-propanol at 50 °C, acetone at 25 °C, water at 25 °C, water / methanol at 25 °C, or ethanol at 25 °C. Compound 2d Form C New Form C of Compound 2d was obtained by slurrying Compound 2d in acetonitrile at 50 °C, water / acetonitrile at 4 °C, and 2-methyltetrahydrofuran at 4 °C. Compound 2d Form D New Form D of Compound 2d was obtained by slurrying Compound 2d in cyclopentyl methyl ether at 50 °C, toluene at 25 °C, and from evaporative crystallization from dichloromethane. Compound 2d Form E New Form E Compound 2d was obtained by slurrying Compound 2d in methanol at 25 °C. Preparation of Hemisulfate Salt Form 1 of Compound 2d In a 50 mL vial was dissolved 883.2 mg of Compound 2d was dissolved in 35 mL methanol. Then, <com:Math><semantics>H2SO4<annotation encoding="application / x-tex">H_2SO_4< / annotation>< / semantics>< / com:Math> (1920 <com:Math><semantics>μ<annotation encoding="application / x-tex">\mu< / annotation>< / semantics>< / com:Math>L, 1M in <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>, 1 equivalent) was pipetted in. The solvent was allowed to evaporate under N<com:Sub>2< / com:Sub>. Once evaporated, 2-propanol (18 mL) was pipetted in followed by a stir bar. The vial was capped and placed on a 50°C stir plate for 1 hour, then the temperature was dropped to 25°C, where it stirred for 1 day. After 1 day, the solids were filtered under vacuum and allowed to air dry. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.85 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.74 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.36 (s, 1H), 7.27 (t, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.02 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.85 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.62 (d, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 7.2 Hz, 1H), 5.26 (s, 2H), 3.96 (t, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.21-2.16 (m, 4H), 1.96 (dd, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math>, 15.2 Hz, 1H), 1.83-1.80 (m, 1H), 1.67-1.59 (m, 2H), 1.35-1.31 (m, 1H), 1.28-1.18 (m, 1H), 0.85 <com:Math><semantics>(d,J=6.4Hz,3H).<annotation encoding="application / x-tex">(d, J = 6.4 Hz, 3H).< / annotation>< / semantics>< / com:Math> Mass Spectrum (ESI) m / e 461.2. Elemental Analysis: Calculated: C 58.93%; H 5.54%; N 5.50%; S 3.15. Observed: C 58.30%; H 5.36%; N 5.42%; S 3.47. The hemisulfate salt form 1 of Compound 2d was also obtained according to the same manner as that mentioned above using acetonitrile (18 mL) as a solvent instead of 2-propanol <com:Math><semantics>(18 mL).<annotation encoding="application / x-tex">(18 \text{ mL}).< / annotation>< / semantics>< / com:Math> Preparation of Hemisulfate Salt Form 2 of Compound 2d Approxamately 90 to 110 mg of hemisulfate form 1 of Compound 2d was weighed out and transferred to a 4 mL amber glass vial followed by 0.8 mL of methanol and a magnetic stir bar. The vial was sealed and placed onto a temperature controlled stir plate set to 25°C and stirred for 15 days at 500 rpm. The solid isolate from this experiment, identified as hemisulfate form 2 of Compound 2d, was obtained and characterized, in particular, by XRPD. Example-2e: Synthesis of <com:Math><semantics>(E)<annotation encoding="application / x-tex">(E)< / annotation>< / semantics>< / com:Math>-4-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(4−(trifluoromethoxy)phenyl)−1H−imidazol−<annotation encoding="application / x-tex">(2-((5-methyl-2-(4-(trifluoromethoxy)phenyl)-1H-imidazol-< / annotation>< / semantics>< / com:Math> 1-yl)methyl)phenoxy)hex-4-enoic acid (Compound 2e) [Image disponible dans le document PDF, Image available in the PDF document] Scheme: [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of methyl (E)-4-methyl-6-(2-((5-methyl-2-(4-(trifluoromethoxy) phenyl)-1H- imidazol-1-yl)methyl)phenoxy)hex-4-enoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-((5-methyl-2-(4- (trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenol (0.3 g, 0.86 mmol) and methyl (E)-6-bromo-4-methylhex-4-enoate (0.57 g, <com:Math><semantics>2.58 mmol<annotation encoding="application / x-tex">2.58 \text{ mmol}< / annotation>< / semantics>< / com:Math>) (a procedure for the preparation of which is disclosed in U.S. Application No. 62 / 061,483) following the experimental procedure described in step-1 of Example-2c. Yield: 0.180 g. LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 489.4 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of (E)-4-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(4−(trifluoromethoxy)phenyl)−1H−<annotation encoding="application / x-tex">(2-((5-methyl-2-(4-(trifluoromethoxy)phenyl)-1H-< / annotation>< / semantics>< / com:Math> imidazol-1-yl)methyl)phenoxy)hex-4-enoic acid (Compound 2e): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from methyl (<com:Math><semantics>E<annotation encoding="application / x-tex">E< / annotation>< / semantics>< / com:Math>)-4-methyl-6-(2-((5-methyl-2-(4- (trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hex-4-enoate (0.18 g, 0.36 mmol) following the experimental procedure described in step-11 of Example-2a. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.69 (d, <com:Math><semantics>J=8.8<annotation encoding="application / x-tex">J = 8.8< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.49 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.44 (s, 1H), 7.26 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.01 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.83 (t, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.72 (d, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 6.8 Hz, 1H), 5.33-5.28 (m, 3H), 4.52 (d, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.34-2.27 (m, 4H), 2.22 (s, 3H), 1.66 (s, 3H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ -56.77 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 475.3 (M+H)<com:Sup>+< / com:Sup>. HPLC: 95.75 % (210 nm). Example-2f: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(p−tolyl)−1H−imidazol−1−yl)methyl)phenoxy)<annotation encoding="application / x-tex">(2-((5-methyl-2-(p-tolyl)-1H-imidazol-1-yl)methyl)phenoxy)< / annotation>< / semantics>< / com:Math> hexanoic acid (Compound 2f): [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of 1-(2-methoxybenzyl)-5-methyl-2-(p-tolyl)-1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] In a 50 mL re-sealable reaction tube, 2-(4-iodophenyl)-1-(2-methoxybenzyl)-5- methyl-1H-imidazole (0.4 g, 0.99 mmol) and methyl boronic acid (0.088 g, 1.48 mmol) were dissolved in degassed toluene (10 mL) at RT under nitrogen atmosphere. Pd(OAc)<com:Sub>2< / com:Sub> (0.011 g, <com:Math><semantics>0.049 mmol<annotation encoding="application / x-tex">0.049 \text{ mmol}< / annotation>< / semantics>< / com:Math>) tricyclohexyl phosphine (<com:Math><semantics>0.027g<annotation encoding="application / x-tex">0.027g< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>0.09 mmol<annotation encoding="application / x-tex">0.09 \text{ mmol}< / annotation>< / semantics>< / com:Math>) and <com:Math><semantics>K3PO4<annotation encoding="application / x-tex">K_3PO_4< / annotation>< / semantics>< / com:Math> (<com:Math><semantics>0.63g<annotation encoding="application / x-tex">0.63 g< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2.97 mmol<annotation encoding="application / x-tex">2.97 \text{ mmol}< / annotation>< / semantics>< / com:Math>) were added to the above solution under nitrogen atmosphere. The resulting mixture was degassed by purging argon gas for 15 min, and reaction mixture was heated to 90 °C until completion of the reaction (monitored by TLC). The reaction mixture was cooled to RT, diluted with cold water and washed with ethyl acetate (30 mL x 3). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to get the title compound (0.26 g, 89.9%). <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.37 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.29 (d, <com:Math><semantics>J=7.8<annotation encoding="application / x-tex">J = 7.8< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.14 (d, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 8.4 Hz, 2H), 6.97 (s, 1H), 6.91(d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 2H), 6.62 (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.12 (s, 2H), 3.84 (s, 3H), 2.34 (s, 3H), 2.10 (s, 3H). Step-2: Synthesis of <com:Math><semantics>2−((5−methyl−2−(p−tolyl)−1H−imidazol−1−yl)methyl)<annotation encoding="application / x-tex">2-((5-methyl-2-(p-tolyl)-1H-imidazol-1-yl)methyl)< / annotation>< / semantics>< / com:Math> phenol: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 1-(2-methoxybenzyl)-5-methyl-2-(p-tolyl)- 1H-imidazole (0.25 g, 0.85 mmol) following the experimental procedure described in step-9 of Example-2a. Yield: 0.23 g. LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 279.3 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of ethyl <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(p−tolyl)−1H−imidazol−1−<annotation encoding="application / x-tex">(2-((5-methyl-2-(p-tolyl)-1H-imidazol-1-< / annotation>< / semantics>< / com:Math> yl)methyl)phenoxy)hexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-((5-methyl-2-(p-tolyl)-1H-imidazol-1- yl)methyl)phenol (0.23 g, 0.83 mmol) and ethyl (<com:Math><semantics>R<annotation encoding="application / x-tex">R< / annotation>< / semantics>< / com:Math>)-6-bromo-3-methylhexanoate (0.392 g, 1.65 mmol) following the experimental procedure described in step-1 of Example-2c. Yield: 0.21 g (58.4 %). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 436.5 (M+H)<com:Sup>+< / com:Sup>. Step-4: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(p−tolyl)−1H−imidazol−1−yl)methyl)<annotation encoding="application / x-tex">(2-((5-methyl-2-(p-tolyl)-1H-imidazol-1-yl)methyl)< / annotation>< / semantics>< / com:Math> phenoxy)hexanoic acid (Compound 2f): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from ethyl (<com:Math><semantics>R<annotation encoding="application / x-tex">R< / annotation>< / semantics>< / com:Math>)-3-methyl-6-(2-((5-methyl-2-(p- tolyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate (0.2 g, 0.46 mmol) following the experimental procedure described in step-11 of Example-2a and purified by preparative HPLC [Luna C18 (21.2 mm x 250mm, <com:Math><semantics>5μ<annotation encoding="application / x-tex">5\mu< / annotation>< / semantics>< / com:Math>m); flow: 18 mL / min; mobile phase: A / B =0.1% TFA in water / MeCN; <com:Math><semantics>T / %B=0 / 30<annotation encoding="application / x-tex">T / \%B = 0 / 30< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2 / 40 / 8 / 80<annotation encoding="application / x-tex">2 / 40 / 8 / 80< / annotation>< / semantics>< / com:Math>]. Yield: 0.029 g (15.5 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>, 80°C): δ 7.34 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.25-7.22 (m, 1H), 7.16 (d, <com:Math><semantics>J=8.0 Hz,2H,7.00 (d, J=8.0 Hz,1H),6.87−6.84 (m, 2H),6.48 (brs, 1H),5.13 (s, 2H),<annotation encoding="application / x-tex">J = 8.0 \text{ Hz}, 2\text{H}, 7.00 \text{ (d, } J = 8.0 \text{ Hz}, 1\text{H}), 6.87-6.84 \text{ (m, 2H)}, 6.48 \text{ (brs, 1H)}, 5.13 \text{ (s, 2H)},< / annotation>< / semantics>< / com:Math> <com:Math><semantics>4.04<annotation encoding="application / x-tex">4.04< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>2.30<annotation encoding="application / x-tex">2.30< / annotation>< / semantics>< / com:Math> (s, 3H), <com:Math><semantics>2.14−2.13<annotation encoding="application / x-tex">2.14-2.13< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>2.07<annotation encoding="application / x-tex">2.07< / annotation>< / semantics>< / com:Math> (s, 3H), <com:Math><semantics>2.05−1.99<annotation encoding="application / x-tex">2.05-1.99< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>1.91−1.86<annotation encoding="application / x-tex">1.91-1.86< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>1.71−1.69<annotation encoding="application / x-tex">1.71-1.69< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>1.48−1.40<annotation encoding="application / x-tex">1.48-1.40< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>1.35−1.23<annotation encoding="application / x-tex">1.35-1.23< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>0.91<annotation encoding="application / x-tex">0.91< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J=8.0< / annotation>< / semantics>< / com:Math> Hz, 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 407.1 (M+H)<com:Sup>+< / com:Sup>. HPLC: 99.28 % (210 nm). 5 Example-2g: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-<com:Math><semantics>(2−((2−(4−fluorophenyl)−5−methyl−1H−imidazol−1−yl)methyl)phenoxy)−<annotation encoding="application / x-tex">(2-((2-(4-fluorophenyl)-5-methyl-1H-imidazol-1-yl)methyl)phenoxy)-< / annotation>< / semantics>< / com:Math> 3-methylhexanoic acid (Compound 2g) [Image disponible dans le document PDF, Image available in the PDF document] Scheme: [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of 4-fluoro-N-(prop-2-yn-1-yl)benzamide: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-fluorobenzoic acid (5.0 g, 35.68 mmol) and prop-2-yn-1-amine (2.35 g, 42.81 mmol) following the experimental procedure described in step-7 of Example-2a. Yield: 4.25 g (67.22 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.82-7.77 (m, 2H), 7.12 (t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 2H), 6.21 (bs, 1H), <com:Math><semantics>4.26−4.23<annotation encoding="application / x-tex">4.26-4.23< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>2.29<annotation encoding="application / x-tex">2.29< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=2.8<annotation encoding="application / x-tex">J = 2.8< / annotation>< / semantics>< / com:Math> Hz, 1H). Step-2: Synthesis of 2-(4-fluorophenyl)-1-(2-methoxybenzyl)-5-methyl-1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-fluoro-N-(prop-2-yn-1-yl)benzamide (3.0 g, 16.93 mmol) and 2-methoxybenzyl amine (3.47 g, 25.39 mmol) following the experimental procedure described in step-8 of Example-2a. Yield: 3.51 g (69.9 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.46-7.41 (m, 2H), 7.30 (d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.04- 6.87 (m, 5H), <com:Math><semantics>6.58<annotation encoding="application / x-tex">6.58< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>5.08<annotation encoding="application / x-tex">5.08< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>3.85<annotation encoding="application / x-tex">3.85< / annotation>< / semantics>< / com:Math> (s, 3H), <com:Math><semantics>2.11<annotation encoding="application / x-tex">2.11< / annotation>< / semantics>< / com:Math> (s, 3H). <com:Sup>19< / com:Sup>F NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> -113.0 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 297.3 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of 2-((2-(4-fluorophenyl)-5-methyl-1H-imidazol-1-yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-(4-fluorophenyl)-1-(2-methoxybenzyl)-5- methyl-1H-imidazole (3.5 g, 11.81 mmol) following the experimental procedure described in step-9 of Example-2a. Yield: 2.7 g (81.1%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 283.3 (M+H)<com:Sup>+< / com:Sup>. Step-4: Synthesis of ethyl (R)-6-(2-((2-(4-fluorophenyl)-5-methyl-1H-imidazol-1- yl)methyl)phenoxy)-3-methylhexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-((2-(4-fluorophenyl)-5-methyl-1H- imidazol-1-yl)methyl)phenol (0.6 g, 2.12 mmol) and ethyl (R)-6-bromo-3-methylhexanoate (1.51 g, 6.38 mmol) following the experimental procedure described in step-10 of Example- 2a. Yield: 0.62 g. LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 439.4 (M+H)<com:Sup>+< / com:Sup>. Step-5: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-<com:Math><semantics>(2−((2−(4−fluorophenyl)−5−methyl−1H−imidazol−1−yl)methyl)<annotation encoding="application / x-tex">(2-((2-(4-fluorophenyl)-5-methyl-1H-imidazol-1-yl)methyl)< / annotation>< / semantics>< / com:Math> phenoxy)-3-methylhexanoic acid (Compound 2g): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from ethyl (<com:Math><semantics>R<annotation encoding="application / x-tex">R< / annotation>< / semantics>< / com:Math>)-6-(2-((2-(4-fluorophenyl)-5- methyl-1H-imidazol-1-yl)methyl)phenoxy)-3-methylhexanoate (0.62 g, 1.41 mmol) following the experimental procedure described in step-11 of Example-2a and purified by preparative HPLC [Phenomenex Luna C 18 (21.2 mm x 250 mm, 5µm); flow: 15 mL / min; mobile phase: A / B = <com:Math><semantics>0.1%<annotation encoding="application / x-tex">0.1\%< / annotation>< / semantics>< / com:Math> TFA in water / MeCN; T / %B = <com:Math><semantics>0 / 40<annotation encoding="application / x-tex">0 / 40< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2 / 40 / 8 / 80<annotation encoding="application / x-tex">2 / 40 / 8 / 80< / annotation>< / semantics>< / com:Math>]. Yield: 0.111 g (18.9 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>, 80 °C): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.50-7.47 (m, 2H), 7.28-7.16 (m, 3H), 7.03 (d, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 8.0 Hz, 1H), 6.89-6.85 (m, 2H), 6.46 (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.14 (s, 2H), 4.03 (t, <com:Math><semantics>J=5.6<annotation encoding="application / x-tex">J = 5.6< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.24-2.20 (m, 1H), 2.11 (s, 3H), 2.08-2.03 (m, 1H), 1.95-1.90 (m, 1H), 1.80-1.67 (m, 2H), 1.50-1.42 (m, 1H), 1.38-1.28 (m, 1H), 0.93 (d, <com:Math><semantics>J=6.8<annotation encoding="application / x-tex">J = 6.8< / annotation>< / semantics>< / com:Math> Hz, 3H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ -113.00 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 411.4 (M+H)<com:Sup>+< / com:Sup>. HPLC: 99.3 % (210 nm). Example-2h: <Formule mathématique disponible dans le document PDF, Math available in the PDF document>$Synthesis \ of \ 6-(2-((2-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-1 \\ H-imidazol-1-(trifluoromethyl)phenyl)-5-methyl-1 \\ H-imidazol-1-(trifluoromethyl)phenyl)-5-methyl-1 \\ H-imidazol-1-(trifluoromethyl)phenyl)-5-me$ yl)methyl)phenoxy)-2,2-dimethylhexanoic acid (Compound 2h): [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of 3-fluoro-N-(prop-2-yn-1-yl)-4-(trifluoromethyl)benzamide: ) H F<com:Sub>3< / com:Sub>C The title compound was synthesized from 3-fluoro-4-(trifluoromethyl)benzoic acid (5.0 g, 24.03 mmol) and prop-2-yn-1-amine (1.59 g, 28.84 mmol) following the experimental procedure described in step-7 of Example-2a. Yield: 4.71 g (79.7 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO- d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.25 (t, <com:Math><semantics>J=5.2<annotation encoding="application / x-tex">J = 5.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.93-7.83 (m, 3H), 4.07-4.05 (m, 2H), <com:Math><semantics>3.16<annotation encoding="application / x-tex">3.16< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=2.4<annotation encoding="application / x-tex">J = 2.4< / annotation>< / semantics>< / com:Math> Hz, <com:Math><semantics>1<annotation encoding="application / x-tex">1< / annotation>< / semantics>< / com:Math>H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO- <com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>): δ:-115.11, -60.32 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 246.1 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of 2-(3-fluoro-4-(trifluoromethyl)phenyl)-1-(2-methoxybenzyl)-5-methyl- 1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 3-fluoro-N-(prop-2-yn-1-yl)-4- (trifluoromethyl)benzamide (2.5 g, 10.1 mmol) and 2-methoxybenzyl amine (2.1 g, 15.2 mmol) following the experimental procedure described in step-8 of Example-2a. Yield: 2.3 g (61.8 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.78 (t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.8 Hz ,1H), 7.52 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 12.3 Hz, 1H), 7.45 <com:Math><semantics>(d,J=8.4 Hz,1H),7.30−7.24 (m, 1H),7.04 (d, J=7.8 Hz,1H),6.96 (s, 1H),6.88−6.83 (m, 1H)<annotation encoding="application / x-tex">(d, J = 8.4 \text{ Hz}, 1\text{H}), 7.30-7.24 \text{ (m, 1H)}, 7.04 \text{ (d, } J = 7.8 \text{ Hz}, 1\text{H}), 6.96 \text{ (s, 1H)}, 6.88-6.83 \text{ (m, 1H)}< / annotation>< / semantics>< / com:Math> 1H), 6.38 (d, <com:Math><semantics>J=7.5<annotation encoding="application / x-tex">J = 7.5< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.21 (s, 2H), 3.78 (s, 3H), 2.10 (s, 3H). <com:Sup>19< / com:Sup>F NMR(400 MHz, DMSO- d<com:Sub>6< / com:Sub>): δ: -115.36, -59.90 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 365.0 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of 2-((2-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-1- yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-(3-fluoro-4-(trifluoromethyl)phenyl)-1- (2-methoxybenzyl)-5-methyl-1H-imidazole (1.0 g, 2.74 mmol) following the experimental procedure described in step-9 of Example-2a. Yield: 1.1 g, (crude) LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 351.2 (M+H)<com:Sup>+< / com:Sup>. Step-4: Synthesis of ethyl 6-(2-((2-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-1H- imidazol-1-yl)methyl)phenoxy)-2,2-dimethylhexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-((2-(3-fluoro-4-(trifluoromethyl)phenyl)- 5-methyl-1H-imidazol-1-yl)methyl)phenol (0.5 g, 1.42 mmol) and ethyl 6-bromo-2,2- dimethylhexanoate (1.07 g, 4.28 mmol) (procedures for the preparation of which are disclosed in U.S. Application No. 62 / 061,483) following the experimental procedure described in step-1 of Example-2c. Yield: 0.31 g (41.81 %). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 520.7 (M+H)<com:Sup>+< / com:Sup>. Step-5: Synthesis of 6-(2-((2-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-1H-imidazol-1- yl)methyl)phenoxy)-2,2-dimethylhexanoic acid (Compound 2h): [Image disponible dans le document PDF, Image available in the PDF document] - The title compound was synthesized from ethyl 6-(2-((2-(3-fluoro-4- (trifluoromethyl)phenyl)-5-methyl-1H-imidazol-1-yl)methyl)phenoxy)-2,2- dimethylhexanoate (0.3 g, 0.57 mmol) following the experimental procedure described in step-11 of Example-2a. Yield: 0.120 g, (46.4 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>, 80°C): δ 7.73 (t, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.49-7.45 (m, 2H),7.26 (m, <com:Math><semantics>J=7.6 Hz<annotation encoding="application / x-tex">J = 7.6 \text{ Hz}< / annotation>< / semantics>< / com:Math>, 1H), 7.04 (d, <com:Math><semantics>J=8.4 Hz<annotation encoding="application / x-tex">J = 8.4 \text{ Hz}< / annotation>< / semantics>< / com:Math>, 1H), 6.96 (s, 1H), 6.86 (t, <com:Math><semantics>J=7.6 Hz<annotation encoding="application / x-tex">J = 7.6 \text{ Hz}< / annotation>< / semantics>< / com:Math>, 1H), 6.46 (d, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 7.2 Hz, 1H), 5.23 (s, 2H), 4.03 (t, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.14 (s, 3H), 1.71-1.67 (m, 2H), 1.53-1.49 (m, 2H), 1.41-1.36 (m, 2H), 1.06 (s, 6H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ -115.25, -59.87 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 493.3 (M+H)<com:Sup>+< / com:Sup>. HPLC: 97.62 % (210 nm): Example-2i: Synthesis of 6-(2-((2-(4-chloro-3-fluorophenyl)-5-methyl-1H-imidazol-1-yl)methyl)- phenoxy)-2,2-dimethylhexanoic acid (Compound 2i) [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of 4-chloro-3-fluoro-N-(prop-2-yn-1-yl)benzamide: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-chloro-3-fluorobenzoic acid (5.0 g, 28.73 mmol) and prop-2-yn-1-amine (1.89 g, 34.48 mmol) following the experimental procedure described in step-7 of Example-2a. Yield: 5.2 g, (85.5%). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.09 (t, <com:Math><semantics>J=5.2<annotation encoding="application / x-tex">J = 5.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.82 (dd, <com:Math><semantics>J=10.0<annotation encoding="application / x-tex">J = 10.0< / annotation>< / semantics>< / com:Math>, 0.8 Hz, 1H), <com:Math><semantics>7.72−7.69<annotation encoding="application / x-tex">7.72-7.69< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>4.04−4.02<annotation encoding="application / x-tex">4.04-4.02< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>3.13<annotation encoding="application / x-tex">3.13< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=2.4<annotation encoding="application / x-tex">J = 2.4< / annotation>< / semantics>< / com:Math> Hz, 1H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ:-115.48 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 212.0, 214.0 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of 2-(4-chloro-3-fluorophenyl)-1-(2-methoxybenzyl)-5-methyl-1H- imidazole: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-chloro-3-fluoro-N-(prop-2-yn-1- yl)benzamide (3.5 g, 16.54 mmol) and 2-methoxybenzyl amine (4.54 g, 33.08 mmol) following the experimental procedure described in step-8 of Example-2a. Yield: 1.3 g, (23.7%). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): δ 7.36-7.28 (m, 3H), 7.21-7.17 (m, 1H), 6.99 (brs, 1H), 6.95- 6.88 (m, 2H), 6.56 (d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.11 (s, 2H), 3.87 (s, 3H), 2.13 (s, 3H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ -114.79 LCMS (ESI<com:Sub>+< / com:Sub>, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 330.7, 332.7 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of 2-((2-(4-chloro-3-fluorophenyl)-5-methyl-1H-imidazol-1- yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-(4-chloro-3-fluorophenyl)-1-(2- methoxybenzyl)-5-methyl-1H-imidazole (1.3 g, 3.93 mmol) following the experimental procedure described in step-9 of Example-2a. Yield: 1.1 g, (88.7 %). 5 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 317.0, 319.0 (M+H)<com:Sup>+< / com:Sup>. Step-4: Synthesis of ethyl 6-(2-((2-(4-chloro-3-fluorophenyl)-5-methyl-1H-imidazol-1- yl)methyl)phenoxy)-2,2-dimethylhexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-((2-(4-chloro-3-fluorophenyl)-5-methyl- 1H-imidazol-1-yl)methyl)phenol (0.35 g, 1.11 mmol) and ethyl 6-bromo-2,2- dimethylhexanoate (0.831 g, 3.32 mmol) (procedures for the preparation of which are disclosed in U.S. Application No. 62 / 061,483) following the experimental procedure described in step-10 of Example-2a. Yield: 0.25 g, (46.3%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 486.9, 488.9 (M+H)<com:Sup>+< / com:Sup>. Step-5: Synthesis of 6-(2-((2-(4-chloro-3-fluorophenyl)-5-methyl-1H-imidazol-1- yl)methyl)phenoxy)-2,2-dimethylhexanoic acid (Compound 2i): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from ethyl 6-(2-((2-(4-chloro-3-fluorophenyl)-5- methyl-1H-imidazol-1-yl)methyl)phenoxy)-2,2-dimethylhexanoate (0.25 g, 0.51 mmol) following the experimental procedure described in step-11 of Example-2a and purified by preparative HPLC [Column: Zorbax C18 (21.2 mm x 150 mm, 5µm); Flow: 20 mL / min; mobile phase: A / B = <com:Math><semantics>0.1%<annotation encoding="application / x-tex">0.1\%< / annotation>< / semantics>< / com:Math> TFA in water / MeCN; T / %B = <com:Math><semantics>0 / 20<annotation encoding="application / x-tex">0 / 20< / annotation>< / semantics>< / com:Math>, 2 / 20, 8 / 70]. Yield: 0.070 g (29.8 %) <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>, 80°C): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 12.02 (brs, 1H), 7.59 (t, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.38 (d, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 10.8 Hz, 1H), 7.28-7.24 (m, 2H), 7.05 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.93 (s, 1H), 6.87 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.38 (d, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.15 (s, 2H), 4.02 (t, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.10 (s, 3H), 1.69-1.65 (m, 2H), 1.50-1.46 (m, 2H), 1.41-1.33 (m, 2H), 1.08 (s, 6H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ -110.89 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 459.2, 461.2 (M+H)<com:Sup>+< / com:Sup>. HPLC: 98.95 % (210 nm). Example-2j: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-<com:Math><semantics>(2−((2−(4−chloro−3−fluorophenyl)−5−methyl−1<math>H<annotation encoding="application / x-tex">(2-((2-(4-chloro-3-fluorophenyl)-5-methyl-1H< / annotation>< / semantics>< / com:Math>-imidazol-1- yl)methyl)phenoxy)-3-methylhexanoic acid (Compound 2j): [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of ethyl (R)-6-(2-((2-(4-chloro-3-fluorophenyl)-5-methyl-1H-imidazol-1- yl)methyl)phenoxy)-3-methylhexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-((2-(4-chloro-3-fluorophenyl)-5-methyl- <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>-imidazol-1-yl)methyl)phenol (0.350 g, 1.11 mmol) and ethyl (<com:Math><semantics>R<annotation encoding="application / x-tex">R< / annotation>< / semantics>< / com:Math>)-6-bromo-3- methylhexanoate (0.784 g, 3.32 mmol) following the experimental procedure described in step-10 of Example-2a. Yield: 0.15 g (28.6 %). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 472.9, 474.9 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-<com:Math><semantics>(2−((2−(4−chloro−3−fluorophenyl)−5−methyl−1H−imidazol−1−<annotation encoding="application / x-tex">(2-((2-(4-chloro-3-fluorophenyl)-5-methyl-1H-imidazol-1-< / annotation>< / semantics>< / com:Math> yl)methyl)phenoxy)-3-methylhexanoic acid (Compound 2j): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from ethyl <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-<com:Math><semantics>(2−((2−(4−chloro−3−<annotation encoding="application / x-tex">(2-((2-(4-chloro-3-< / annotation>< / semantics>< / com:Math> fluorophenyl)-5-methyl-1H-imidazol-1-yl)methyl)phenoxy)-3-methylhexanoate (0.15 g, 0.32 mmol) following the experimental procedure described in step-11 of Example-2a. Yield: 0.115 g (81.5 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>, 80°C): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 12.02 (brs, 1H), 7.61 (t, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.43 (d, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 10.8 Hz, 1H), 7.29-7.24 (m, 2H), 7.04 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.99 (s, 1H), 6.86 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.43 (d, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.18 (s, 2H), 4.00 (t, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.23-2.18 (m, 1H), 2.11 (s, 3H), 2.02-1.99 (m, 1H), 1.89-1.80 (m, 1H), 1.75-1.64 (m, 2H), 1.45-1.35 (m, 1H), 1.31- 1.25 (m, 1H), 0.87 (d, <com:Math><semantics>J=6.8<annotation encoding="application / x-tex">J = 6.8< / annotation>< / semantics>< / com:Math> Hz, 3H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> -115.50 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 445.2, 447.2 (M+H)<com:Sup>+< / com:Sup>. HPLC: 97.30 % (210 nm). Example-2k: Synthesis of (R)-6-(4-fluoro-2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1- yl)methyl)phenoxy)-3-methylhexanoic acid (Compound 2k) [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of 1-(5-fluoro-2-methoxybenzyl)-5-methyl-2-(4-(trifluoromethyl) phenyl)- 1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from N-(prop-2-yn-1-yl)-4- (trifluoromethyl)benzamide (1.0 g, 4.39 mmol) and 5-fluoro-2-methoxybenzyl amine (1.36 g, 8.79 mmol) following the experimental procedure described in step-8 of Example-2a. Yield: 0.901 g (56.3 %). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 365.6 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of 4-fluoro-2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1- yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 1-(5-fluoro-2-methoxybenzyl)-5-methyl-2- (4-(trifluoromethyl)phenyl)-1H-imidazole (0.45 g, 1.24 mmol) following the experimental procedure described in step-9 of Example-2a. Yield: 0.3 g (crude). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 350.9 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of ethyl (R)-6-(4-fluoro-2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H- imidazol-1-yl)methyl)phenoxy)-3-methylhexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-fluoro-2-((5-methyl-2-(4- (trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenol (0.3 g, 0.86 mmol) and ethyl (R)- 6-bromo-3-methylhexanoate (0.61 g, 2.57 mmol) following the experimental procedure described in step-10 of Example-2a. Yield: 0.2 g (46.2%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 507.5 (M+H)<com:Sup>+< / com:Sup>. Step-4: Synthesis of (R)-6-(4-fluoro-2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol- 1-yl)methyl)phenoxy)-3-methylhexanoic acid (Compound 2k): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from ethyl (<com:Math><semantics>R<annotation encoding="application / x-tex">R< / annotation>< / semantics>< / com:Math>)-6-(4-fluoro-2-((5-methyl-2-(4- (trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)-3-methylhexanoate (0.1 g, 0.19 mmol) following the experimental procedure described in step-11 of Example-2a. Yield: 0.06 g (63.4 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 12.08 (brs, 1H), 7.76 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.67 (d, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>7.08<annotation encoding="application / x-tex">7.08< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>6.97<annotation encoding="application / x-tex">6.97< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>6.14<annotation encoding="application / x-tex">6.14< / annotation>< / semantics>< / com:Math> (brs, 1H), <com:Math><semantics>5.18<annotation encoding="application / x-tex">5.18< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>3.97<annotation encoding="application / x-tex">3.97< / annotation>< / semantics>< / com:Math> (brs, 2H), 2.25-2.13 (m, 1H), 2.13 (s, 3H), 2.02-1.97 (m, 1H), 1.86-1.82 (m, 1H), 1.75-1.62 (m, 2H), <com:Math><semantics>1.45−1.35<annotation encoding="application / x-tex">1.45-1.35< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>1.29−1.19<annotation encoding="application / x-tex">1.29-1.19< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>0.86<annotation encoding="application / x-tex">0.86< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 3H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> -123.14, -61.17 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 478.8 (M+H)<com:Sup>+< / com:Sup>. HPLC: 94.6 % (210 nm). Example-21: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-<com:Math><semantics>(2−((2−(4−(difluoromethoxy)phenyl)−5−methyl−1H−imidazol−1−<annotation encoding="application / x-tex">(2-((2-(4-(difluoromethoxy)phenyl)-5-methyl-1H-imidazol-1-< / annotation>< / semantics>< / com:Math> yl)methyl)phenoxy)-3-methylhexanoic acid (Compound 21) [Image disponible dans le document PDF, Image available in the PDF document] Scheme: [Image disponible dans le document PDF, Image available in the PDF document] 5 Step-1: Synthesis of 4-(difluoromethoxy)-N-(prop-2-yn-1-yl)benzamide: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-(difluoromethoxy)benzoic acid (2.0 g, 10.63 mmol) and prop-2-yn-1-amine (0.70 g, 12.76 mmol) following the experimental procedure described in step-7 of Example-2a. Yield: 1.61 g (66.9 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.97 (t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 5.1 Hz, 1H), 7.92 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.7 Hz, 2H), 7.36 (t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 73.8 Hz, 1H), 7.26 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.7 Hz, 2H), 4.07-4.04 (m, 2H), 3.14 (t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.4 Hz, 1H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 226.0 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of 1-(2-chlorobenzyl)-2-(4-(difluoromethoxy)phenyl)-5-methyl-1H- imidazole: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-(difluoromethoxy)-N-(prop-2-yn-1- yl)benzamide (1.6 g, 7.10 mmol) and 2-chlorobenzyl amine (2.0 g, 14.21 mmol) following the experimental procedure described in step-8 of Example-2a. Yield: 2.5 g (crude). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 349.3, 351.3 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of 2-(4-(difluoromethoxy)phenyl)-5-methyl-1-(2-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzyl)-1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] In a 100 mL re-sealable reaction tube, 1-(2-chlorobenzyl)-2-(4- (difluoromethoxy)phenyl)-5-methyl-1H-imidazole (1.0 g, 2.86 mmol) and 4,4,4',4',5,5,5',5'- octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.18 g, 8.60 mmol) were dissolved in degassed 1,4- dioxane (10 mL) at RT under nitrogen atmosphere. Pd<com:Sub>2< / com:Sub>(dba)<com:Sub>3< / com:Sub> (0.13 g, 0.14 mmol), Xphos (0.14 g, 0.29 mmol) and KOAc (0.84 g, 8.61 mmol) were added to the above solution under nitrogen atmosphere. The resulting mixture was degassed by purging argon gas for 15 min, and reaction mixture was heated to 90 °C until completion of the reaction (monitored by TLC). The reaction mixture was cooled to RT. The solids were filtered through a Celite® pad and filtrate was washed with water (2 x 20 mL). The organic extract was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and solution was concentrated under reduced pressure. The residue obtained was purified using Combiflash<com:Sup>TM< / com:Sup> MPLC (Silasep<com:Sup>TM< / com:Sup>, gradient elutions 50-60 % EtOAc in hexanes) to give the title compound (0.45 g, 35.7%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 441.2 (M+H)<com:Sup>+< / com:Sup> Step-4: Synthesis of 2-((2-(4-(difluoromethoxy)phenyl)-5-methyl-1H-imidazol-1- yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] In a 100 mL round bottom flask, a solution of 2-(4-(difluoromethoxy)phenyl)-5- methyl-1-(2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1H-imidazole (0.45 g, 1.02 mmol) in THF-H<com:Sub>2< / com:Sub>O (1:1, 10 mL) was treated with NaBO<com:Sub>3< / com:Sub>. 4H<com:Sub>2< / com:Sub>O (0.47 g, 3.07 mmol) at RT. The reaction mixture was stirred at RT for 2 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc. The organic extract was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and solution was concentrated under reduced pressure. The residue obtained was purified using Combiflash MPLC (Silasep<com:Sup>TM< / com:Sup>, gradient elutions, 50-60 % EtOAc in hexanes) to give the title compound (0.33 g, 97.9%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 331.4 (M+H)<com:Sup>+< / com:Sup>. Step-5: Synthesis of ethyl (R)-6-<com:Math><semantics>(2−((2−(4−(difluoromethoxy)phenyl)−5−methyl−1H−imidazol−1−<annotation encoding="application / x-tex">(2-((2-(4-(difluoromethoxy)phenyl)-5-methyl-1H-imidazol-1-< / annotation>< / semantics>< / com:Math> yl)methyl)phenoxy)-3-methylhexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-((2-(4-(difluoromethoxy)phenyl)-5- methyl-1H-imidazol-1-yl)methyl)phenol (0.33 g, 0.99 mmol) and ethyl (R)-6-bromo-3- methylhexanoate (0.71 g, 2.99 mmol) following the experimental procedure described in step-10 of Example-2a. Yield: 0.25 g (51.4%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 487.6 (M+H)<com:Sup>+< / com:Sup>. Step-6: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-<com:Math><semantics>(2−((2−(4−(difluoromethoxy)phenyl)−5−methyl−1H−imidazol−1−<annotation encoding="application / x-tex">(2-((2-(4-(difluoromethoxy)phenyl)-5-methyl-1H-imidazol-1-< / annotation>< / semantics>< / com:Math> yl)methyl)phenoxy)-3-methylhexanoic acid (Compound 21): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from ethyl <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-<com:Math><semantics>(2−(4−<annotation encoding="application / x-tex">(2-(4-< / annotation>< / semantics>< / com:Math> (difluoromethoxy)phenyl)-5-methyl-1H-imidazol-1-yl)methyl)phenoxy)-3-methylhexanoate (0.1 g, 0.19 mmol) following the experimental procedure described in step-11 of Example-2a. Yield: 0.05 g (53.2 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.50 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.8 Hz, 2H), 7.24 (t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.6 Hz, 1H), 7.16 (d, <com:Math><semantics>J=8.8 Hz,2H,7.14 (d, J=74.0 Hz,1H),7.01 (d, J=8.8 Hz,1H),6.87−6.83 (m, 2H),6.46<annotation encoding="application / x-tex">J = 8.8 \text{ Hz}, 2\text{H}, 7.14 \text{ (d, } J = 74.0 \text{ Hz}, 1\text{H}), 7.01 \text{ (d, } J = 8.8 \text{ Hz}, 1\text{H}), 6.87-6.83 \text{ (m, 2H)}, 6.46< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(d,J=7.6 Hz,1H),5.15 (s, 2H),4.01 (t, J=6.4 Hz,2H),2.23−2.18 (m, 1H),2.09 (s, 3H),<annotation encoding="application / x-tex">(d, J = 7.6 \text{ Hz}, 1\text{H}), 5.15 \text{ (s, 2H)}, 4.01 \text{ (t, } J = 6.4 \text{ Hz}, 2\text{H)}, 2.23-2.18 \text{ (m, 1H)}, 2.09 \text{ (s, 3H)},< / annotation>< / semantics>< / com:Math> 2.08-2.02 (m, 1H), 1.93-1.88 (m, 1H), 1.75-1.69 (m, 2H), 1.49-1.43 (m, 1H), 1.33-1.27 (m, 1H), <com:Math><semantics>0.93<annotation encoding="application / x-tex">0.93< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 3H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ -82.36 LCMS (ESI<com:Sub>+< / com:Sub>, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 458.9 (M+H)<com:Sup>+< / com:Sup>. HPLC: 95.49 % (210 nm). Example-2m: <com:Math><semantics>Synthesisof(𝑅)−3−methyl−6−(4−methyl−2−((5−methyl−2−(4−(trifluoromethoxy)phenyl)−1𝐻-<annotation encoding="application / x-tex">Synthesis of \textit{(R)}-3-methyl-6-(4-methyl-2-((5-methyl-2-(4-(trifluoromethoxy)phenyl)-1 \textit{H-}< / annotation>< / semantics>< / com:Math> imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound 2m) [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of 1-(2-methoxy-5-methylbenzyl)-5-methyl-2-(4-(trifluoromethoxy)phenyl)- 1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from N-(prop-2-yn-1-yl)-4- (trifluoromethoxy)benzamide (0.7 g, 2.88 mmol) and 2-methoxy-5-methylbenzyl amine (1.36 g, 8.79 mmol) following the experimental procedure described in step-8 of Example-2a. Yield: 0.35 g (32.3 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.51 (d, <com:Math><semantics>J=6.9<annotation encoding="application / x-tex">J = 6.9< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.17 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.09 (d, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 8.1Hz, 1H), 6.98 (s, 1H), 6.81 (d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.38 (s, 1H), 5.08 (s, 2H), 3.83 (s, 3H), 2.19 (s, 3H), 2.12 (s, 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 377.3 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of 4-methyl-2-((5-methyl-2-(4-(trifluoromethoxy)phenyl)-1H-imidazol-1-yl) methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 1-(2-methoxy-5-methylbenzyl)-5-methyl-2- (4-(trifluoromethoxy)phenyl)-1H-imidazole (0.35 g, 0.93 mmol) following the experimental procedure described in step-9 of Example-2a. Yield: 0.22 g (65.4%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 363.3 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of ethyl <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-methyl-2-<com:Math><semantics>((5<annotation encoding="application / x-tex">((5< / annotation>< / semantics>< / com:Math>-methyl-2-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(trifluoromethoxy))<annotation encoding="application / x-tex">(trifluoromethoxy))< / annotation>< / semantics>< / com:Math> phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-methyl-2-((5-methyl-2-(4- (trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenol (0.1 g, 0.27 mmol) and ethyl <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-bromo-3-methylhexanoate (0.196 g, 0.83 mmol) following the experimental procedure described in step-10 of Example-2a. Yield: 0.14 g (98.5%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 519.0 (M+H)<com:Sup>+< / com:Sup>. Step-4: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-methyl-2-<com:Math><semantics>((5<annotation encoding="application / x-tex">((5< / annotation>< / semantics>< / com:Math>-methyl-2-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(trifluoromethoxy)phenyl)<annotation encoding="application / x-tex">(trifluoromethoxy)phenyl)< / annotation>< / semantics>< / com:Math>- 1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound 2m): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from ethyl <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-methyl-2-<com:Math><semantics>((5<annotation encoding="application / x-tex">((5< / annotation>< / semantics>< / com:Math>- methyl-2-(4-(trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate (0.15 g, 0.29 mmol) following the experimental procedure described in step-11 of Example-2a. Yield: 0.01 g (10.6 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>, 90°C): δ 7.57 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.27 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>6.99(d,J=8.0Hz,1H),6.85−6.82(m,2H),6.36(s,1H),5.09(s,2H),3.89(d,J=4.8Hz,<annotation encoding="application / x-tex">6.99 (d, J = 8.0 Hz, 1H), 6.85-6.82 (m, 2H), 6.36 (s, 1H), 5.09 (s, 2H), 3.89 (d, J = 4.8 Hz,< / annotation>< / semantics>< / com:Math> 2H), 2.09 (s, 6H), 2.08-2.03 (m, 2H), 1.86-1.82 (m, 1H), 1.60-1.59 (m, 2H), 1.38-1.18 (m, 2H), <com:Math><semantics>0.87(d,J=6.4Hz,3H)<annotation encoding="application / x-tex">0.87(d, J = 6.4 Hz, 3H)< / annotation>< / semantics>< / com:Math>. LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 490.8 (M+H)<com:Sup>+< / com:Sup>. HPLC: 95.7 % (210 nm). 5 Example-2n: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(6−(trifluoromethyl)pyridin−3−yl)−1H−)<annotation encoding="application / x-tex">(2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1H-)< / annotation>< / semantics>< / com:Math> imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound 2n). [Image disponible dans le document PDF, Image available in the PDF document] Scheme: [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of N-(prop-2-yn-1-yl)-6-(trifluoromethyl)nicotinamide: [Image disponible dans le document PDF, Image available in the PDF document] In a 100 mL round bottom flask, a stirred solution of 6-(trifluoromethyl)nicotinic acid (3 g, 15.70 mmol) and prop-2-yn-1-amine (1.05 g, 18.84 mmol) in DMF (50 mL) was treated with HATU (7.2 g, 18.84 mmol) and Et<com:Sub>3< / com:Sub>N (3.1 mL, 23.55 mmol) at RT under nitrogen atmosphere. The resulting reaction mixture was stirred at RT for 3 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with cold water and solid precipitated was filtered, washed with water and dried under reduced pressure to get the title compound (2.6 g, 72.6 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.08 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.1 Hz, 1H), 8.32 (dd, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4, 2.4 Hz, 1H), 7.78 <com:Math><semantics>(d,J=7.8 Hz,1H),6.62 (brs, 1H),4.30−4.28 (m, 2H),2.33 (t, J=2.4 Hz,1H).<annotation encoding="application / x-tex">(d, J = 7.8 \text{ Hz}, 1\text{H}), 6.62 \text{ (brs, 1H)}, 4.30-4.28 \text{ (m, 2H)}, 2.33 \text{ (t, } J = 2.4 \text{ Hz}, 1\text{H)}.< / annotation>< / semantics>< / com:Math> LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 229.2 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of 5-(1-(2-methoxybenzyl)-5-methyl-1H-imidazol-2-yl)-2-(trifluoromethyl) pyridine: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from N-(prop-2-yn-1-yl)-6- (trifluoromethyl)nicotinamide (1.0 g, 4.38 mmol) and 2-methoxyphenybenzyl amine (1.2 g, 8.77 mmol) following the experimental procedure described in step-8 of Example-2a. Yield: 0.8 g (52.6 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.79 (s, 1H), 8.07 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.1 Hz, 1H), 7.68 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.1 Hz, 1H), 7.31 (t, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.09 (s, 1H), 6.94-6.87 (m, 2H), 6.56 (d, <com:Math><semantics>J=7.5<annotation encoding="application / x-tex">J = 7.5< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.16 (s, 2H), 3.87 (s, 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 348.3 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of 2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1H-imidazol-1-yl) methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from <com:Math><semantics>5−(1−(2−methoxybenzyl)−5−methyl−1H−<annotation encoding="application / x-tex">5-(1-(2-\text{methoxybenzyl})-5-\text{methyl}-1H-< / annotation>< / semantics>< / com:Math> imidazol-2-yl)-2-(trifluoromethyl)pyridine (0.8 g, 2.31 mmol) following the experimental procedure described in step-9 of Example-2a. Yield: 0.5 g (65.1 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.92 (s, 1H), 8.83 (s, 1H), 8.12 (d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.94 <com:Math><semantics>(d,J=8.1 Hz,1H),7.12(d,J=6.9 Hz,1H),7.02(s,1H),6.87(d,J=7.8 Hz1H),6.73(t,J=7.8 Hz)<annotation encoding="application / x-tex">(d, J = 8.1 \text{ Hz}, 1\text{H}), 7.12 (d, J = 6.9 \text{ Hz}, 1\text{H}), 7.02 (s, 1\text{H}), 6.87 (d, J = 7.8 \text{ Hz} 1\text{H}), 6.73 (t, J = 7.8 \text{ Hz})< / annotation>< / semantics>< / com:Math> 7.2 Hz, 1H), 6.37 (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.20 (s, 2H), 2.15 (s, 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 334.3 (M+H)<com:Sup>+< / com:Sup>. Step-4: Synthesis of ethyl <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2<annotation encoding="application / x-tex">(2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>((5<annotation encoding="application / x-tex">((5< / annotation>< / semantics>< / com:Math>-methyl-2-<com:Math><semantics>(6<annotation encoding="application / x-tex">(6< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(trifluoromethyl)pyridin−3−yl)−<annotation encoding="application / x-tex">(trifluoromethyl)pyridin-3-yl)-< / annotation>< / semantics>< / com:Math> 1H-imidazol-1-yl)methyl)phenoxy)hexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-((5-methyl-2-(6-(trifluoromethyl)pyridin- <com:Math><semantics>3−yl<annotation encoding="application / x-tex">3-yl< / annotation>< / semantics>< / com:Math>)-<com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>-imidazol-<com:Math><semantics>1−yl<annotation encoding="application / x-tex">1-yl< / annotation>< / semantics>< / com:Math>)methyl)phenol (0.5 g, 1.50 mmol) and ethyl (R)-<com:Math><semantics>6<annotation encoding="application / x-tex">6< / annotation>< / semantics>< / com:Math>-bromo-<com:Math><semantics>3<annotation encoding="application / x-tex">3< / annotation>< / semantics>< / com:Math>- methylhexanoate (0.710 g, 3.00 mmol) following the experimental procedure described in step-1 of Example-2c. Yield: 0.45 g (61.3%). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 491.0 (M+H)<com:Sup>+< / com:Sup>. Step-5: Synthesis of (R)-3-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(6−(trifluoromethyl)pyridin−3−yl)−1H−<annotation encoding="application / x-tex">(2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1H-< / annotation>< / semantics>< / com:Math> imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound 2n): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from ethyl <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(6−methyl−2−(6−methyl−2−(6−methyl−2−(6−methyl−2−(6−methyl−2−(6−methyl−2−(6−methyl−2−(6−methyl−2−(6−methyl−2−(6−methyl−2−(6−methyl−2−(6−methyl<annotation encoding="application / x-tex">(2-((5-methyl-2-(6-methyl-2-(6-methyl-2-(6-methyl-2-(6-methyl-2-(6-methyl-2-(6-methyl-2-(6-methyl-2-(6-methyl-2-(6-methyl-2-(6-methyl-2-(6-methyl-2-(6-methyl< / annotation>< / semantics>< / com:Math> (trifluoromethyl)pyridin-3-yl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate (0.45 g, 0.92 mmol) following the experimental procedure described in step-11 of Example-2a. Yield: 0.166 g (39.2 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>11.96 (brs, 1H), 8.79 (s, 1H), 8.05 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.0 Hz, 1H), 7.90 <com:Math><semantics>(d,J=8.0 Hz,1H),7.24(t,J=7.6 Hz,1H),7.02(d,J=8.4 Hz,1H),7.00(s,1H),6.84(t,J=8.4 Hz,1H),7.00(s,1H),6.84(t,J=8.4 Hz,1H),7.00(s,1H),6.84(t,<annotation encoding="application / x-tex">(d, J = 8.0 \text{ Hz}, 1\text{H}), 7.24 (t, J = 7.6 \text{ Hz}, 1\text{H}), 7.02 (d, J = 8.4 \text{ Hz}, 1\text{H}), 7.00 (s, 1\text{H}), 6.84 (t, J = 8.4 \text{ Hz}, 1\text{H}), 7.00 (s, 1\text{H}), 6.84 (t, J = 8.4 \text{ Hz}, 1\text{H}), 7.00 (s, 1\text{H}), 6.84 (t,< / annotation>< / semantics>< / com:Math> 7.6 Hz, 1H), 6.43 (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.21 (s, 2H), 3.98 (t, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.19-2.14 (m, 1H), 2.13 (s, 3H), 2.03-1.94 (m, 1H), 1.85-1.80 (m, 1H), 1.68-1.66 (m, 2H), 1.38-1.36 (m, 1H), 1.28-1.18 (m, 1H), 0.85 (d, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 3H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ -66.46 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 462.3 (M+H)<com:Sup>+< / com:Sup>. HPLC: 95.11 % (210 nm). Preparation of Meglumine Salt of Compound 2n Two separate methods were used to generate a meglumine salt of compound <com:Math><semantics>2n<annotation encoding="application / x-tex">2n< / annotation>< / semantics>< / com:Math>. Method 1 Compound 2n (102.7 mg) was combined with meglumine (43.7 mg) and 2 mL of 2- propanol in a 4 mL glass vial. The vial was sealed with a cap and the contents were subjected to sonication at 25 °C for 20 minutes followed by stirring at 50 °C for 60 minutes. The vial was then moved to a new stir plate and the slurry in the vial was stirred at 25 °C. Method 2 Compound 2n (102.2 mg) was combined with meglumine (43.2 mg) and 2 mL of acetonitrile in a 4 mL glass vial. The vial was sealed with a cap and the contents were subjected to sonication at 25 °C for 20 minutes followed by stirring at 50 °C for 60 minutes. The vial was then moved to a new stir plate and the slurry in the vial was stirred at 25 °C. For both method 1 and method 2, after 2 days of stirring at 25 °C, both samples were centrifuged, supernatants discarded, and solids were air dried. Preparation of Hydrate of Meglumine Salt of Compound 2n In a 500 mL round bottom flask, a stirred solution of <com:Math><semantics>((R)−3−methyl−6−(2−((5−methyl−4)−4)))<annotation encoding="application / x-tex">((R)-3-methyl-6-(2-((5-methyl-4)-4)))< / annotation>< / semantics>< / com:Math> 2-(6-(trifluoromethyl) pyridin-3-yl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid (20 g, 43.33 mmol) in THF (100 mL) and water (100 mL) was treated meglumine (8.45 g, 43.33 mmol) at 0°C. The resulting reaction mixture was stirred at RT for 6 h. The reaction mixture was concentrated under reduced pressure and solid obtained was dried under reduced pressure (3h) to afford the title compound as a white solid (28.5 g, 98.95%). <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.75 (s, 1H), 8.02 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 1H), 7.82 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.0 Hz 1H), 7.26 (t, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.03 (s, 1H), 6.99 (d, <com:Math><semantics>J=8<annotation encoding="application / x-tex">J = 8< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.85 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.50 (d, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.25 (s, 2H), 4.09-3.99 (m, 3H), 3.97-3.77 (m, 2H), 3.74-3.61 (m, 3H), 3.29-3.06 (m, 2H), 2.64 (s, 3H), 2.22 (s, 3H), 2.18-2.14 (m, 1H), 1.99 - 1.94 (m, 2H), <com:Math><semantics>1.83−1.75<annotation encoding="application / x-tex">1.83 - 1.75< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>1.51−1.38<annotation encoding="application / x-tex">1.51 - 1.38< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>1.32−1.22<annotation encoding="application / x-tex">1.32 - 1.22< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>0.86<annotation encoding="application / x-tex">0.86< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 3H). <com:Sup>19< / com:Sup>F NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> -69.39 Elemental Analysis: Calcd for <com:Math><semantics>C31H43F3N4O8<annotation encoding="application / x-tex">C_{31}H_{43}F_3N_4O_8< / annotation>< / semantics>< / com:Math>. <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>: C, 55.18; H, 6.72; N, 8.30. Found: C, 54.95; H, 6.89; N, 8.07 Moisture Content (Karl Fischer): 2.33% Example-20: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-6-<com:Math><semantics>(2−((2−(4−(difluoromethyl)phenyl)−5−methyl−1<math>H<annotation encoding="application / x-tex">(2-((2-(4-(difluoromethyl)phenyl)-5-methyl-1H< / annotation>< / semantics>< / com:Math>-imidazol-1-yl)methyl) phenoxy)-3-methylhexanoic acid (Compound 20) [Image disponible dans le document PDF, Image available in the PDF document] 5 Scheme: [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of 4-(difluoromethyl)-N-(prop-2-yn-1-yl)benzamide: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-(difluoromethyl)benzoic acid (2.0 g, 11.61 mmol) and prop-2-yn-1-amine (0.77 g, 13.94 mmol) following the experimental procedure described in step-7 of Example-2a. Yield: 1.5 g (62.5 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.88 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.60 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 2H), 6.70 (t, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 56.0 Hz, 1H), 6.47 (brs, 1H), 4.29-4.27 (m, 2H), 2.31 (t, <com:Math><semantics>J=2.4<annotation encoding="application / x-tex">J = 2.4< / annotation>< / semantics>< / com:Math> Hz, 1H). Step-2: Synthesis of 1-(2-bromobenzyl)-2-(4-(difluoromethyl)phenyl)-5-methyl-1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-(difluoromethyl)-N-(prop-2-yn-1- yl)benzamide (3.0 g, 14.44 mmol) and 2-bromobenzyl amine (5.4 g, 28.88 mmol) following the experimental procedure described in step-8 of Example-2a. Yield: 2.3 g (43.3 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.65 (dd, <com:Math><semantics>J=7.8<annotation encoding="application / x-tex">J = 7.8< / annotation>< / semantics>< / com:Math>, 1.2 Hz, 1H), 7.55-7.48 (m, 4H), 7.32-7.19 <com:Math><semantics>(m,2H),7.04(m,1H),6.64(t,J=56.0Hz,1H),6.63−6.62(m,1H),5.16(s,2H),2.13(s,2H)<annotation encoding="application / x-tex">(m, 2H), 7.04 (m, 1H), 6.64 (t, J = 56.0 Hz, 1H), 6.63-6.62 (m, 1H), 5.16 (s, 2H), 2.13 (s, 2H)< / annotation>< / semantics>< / com:Math> 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 376.8, 378.8 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of 2-(4-(difluoromethyl)phenyl)-5-methyl-1-(2-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzyl)-1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 1-(2-bromobenzyl)-2-(4- (difluoromethyl)phenyl)-5-methyl-1H-imidazole (0.5 g, 1.32 mmol) following the experimental procedure described in step-3 of Example-21. Yield: 0.18 g (32.2 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.92 (dd, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math>, 1.5 Hz, 1H), 7.59 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.46 <com:Math><semantics>(d,J=8.1 Hz,2H),7.42−7.36 (m, 1H),7.32−7.26 (m, 1H),7.02 (bs, 1H),6.75 (d, J=7.8 Hz,<annotation encoding="application / x-tex">(d, J = 8.1 \text{ Hz}, 2H), 7.42-7.36 \text{ (m, 1H)}, 7.32-7.26 \text{ (m, 1H)}, 7.02 \text{ (bs, 1H)}, 6.75 \text{ (d, } J = 7.8 \text{ Hz},< / annotation>< / semantics>< / com:Math> 1H), 6.62 (t, <com:Math><semantics>J=56.1<annotation encoding="application / x-tex">J = 56.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.48 (s, 2H), 2.11 (s, 3H), 1.31-1.23 (s, 12). <com:Sup>19< / com:Sup>F NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> -111.02 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 424.0 (M+H)<com:Sup>+< / com:Sup>. Step-4: Synthesis of 2-((2-(4-(difluoromethyl)phenyl)-5-methyl-1H-imidazol-1- yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-(4-(difluoromethyl)phenyl)-5-methyl-1- (2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1H-imidazole (0.18 g, 0.424 mmol) following the experimental procedure described in step-4 of Example-21. Yield: 0.12 g (44.4 %). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 314.7 (M+H)<com:Sup>+< / com:Sup>. Step-5: Synthesis of ethyl (R)-6-(2-((2-(4-(difluoromethyl)phenyl)-5-methyl-1H-imidazol-1- yl)methyl)phenoxy)-3-methylhexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-((2-(4-(difluoromethyl)phenyl)-5-methyl- 1H-imidazol-1-yl)methyl)phenol (0.11 g, 1.5 mmol) and ethyl (R)-6-bromo-3- methylhexanoate (0.25 g, 1.05 mmol) following the experimental procedure described in step-1 of Example-2c. Yield: 0.13 g (crude). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 471.1 (M+H)<com:Sup>+< / com:Sup>. Step-6: Synthesis of (R)-6-(2-((2-(4-(difluoromethyl)phenyl)-5-methyl-1H-imidazol-1- yl)methyl)phenoxy)-3-methylhexanoic acid (Compound 20): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from ethyl (<com:Math><semantics>R<annotation encoding="application / x-tex">R< / annotation>< / semantics>< / com:Math>)-6-(2-((2-(4- (difluoromethyl)phenyl)-5-methyl-1H-imidazol-1-yl)methyl)phenoxy)-3-methylhexanoate (0.30 g, 0.638 mmol) following the experimental procedure described in step-11 of Example- 2a. Yield: 0.091 g (32.3 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ 12.03 (s, 1H), 7.57 (bs, 4H), 7.26-7.23 (m, 1H), 7.04-7.01 (m, 1H), <com:Math><semantics>7.02<annotation encoding="application / x-tex">7.02< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=56.0<annotation encoding="application / x-tex">J = 56.0< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>6.93<annotation encoding="application / x-tex">6.93< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>6.90−6.84<annotation encoding="application / x-tex">6.90-6.84< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>6.39−6.37<annotation encoding="application / x-tex">6.39-6.37< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>5.16<annotation encoding="application / x-tex">5.16< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(s,2H),3.99(t,J=6.4Hz,2H),2.19−2.17(m,1H),2.09(s,3H),2.02−1.97(m,1H),1.86−1.00(s,2H),3.99(t,J=6.4Hz,2H),2.19−2.17(m,1H),2.09(s,3H),2.02−1.97(m,1H),1.86−1.00(s,2H),2.19−2.17(m,2H)<annotation encoding="application / x-tex">(s, 2H), 3.99 (t, J = 6.4 Hz, 2H), 2.19-2.17 (m, 1H), 2.09 (s, 3H), 2.02-1.97 (m, 1H), 1.86-1.00 (s, 2H), 3.99 (t, J = 6.4 Hz, 2H), 2.19-2.17 (m, 1H), 2.09 (s, 3H), 2.02-1.97 (m, 1H), 1.86-1.00 (s, 2H), 2.19-2.17 (m, 2H)< / annotation>< / semantics>< / com:Math> 1.84 (m, 1H), 1.70-1.62 (m, 2H), 1.45-1.42 (m, 1H), 1.28-1.18 (m, 1H), 0.87 (d, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 2H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> -110.00 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 443.0 (M+H)<com:Sup>+< / com:Sup>. HPLC: 95.65 % (210 nm). Example-2p: Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(4−(methylthio)phenyl)−1H−imidazol−1−<annotation encoding="application / x-tex">(2-((5-methyl-2-(4-(methylthio)phenyl)-1H-imidazol-1-< / annotation>< / semantics>< / com:Math> yl)methyl)phenoxy)hexanoic acid (Compound 2p) [Image disponible dans le document PDF, Image available in the PDF document] Scheme: [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of 4-(methylthio)-N-(prop-2-yn-1-yl)benzamide: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-(methylthio)benzoic acid (12.0 g, 58.53 mmol) and prop-2-yn-1-amine (5.89 g, 107.14 mmol) following the experimental procedure described in step-7 of Example-2a. Yield: 13.81 g (94.5 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.70 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.26 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 6.32 (brs, 1H), <com:Math><semantics>4.26−4.24<annotation encoding="application / x-tex">4.26-4.24< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>2.51<annotation encoding="application / x-tex">2.51< / annotation>< / semantics>< / com:Math> (s, 3H), <com:Math><semantics>2.29<annotation encoding="application / x-tex">2.29< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=2.7<annotation encoding="application / x-tex">J = 2.7< / annotation>< / semantics>< / com:Math> Hz, 1H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 206.3 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of 1-(2-bromobenzyl)-5-methyl-2-(4-(methylthio)phenyl)-1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 4-(methylthio)-N-(prop-2-yn-1- yl)benzamide (3.0 g, 14.63 mmol) and 2-bromobenzyl amine, (4.0 g, 21.95 mmol) following the experimental procedure described in step-8 of Example-2a. Yield: 4.38 g (80.3 %). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 372.9, 374.9 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of 5-methyl-2-(4-(methylthio)phenyl)-1-(2-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzyl)-1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 1-(2-bromobenzyl)-5-methyl-2-(4- (methylthio)phenyl)-1H-imidazole (1.5 g, 4.02 mmol) and 4,4,4',4',5,5,5',5'-octamethyl- 2,2'-bi(1,3,2-dioxaborolane) (1.22 g, 4.82 mmol) following the experimental procedure described in step-3 of Example-21. Yield: 2.1g LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 421.2 (M+H)<com:Sup>+< / com:Sup> Step-4: Synthesis of 2-((5-methyl-2-(4-(methylthio)phenyl)-1H-imidazol-1-yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 5-methyl-2-(4-(methylthio)phenyl)-1-(2- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1H-imidazole (1.0 g, 2.38 mmol) following the experimental procedure described in step-4 of Example-21. Yield: 0.530 g. LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 311.4 (M+H)<com:Sup>+< / com:Sup>. Step-5: Synthesis of ethyl (R)-3-methyl-6-(2-((5-methyl-2-(4-(methylthio)phenyl)-1H- imidazol-1-yl)methyl)phenoxy)hexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-((5-methyl-2-(4-(methylthio)phenyl)-1H- imidazol-1-yl)methyl)phenol (0.3 g, 0.96 mmol) and ethyl (R)-6-bromo-3-methylhexanoate (0.685 g, 2.90 mmol) following the experimental procedure described in step-1 of Example- 2c. Yield: 0.43 g LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 467.3 (M+H)<com:Sup>+< / com:Sup>. Step-6: Synthesis of (R)-3-methyl-6-(2-((5-methyl-2-(4-(methylthio)phenyl)-1H-imidazol-1- yl)methyl)phenoxy)hexanoic acid (Compound 2p): [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from ethyl (<com:Math><semantics>R<annotation encoding="application / x-tex">R< / annotation>< / semantics>< / com:Math>)-3-methyl-6-(2-((5-methyl-2-(4- (methylthio)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate (0.310 g, 0.66 mmol) following the experimental procedure described in step-11 of Example-2a. Yield: 0.075 g (25.7%). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>, 90 °C): δ 7.38 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.26–7.22 (m, 3H), 7.02 <com:Math><semantics>(d,J=8.4 Hz,1H),6.88−6.84 (m, 2H),6.42 (d, J=7.6 Hz,1H),5.14 (s, 2H),4.03 (t, J=6.4 Hz)<annotation encoding="application / x-tex">(d, J = 8.4 \text{ Hz}, 1\text{H}), 6.88-6.84 \text{ (m, 2H)}, 6.42 \text{ (d, } J = 7.6 \text{ Hz}, 1\text{H)}, 5.14 \text{ (s, 2H)}, 4.03 \text{ (t, } J = 6.4 \text{ Hz})< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.47 (s, 3H), 2.24-2.18 (m, 1H), 2.06 (s, 3H), 2.04 -1.99 (m, 1H), 1.92-1.89 (m, 1H), <com:Math><semantics>1.76−1.70<annotation encoding="application / x-tex">1.76-1.70< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>1.49−1.43<annotation encoding="application / x-tex">1.49-1.43< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>1.35−1.26<annotation encoding="application / x-tex">1.35-1.26< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>0.92<annotation encoding="application / x-tex">0.92< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.8<annotation encoding="application / x-tex">J = 6.8< / annotation>< / semantics>< / com:Math> Hz, 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 439.0 (M+H)<com:Sup>+< / com:Sup>. HPLC: 98.5% (210 nm). Example-2q: Synthesis of 2, 2-dimethyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1- yl)methyl)phenoxy)hexanoic acid (Compound 2q) [Image disponible dans le document PDF, Image available in the PDF document] Scheme: [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of ethyl 2,2-dimethyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H- imidazol-1-yl)methyl)phenoxy)hexanoate: [Image disponible dans le document PDF, Image available in the PDF document] The title compound was synthesized from 2-((5-methyl-2-(4-(trifluoromethyl)phenyl)- 1H-imidazol-1-yl)methyl)phenol (0.25 g, 0.75 mmol) and ethyl 6-bromo-2,2- dimethylhexanoate (0.6 g, 2.25 mmol) following the experimental procedure described in step-1 of example-2c. Yield: 0.121 g. LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 502.7 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of 2, 2-dimethyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H- imidazol-1-yl)methyl)phenoxy)hexanoic acid [Image disponible dans le document PDF, Image available in the PDF document] • The title compound was synthesized from ethyl 2, 2-dimethyl-6-(2-((5-methyl-2-(4- (trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate (0.12 g, 0.24 mmol) following the experimental procedure described in step-11 of Example 2a. Yield: 0.04 g (35.0%) <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.71-7.66 (m, 4H), 7.26-7.22 (m, 1H), 7.02 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.0 Hz, 1H), 6.94 (s, 1H), 6.86 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.45 (d, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.20 (s, 2H), 4.03 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.94 (s, 1H), 5.20 (s, 2H), 4.03 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.94 (s, 1H), 5.20 (s, 2H), 4.03 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> H 6.4 Hz, 2H), 2.12 (s, 3H), 1.71-1.54 (m, 2H), 1.52-1.49 (m, 2H), 1.41-1.34 (m, 2H), 1.07 (s, 6H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ -61.16 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 474.8 (M+H)<com:Sup>+< / com:Sup>. HPLC: 98.49 % (210 nm). Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2−((5−(methyl−d3)−2−(4−(trifluoromethyl)phenyl)−1H−<annotation encoding="application / x-tex">(2-((5-(methyl-d_3)-2-(4-(trifluoromethyl)phenyl)-1H-< / annotation>< / semantics>< / com:Math> imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound 2r) [Image disponible dans le document PDF, Image available in the PDF document] Scheme 1: [Image disponible dans le document PDF, Image available in the PDF document] Scheme 2: [Image disponible dans le document PDF, Image available in the PDF document] 5 Step-1: Synthesis of 2-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] In a 250 mL round bottom flask, a stirred solution 4-(trifluoromethyl)benzaldehyde (5.0 g, 27.17 mmol) and ethane-1,2-diamine (1.80 g, 29.89 mmol) in <com:Sup>t< / com:Sup>BuOH (80 mL) was treated with iodine (8.60 g, 33.96 mmol) and K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (11.30 g, 81.51 mmol) at RT. The reaction mixture was heated at 85°C for 3 h under nitrogen atmosphere. Upon completion of reaction (TLC), the reaction mixture was quenched with saturated Na<com:Sub>2< / com:Sub>S<com:Sub>2< / com:Sub>O<com:Sub>3< / com:Sub> solution and extracted with ethyl acetate (100 mL x 3). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to get desired product as a yellow solid, which was taken to next step without any purification (5.1 g, 83.1 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.02 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.1 Hz, 2H), 7.81 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.1 Hz, 2H), 3.64 (s, 4H). <com:Sup>19< / com:Sup>F NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>) : δ -66.22 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 215.2 (M+H)<com:Sup>+< / com:Sup>. HPLC (210 nm): 90.59% Step-2: Synthesis of 2-(4-(trifluoromethyl)phenyl)-1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] In a 250 mL round bottom flask, a stirred solution 2-(4-(trifluoromethyl)phenyl)-4,5- dihydro-1H-imidazole (5.0 g, 23.36 mmol) in DMSO (80 mL) was treated with K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (3.55 g, 25.7 mmol) and (diacetoxyiodo)benzene (8.30 g, 25.7 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 12 h under nitrogen atmosphere. Upon completion of reaction (TLC), the reaction mixture was diluted with ice cold water and extracted with ethyl acetate (100 mL x 3). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (elution, 40% EtOAc in hexanes) to afford the title compound as a yellow solid (2.70 g, 54.7%) <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 12.81 (brs, 1H), 8.14 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.8 Hz, 2H), 7.81 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.8 Hz, 2H), 7.23 (s, 2H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) : δ -60.98 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 213.0 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of 1-(2-methoxybenzyl)-2-(4-(trifluoromethyl)phenyl)-1H-imidazole: [Image disponible dans le document PDF, Image available in the PDF document] In a 250 mL round bottom flask, a stirred solution 2-(4-(trifluoromethyl)phenyl)-1H- imidazole (6.5 g, 30.66 mmol) in DMF (70 mL) was treated with NaH (60% dispersion, 1.41 g, 36.79 mmol) at 0°C and stirred for 30 min at same temperature under nitrogen atmosphere. After 30 min, the mixture was treated with 2-methoxybenzyl bromide (7.40 g, 36.79 mmol) and reaction mixture was stirred at RT for 4 h under nitrogen atmosphere. Upon completion of reaction (TLC), the reaction mixture was quenched with saturated NH<com:Sub>4< / com:Sub>Cl solution and extracted with ethyl acetate (100 mL x 3). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (elution, 20% EtOAc in hexanes) to afford the title compound as a colorless solid (8 g, 82.5%) <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ 7.80 (brs, 4H), 7.30-7.26 (m, 2H), 7.10 (s, 1H), 7.01 (d, J <com:Math><semantics>=8.1 Hz,1H,6.89 (t, J=6.9 Hz,1H)6.75 (dd, J=7.5,1.8 Hz,1H),5.29 (s, 2H),3.68 (s, 2H)<annotation encoding="application / x-tex">= 8.1 \text{ Hz}, 1\text{H}, 6.89 \text{ (t, } J = 6.9 \text{ Hz}, 1\text{H}) 6.75 \text{ (dd, } J = 7.5, 1.8 \text{ Hz}, 1\text{H}), 5.29 \text{ (s, 2H)}, 3.68 \text{ (s, 2H)}< / annotation>< / semantics>< / com:Math> 3H). <com:Sup>19< / com:Sup>F NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>) : δ -61.10 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 333.2 (M+H)<com:Sup>+< / com:Sup>. Step-4: Synthesis of 5-bromo-1-(2-methoxybenzyl)-2-(4-(trifluoromethyl)phenyl)-1H- imidazole: [Image disponible dans le document PDF, Image available in the PDF document] In a 50 mL round bottom flask, a stirred solution of 1-(2-methoxybenzyl)-2-(4- (trifluoromethyl)phenyl)-1H-imidazole (1 g, 3.01 mmol) in DMF (10 mL) was treated with a NBS (0.643 g, 3.61 mmol) at RT under nitrogen atmosphere. The reaction mixture was strirred at 45°C for 3 h. The reaction mixture was quenched with ice water and extracted with ethyl acetate (30 mL X 2). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (gradient elution, 5 % EtOAc in hexanes) to afford the title compound as a white solid (0.4 g, 33.4 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>): δ 7.59 (s, 4H), 7.33 - 7.29 (m, 1H), 7.27 (s, 1H), 6.93 - 6.90 (m, 2H), <com:Math><semantics>6.62<annotation encoding="application / x-tex">6.62< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>5.24<annotation encoding="application / x-tex">5.24< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>3.85<annotation encoding="application / x-tex">3.85< / annotation>< / semantics>< / com:Math> (s, 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 410.5 (M+H)<com:Sup>+< / com:Sup>. Step-5: Synthesis of 1-(2-methoxybenzyl)-5-(methyl-<com:Math><semantics>d3<annotation encoding="application / x-tex">d_3< / annotation>< / semantics>< / com:Math>)-2-(4-(trifluoromethyl)phenyl)-1H- imidazole: [Image disponible dans le document PDF, Image available in the PDF document] In a 20 mL re-sealable reaction tube, a solution of ZnCl<com:Sub>2< / com:Sub> (0.5 M in THF, 820 mg, 12.0 mL, 6.0 mmol) in THF (5 mL) was treated with CD<com:Sub>3< / com:Sub>MgI (1 M in diethyl ether, 890 mg, 5.3 ml, 5.0 mmol,) dropwise at RT under nitrogen atmosphere. The mixture was stirred at RT for 1 h and treated with 5-bromo-1-(2-methoxybenzyl)-2-(4-(trifluoromethyl)phenyl)-1H- imidazole (100 mg, 0.2 mmol) and Ni(PPh<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>Cl<com:Sub>2< / com:Sub> (8 mg, 0.01 mmol) at same temperature under nitrogen atmosphere. The resulting reaction mixture was stirred at RT for 48h under nitrogen atmosphere. Upon completion of reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and extracted with EtOAc (10 mL x 2). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (gradient elution, 50 % EtOAc in hexanes) to afford the title compound (20 mg) contaminated with debrominated starting material LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 350.1 (M+H)<com:Sup>+< / com:Sup>. Step-6: Synthesis of 2-<com:Math><semantics>((5−(methyl−d3)−2−(4−(trifluoromethyl)phenyl)−1H−imidazol−1−<annotation encoding="application / x-tex">((5-(methyl-d_3)-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-< / annotation>< / semantics>< / com:Math> yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] In a 10 mL round bottom flask, a solution of 1-(2-methoxybenzyl)-5-(methyl-d<com:Sub>3< / com:Sub>)-2- (4-(trifluoromethyl)phenyl)-1H-imidazole (20 mg) in DCM (2 mL) was treated with neat BBr<com:Sub>3< / com:Sub> (0.1 mL) dropwise at -78°C under nitrogen atmosphere. The reaction mixture was stirred at RT for 3 h. Upon completion of reaction (monitored by TLC), the reaction mixture was basified (pH ~ 9) with aqueous NaHCO<com:Sub>3< / com:Sub> and solid obtained was filtered and washed with n-hexane (3 x 5 mL). The solid product was dried under reduced pressure to afford the title compound (12 mg). The crude material was used in next step without further purification. LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 336.3 (M+H)<com:Sup>+< / com:Sup>. Step-7: Synthesis of ethyl <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2−((5−(methyl−d3)−2−(4−(trifluoromethyl)phenyl)−<annotation encoding="application / x-tex">(2-((5-(methyl-d_3)-2-(4-(trifluoromethyl)phenyl)-< / annotation>< / semantics>< / com:Math> 1H-imidazol-1-yl)methyl)phenoxy)hexanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 25 mL round bottom flask, a stirred solution of 2-((5-(methyl-d<com:Sub>3< / com:Sub>)-2-(4- (trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenol (150 mg, 0.44 mmol) in toluene (3 mL) was treated sequentially with DIAD (135 mg, 0.67 mmol) and PPh<com:Sub>3< / com:Sub> (175 mg, 0.67 mmol) at RT under nitrogen atmosphere. The resulting mixture was stirred at RT for 15 min and treated with ethyl (<com:Math><semantics>R<annotation encoding="application / x-tex">R< / annotation>< / semantics>< / com:Math>)-6-bromo-3-methylhexanoate (93 mg, 0.53 mmol) under nitrogen atmosphere. The reaction mixture was gradually warmed to 65°C and stirred at same temperature for 12 h. Upon completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT and quenched with ice cold water before extracting with n-hexane (50 mL). The organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was filtered through by silica gel column (gradient elution, 5-10% EtOAc in hexanes) to afford the title compound (200 mg). The material was used in next step without further purification LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 492.4 (M+H)<com:Sup>+< / com:Sup>. Step-8: Synthesis of (R)-3-methyl-6-<com:Math><semantics>(2−((5−(methyl−d3)−2−(4−(trifluoromethyl)phenyl)−1H−<annotation encoding="application / x-tex">(2-((5-(methyl-d_3)-2-(4-(trifluoromethyl)phenyl)-1H-< / annotation>< / semantics>< / com:Math> imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound 2r): [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL round bottom flask, a stirred solution of ethyl (R)-3-methyl-6-(2-((5- (methyl-d<com:Sub>3< / com:Sub>)-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate (1.0) g, 2.03 mmol) in THF (10 mL), MeOH (10 mL) and water (10 mL), was treated with lithium hydroxide monohydrate (853 mg, 20.3 mmol) at RT. The reaction mixture was stirred at RT for 16 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water and washed with diethyl ether. The aqueous layer was neutralized with 1N HCl and solid obtained was filtered to obtain residue (400 mg). The residue was purified twice using preparative HPLC [Column: WATERS X BRIDGE C18 (150 mm x 21.20 mm, 5.0µ), flow: 15.0 mL / min, mobile phase: A= water, B= MeCN, T / %B = 0 / 30, 3 / 40, 10 / 90] to yield the title compound (40 mg). <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 12.00 (br s, 1H), 7.74 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.65 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>7.28−7.23<annotation encoding="application / x-tex">7.28 - 7.23< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>7.04<annotation encoding="application / x-tex">7.04< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>6.95<annotation encoding="application / x-tex">6.95< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>6.89−6.84<annotation encoding="application / x-tex">6.89 - 6.84< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>6.40<annotation encoding="application / x-tex">6.40< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(d,J=7.5 Hz,1H),5.18 (s, 2H),4.01 (t, J=6.6 Hz,2H),2.27−2.16 (m, 1H),2.03−1.95 (m, 2H)<annotation encoding="application / x-tex">(d, J = 7.5 \text{ Hz}, 1\text{H}), 5.18 \text{ (s, 2H)}, 4.01 \text{ (t, } J = 6.6 \text{ Hz}, 2\text{H}), 2.27-2.16 \text{ (m, 1H)}, 2.03-1.95 \text{ (m, 2H)}< / annotation>< / semantics>< / com:Math> 1H), 1.84 - 1.76 (m, 1H), 1.67 - 1.65 (m, 2H), 1.45 - 1.38 (m, 1H), 1.28 - 1.23 (m, 1H), 0.85 <com:Math><semantics>(d,J=6.6Hz,3H).<annotation encoding="application / x-tex">(d, J = 6.6 Hz, 3H).< / annotation>< / semantics>< / com:Math> <com:Sup>19< / com:Sup>F NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ -61.11 <com:Math><semantics>2<annotation encoding="application / x-tex">^{2}< / annotation>< / semantics>< / com:Math>D NMR (600 MHz, CD<com:Sub>3< / com:Sub>OD): δ 2.04 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 464.4 (M+H)<com:Sup>+< / com:Sup>. HPLC: 98.21 % (210 nm). Example 2s: Synthesis of <com:Math><semantics>(S)<annotation encoding="application / x-tex">(S)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(4−(trifluoromethyl)phenyl)−1H−imidazol−1−<annotation encoding="application / x-tex">(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-< / annotation>< / semantics>< / com:Math> yl)methyl)phenoxy)hexanoic acid (Compound 2s) [Image disponible dans le document PDF, Image available in the PDF document] Scheme A: [Image disponible dans le document PDF, Image available in the PDF document] Scheme B: [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of (S)-3,7-dimethyloct-6-enoic acid: [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL of round bottom flask, a solution of NaOH (12.92 g, 325.0 mmol) in water (100 mL) was treated with AgNO<com:Sub>3< / com:Sub> (25.2 g, 149.0 mmol) in water (100 mL) at 0°C. The reaction mixture was stirred in dark for 30 min and treated (3S)-3,7-dimethyloct-6-enal (10.0 g, 65.0 mmol) at 0°C. The reaction mixture was stirred at RT for 18 h. Upon completion of reaction (monitored by TLC), the reaction mixture was filtered through a Celite® pad and washed with hot water. The combined filtrate was acidified (pH 2) with concentrated HCl and extracted with diethyl ether. The organic extract was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was used in the next step without further purification. Yield: 10.0 g (90.9 %) <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.8 (brs, 1H), 5.09 (t, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 2.39-2.34 (dd, <com:Math><semantics>J=15.0<annotation encoding="application / x-tex">J = 15.0< / annotation>< / semantics>< / com:Math>, 6.0 Hz, 1H), 2.17-2.12 (dd, <com:Math><semantics>J=15.0<annotation encoding="application / x-tex">J = 15.0< / annotation>< / semantics>< / com:Math>, 6.0 Hz, 1H), 2.03-1.94 (m, 3H), 1.67 (s, 3H), 1.59 (s, 3H), 1.36-1.17 (m, 2H), 0.97 (d, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> Hz, 3H). Step-2: Synthesis of ethyl (S)-3,7-dimethyloct-6-enoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL round bottom flask, a suspension of <com:Math><semantics>(S)<annotation encoding="application / x-tex">(S)< / annotation>< / semantics>< / com:Math>-3,7-dimethyloct-6-enoic acid (10.0 g, 58.0 mmol) and K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (20.29 g, 140.0 mmol) in DMF (100 mL) was treated with ethyl bromide (8.25 g, 76.0 mmol) at RT. The reaction mixture was stirred at RT for 16 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water (1000 mL) and extracted with diethyl ether (100 mL x 2). The combined organic extract was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to get the title compound (11.3 g, 96.5 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 5.08 (t, <com:Math><semantics>J=6.9<annotation encoding="application / x-tex">J = 6.9< / annotation>< / semantics>< / com:Math> Hz, 1H), 4.12 (q, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.29 (dd, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> <com:Math><semantics>=14.7,6.0 Hz,1H<annotation encoding="application / x-tex">= 14.7, 6.0 \text{ Hz}, 1\text{H}< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.12−2.05 (m, 1H)<annotation encoding="application / x-tex">2.12-2.05 \text{ (m, 1H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1.99−1.94 (m, 3H)<annotation encoding="application / x-tex">1.99-1.94 \text{ (m, 3H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1.67 (s, 3H)<annotation encoding="application / x-tex">1.67 \text{ (s, 3H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1.59 (s, 3H)<annotation encoding="application / x-tex">1.59 \text{ (s, 3H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1.39−1.39 (s, 3H)<annotation encoding="application / x-tex">1.39-1.39 \text{ (s, 3H)}< / annotation>< / semantics>< / com:Math> 1.16 (m, 2H), 1.24 (t, <com:Math><semantics>J=6.9<annotation encoding="application / x-tex">J = 6.9< / annotation>< / semantics>< / com:Math> Hz, 3H), 0.93 (d, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> Hz, 3H). Step-3: Synthesis of Ethyl <com:Math><semantics>(S)<annotation encoding="application / x-tex">(S)< / annotation>< / semantics>< / com:Math>-5-<com:Math><semantics>(3,3<annotation encoding="application / x-tex">(3,3< / annotation>< / semantics>< / com:Math>-dimethyloxiran-2-yl)-3-methylpentanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 5 L round bottom flask, a solution of ethyl (S)-3,7-dimethyloct-6-enoate (25.0 g, 126.0 mmol) in diethyl ether (200 mL) was treated with a solution of mCPBA (65%, 32.5 g, 189.0 mmol) in diethyl ether (300 mL) dropwise at -30°C. The resulting mixture was warmed to 0 °C and stirred at same temperature for 6 h, before allowing it to stand overnight (~ 14 h) at 0-3 °C. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with diethyl ether (500 L) and washed with 1N NaOH (2 x 1 L), followed by water (1 L). The organic layer was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to afford the title compound (24.0 g, 88.8 %) <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 4.11 (q, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.2 Hz, 2H), 2.69 (t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 5.4 Hz, 1H), 2.30 (dd, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> <com:Math><semantics>=8.7,1.5 Hz,1H,2.17−2.09 (m, 1H),2.04−1.98 (m, 1H),1.55−1.42 (m, 4H),1.30 (s, 3H),<annotation encoding="application / x-tex">= 8.7, 1.5 \text{ Hz}, 1\text{H}, 2.17-2.09 \text{ (m, 1H)}, 2.04 - 1.98 \text{ (m, 1H)}, 1.55-1.42 \text{ (m, 4H)}, 1.30 \text{ (s, 3H)},< / annotation>< / semantics>< / com:Math> 1.27 (s, 3H), 1.25 (t, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 3H), 0.96 (d, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> Hz, 3H). Step-4: Synthesis of ethyl (S)-3-methyl-6-oxohexanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL round bottom flask, a solution of ethyl (S)-5-(3,3-dimethyloxiran-2-yl)-3- methylpentanoate (24.0 g, 11.00 mmol) in 1, 4 - dioxane (240 L) was treated with a solution of NaIO<com:Sub>4< / com:Sub> (71.6 g, 33.0 mol) in water (240 mL) at RT. The reaction mixture was stirred at same temperature for 16 h. Upon completion of reaction (monitored by TLC), the inorganic salts were filtered through Celite® pad and filtrate was extracted with EtOAc (3 x 500 mL). The combined organic extract was washed with water, brine and dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>. The solution was concentrated under reduced pressure to afford the title compound <com:Math><semantics>(20g)<annotation encoding="application / x-tex">(20 g)< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): δ 9.79 (s, 1H), 4.16-4.07 (m, 2H), 2.48-2.43 (m, 2H), 2.27 (dd, <com:Math><semantics>J=15,6.6 Hz,1H,2.17−2.10 (m, 1H),2.02−1.96 (m, 1H),1.72−1.66 (m, 1H),1.54−1.50 (m, 1H)<annotation encoding="application / x-tex">J = 15, 6.6 \text{ Hz}, 1\text{H}, 2.17-2.10 \text{ (m, 1H)}, 2.02-1.96 \text{ (m, 1H)}, 1.72-1.66 \text{ (m, 1H)}, 1.54-1.50 \text{ (m, 1H)}< / annotation>< / semantics>< / com:Math> 1H), 1.25 (t, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 3H), 0.95 (d, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> Hz, 3H). Step 5: Synthesis of ethyl (S)-6-hydroxy-3-methylhexanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 1 L round bottom flask, a solution of ethyl (S)-3-methyl-6-oxohexanoate (20.0 g, 116.0 mmol) in methanol (100 mL) was treated with NaBH<com:Sub>4< / com:Sub> (7.0 g, 186.0 mmol) at RT. The reaction mixture was stirred at RT for 4 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water (500 mL) and extracted with EtOAc The combined organic extract was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to get the title compound (20.0 g, 99.0 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 4.15-4.07 (m, 2H), 3.65 (t, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 6.3 Hz, 2H), 2.30 (dd, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 14.7, 6.6 Hz, 1H), 2.17-2.09 (m, 1H), 2.02-1.96 (m, 1H), 1.67-1.56 (m, 5H), 1.26 (t, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 3H), <com:Math><semantics>0.93<annotation encoding="application / x-tex">0.93< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> Hz, 3H). Step-6: Synthesis of ethyl (S)-3-methyl-6-((methylsulfonyl)oxy)hexanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 100 mL round bottom flask, a solution of ethyl (S)-6-hydroxy-3-methylhexanoate (2.5 g, 14.3 mmol) in DCM (25 mL) was treated Et<com:Sub>3< / com:Sub>N (4.35 g, 43.0 mmol) and MsCl (2.45 g, 21.5 mmol) at 0°C. The reaction mixture was stirred at RT for 3 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water (50 mL) and extracted with DCM (50 mL x 3). The combined organic extract was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to get desired product (2.5 g, 69.5 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): δ 4.23-4.09 (m, 4H), 3.00 (s, 3H), 2.32-2.11 (m, 2H), 2.02-1.96 (m, 1H), <com:Math><semantics>1.78−1.72<annotation encoding="application / x-tex">1.78-1.72< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>1.46−1.41<annotation encoding="application / x-tex">1.46-1.41< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>1.26<annotation encoding="application / x-tex">1.26< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 3H), <com:Math><semantics>0.96<annotation encoding="application / x-tex">0.96< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.6<annotation encoding="application / x-tex">J = 6.6< / annotation>< / semantics>< / com:Math> Hz, 3H). Step-7: Synthesis of N-(prop-2-yn-1-yl)-4-(trifluoromethyl)benzamide: [Image disponible dans le document PDF, Image available in the PDF document] In a 2 L round bottom flask, a stirred solution of 4-(trifluoromethyl)benzoic acid (100 g, 5.26 mol) and prop-2-yn-1-amine (34.73 g, 6.31 mol) in DMF (1000 mL) was treated sequentially with EDCI.HCl (200.8 g, 1.05 mol), HOBt (142 g, 1.052 mol) and Et<com:Sub>3< / com:Sub>N (53.12 g, 1.578 mol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 12 h under nitrogen atmosphere. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with ice cold water and solid precipitated out. The solid was filtered and dried under reduced pressure to afford the title compound (111 g, 93.2 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.90 (d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.71 (d, <com:Math><semantics>J=8.8<annotation encoding="application / x-tex">J = 8.8< / annotation>< / semantics>< / com:Math> Hz, 2H), 6.47 (brs, 1H), <com:Math><semantics>4.28−4.62<annotation encoding="application / x-tex">4.28-4.62< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>3.12<annotation encoding="application / x-tex">3.12< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=2.4<annotation encoding="application / x-tex">J = 2.4< / annotation>< / semantics>< / com:Math> Hz, 1H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 228.2 (M+H)<com:Sup>+< / com:Sup>. Step-8: Synthesis of 1-(2-methoxybenzyl)-5-methyl-2-(4-(trifluoromethyl)phenyl)-1H- imidazole: [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL re-sealable reaction tube, a solution of N-(prop-2-yn-1-yl)-4- (trifluoromethyl)benzamide (30 g, 132.15 mmol) and 2-methoxybenzyl amine (27.31 g, 198.23 mmol) in toluene (300 mL) was treated with Zn(OTf)<com:Sub>2< / com:Sub> (15.06 g, 39.6 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at 100 °C for 16 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc (30 mL). The organic extract was washed with saturated NaHCO<com:Sub>3< / com:Sub>, brine and dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>. The solution was concentrated under reduced pressure and residue obtained was purified by silica gel column chromatography (elution, 25% EtOAc in hexanes) to yield the title compound (30.4 g, 66.6 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>): δ 7.59-7.54 (m, 4H), 7.30-7.23 (m, 1H), 7.00 (s, 1H), 6.91-6.86 <com:Math><semantics>(m,2H),6.57(d,J=7.2Hz,1H),5.11(s,2H),3.84(s,3H),2.11(s,3H),<annotation encoding="application / x-tex">(m, 2H), 6.57 (d, J = 7.2 Hz, 1H), 5.11 (s, 2H), 3.84 (s, 3H), 2.11 (s, 3H),< / annotation>< / semantics>< / com:Math> LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 347.3 (M+H)<com:Sup>+< / com:Sup>. Step-9: Synthesis of 2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1- yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] In a 1000 mL round bottom flask, a solution of 1-(2-methoxybenzyl)-5-methyl-2-(4- (trifluoromethyl)phenyl)-1H-imidazole (60 g, 173.4 mmol) in dichloromethane (600 mL) was treated with BBr<com:Sub>3< / com:Sub> (60 mL) dropwise at -78°C. The reaction mixture was stirred at RT for 3h. Upon completion of reaction (monitored by TLC), the reaction mixture was basified with aqueous NaHCO<com:Sub>3< / com:Sub>. The solid obtained was filtered, washed with n-hexane (500 mL x 3) and dried under reduced pressure to afford the title compound (53.1 g, 92.3 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.99 (s, 1H), 7.88 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 2H), 7.77 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 2H), 7.33 (s, 1H), 7.14-7.10 (m, 1H), 6.83 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.74-6.70 (m, 1H), 6.55 (d, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 6.8 Hz, 1H), 5.21 (s, 2H), 2.16 (s, 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 333.3 (M+H)<com:Sup>+< / com:Sup>. Step-10: Synthesis of ethyl (S)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H- imidazol-1-yl)methyl)phenoxy)hexanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 100 mL round bottom flask, a stirred solution of 2-((5-methyl-2-(4- (trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenol (1.0 g, 3.0 mmol) in DMF (15 mL) was treated with K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (1.24 g, 9.0 mmol) and ethyl (S)-3-methyl-6- ((methylsulfonyl)oxy)hexanoate (1.13 g, 4.5 mmol) at RT under nitrogen atmosphere. The resulting reaction mixture was stirred at 80°C for 16 h. Upon completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT; solid was filtered and washed with ethyl acetate. The combined filtrate was concentrated under reduced pressure and residue obtained was diluted with cold water (50 mL), before extracting with ethyl acetate (50 mL). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (gradient elution, 15-30% EtOAc in hexanes) to afford the title compound (0.8 g, 57.1 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 7.59 (d, <com:Math><semantics>J=1.5<annotation encoding="application / x-tex">J = 1.5< / annotation>< / semantics>< / com:Math> Hz, 4H), 7.33 (s, 1H), 7.02 (d, <com:Math><semantics>J=0.9<annotation encoding="application / x-tex">J = 0.9< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.91 (s, 1H), 6.89 (s, 1H), 6.60 (d, <com:Math><semantics>J=6.8<annotation encoding="application / x-tex">J = 6.8< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.12 (s, 2H), 4.15-4.01 (m, 4H), 2.19-2.14 (m, 1H), 2.10-1.95 (m, 1H), 2.04 (s, 3H), 1.85-1.76 (m, 2H), 1.55-1.45 (m, 1H), <com:Math><semantics>1.40−1.30<annotation encoding="application / x-tex">1.40-1.30< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>1.28−1.18<annotation encoding="application / x-tex">1.28-1.18< / annotation>< / semantics>< / com:Math> (m, 4H), <com:Math><semantics>0.83<annotation encoding="application / x-tex">0.83< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 3H). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 488.5 (M+H)<com:Sup>+< / com:Sup>. Step-11: Synthesis of (S)-3-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(4−(trifluoromethyl)phenyl)−1H−<annotation encoding="application / x-tex">(2-((5-methyl-2-(4-(trifluoromethyl)phenyl)-1H-< / annotation>< / semantics>< / com:Math> imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound 2s): [Image disponible dans le document PDF, Image available in the PDF document] In a 50 mL round bottom flask, a stirred solution of ethyl (S)-3-methyl-6-(2-((5- methyl-2-(4-(trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate (0.4 g, 0.81 mmol) in THF (40 mL) and water (10 mL), was treated with lithium hydroxide monohydrate (60 mg, 2.4 mmol) at RT. The reaction mixture was stirred at RT for 12 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water and washed with diethyl ether. The aqueous layer was neutralized with 1N HCl and solid obtained was filtered. The solid compound was washed with 50% diethyl ether-pentane to afford the title compound as a white solid (180 mg, 48.6 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 12.00 (br s, 1H), 7.74 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.65 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.26 (t, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.04 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.95 (s, 1H), 6.87 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.40 (d, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.18 (s, 2H), 3.99 (t, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.19-2.14 (m, 1H), 2.10 (s, 3H), 1.99-1.93 (m, 1H), 1.84-1.76 (m, 1H), 1.67-1.65 (m, 2H), 1.45-1.38 (m, 1H), 1.28- 1.23 (m, 1H), 0.84 (d, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 3H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): δ -61.61 LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 460.7 (M+H)<com:Sup>+< / com:Sup>. HPLC: 98.65 % (210 nm). Example 2t Synthesis of <com:Math><semantics>(S)<annotation encoding="application / x-tex">(S)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2−((5−methyl−2−(6−(trifluoromethyl)pyridin−3−yl)−1<math>H<annotation encoding="application / x-tex">(2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1H< / annotation>< / semantics>< / com:Math>- imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound 2t) [Image disponible dans le document PDF, Image available in the PDF document] Scheme: [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of N-(prop-2-yn-1-yl)-6-(trifluoromethyl)nicotinamide: [Image disponible dans le document PDF, Image available in the PDF document] In a 3 L round bottom flask, a stirred solution of 6-(trifluoromethyl)nicotinic acid (150 g, 785.34 mmol) and prop-2-yn-1-amine (51.83 g, 942.40 mmol) in DMF (1.5 L) was treated with HATU (447 g, 1177.50 mmol) and Et<com:Sub>3< / com:Sub>N (120 g, 1177.5 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 3 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with ice water and precipitate obtained was filtered, washed with water and 50 % ethyl acetate in hexane. The solid compound was dried under reduced pressure to get the title compound (137 g, 76.5 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.39 (t, <com:Math><semantics>J=5.6<annotation encoding="application / x-tex">J = 5.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 9.14 (s, 1H), 8.46 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>8.05<annotation encoding="application / x-tex">8.05< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>4.12−4.10<annotation encoding="application / x-tex">4.12-4.10< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>3.20<annotation encoding="application / x-tex">3.20< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=0.4<annotation encoding="application / x-tex">J = 0.4< / annotation>< / semantics>< / com:Math> Hz, 1H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> –66.70. LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 229.2 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of 5-(1-(2-methoxybenzyl)-5-methyl-1H-imidazol-2-yl)-2- (trifluoromethyl)pyridine: [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL re-sealable reaction tube, a solution of N-(prop-2-yn-1-yl)-6- (trifluoromethyl)nicotinamide (50 g, 219.29 mmol) and 2-methoxybenzyl amine (39.0 g, 285.08 mmol) in toluene (300 mL) was treated with Zn(OTf)<com:Sub>2< / com:Sub> (23.8 g, 65.78 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at 110°C for 16 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water and extracted with EtOAc (30 mL). The organic extract was washed with saturated NaHCO<com:Sub>3< / com:Sub>, brine and dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>. The solution was concentrated under reduced pressure and residue obtained was purified by washed with diethyl ether to yield the title compound (46 g, 60.65 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.83 (s, 1H), 8.08 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 1H), 7.94 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.6 Hz, 1H), 7.29 (t, <com:Math><semantics>J=9.2<annotation encoding="application / x-tex">J = 9.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.05 (d, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.01 (s, 1H), 6.88 (t, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>6.42<annotation encoding="application / x-tex">6.42< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>5.23<annotation encoding="application / x-tex">5.23< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>3.78<annotation encoding="application / x-tex">3.78< / annotation>< / semantics>< / com:Math> (s, 3H), <com:Math><semantics>2.13<annotation encoding="application / x-tex">2.13< / annotation>< / semantics>< / com:Math> (s, 3H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> –66.43. Step-3: Synthesis of 2-((5-methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1H-imidazol-1- yl)methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] In a 1000 mL round bottom flask, a solution of 5-(1-(2-methoxybenzyl)-5-methyl-1H- imidazol-2-yl)-2-(trifluoromethyl)pyridine (80 g, 230.54 mmol) in dichloromethane (800 mL) was treated with BBr<com:Sub>3< / com:Sub> (80 mL) dropwise at -78°C. The reaction mixture was stirred at RT for 3h. Upon completion of reaction (monitored by TLC), the reaction mixture was basified with aqueous NaHCO<com:Sub>3< / com:Sub>. The solid obtained was filtered, washed with n-hexane (500 mL x 3) and dried under reduced pressure to afford the title compound (65.0 g, 84.66 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.94 (s, 1H), 8.83 (s, 1H), 8.12 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.93 <com:Math><semantics>(d,J=8.4 Hz,1H),7.11 (t, J=8.0 Hz,1H),7.01 (s, 1H),6.86 (d, J=8.0 Hz1H),6.72 (d, J=8.0 Hz)<annotation encoding="application / x-tex">(d, J = 8.4 \text{ Hz}, 1\text{H}), 7.11 \text{ (t, } J = 8.0 \text{ Hz}, 1\text{H}), 7.01 \text{ (s, } 1\text{H}), 6.86 \text{ (d, } J = 8.0 \text{ Hz} 1\text{H}), 6.72 \text{ (d, } J = 8.0 \text{ Hz})< / annotation>< / semantics>< / com:Math> <com:Math><semantics>=8.8 Hz,1H,6.36 (d, J=7.6 Hz,1H),5.20 (s, 2H),2.14 (s, 3H).<annotation encoding="application / x-tex">= 8.8 \text{ Hz}, 1\text{H}, 6.36 \text{ (d, } J = 7.6 \text{ Hz}, 1\text{H}), 5.20 \text{ (s, } 2\text{H}), 2.14 \text{ (s, } 3\text{H}).< / annotation>< / semantics>< / com:Math> <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> –66.44. LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 334.3 (M+H)<com:Sup>+< / com:Sup>. HPLC: 99.23 % (210 nm). Step-4: Synthesis of ethyl <com:Math><semantics>(S)<annotation encoding="application / x-tex">(S)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2<annotation encoding="application / x-tex">(2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>((5<annotation encoding="application / x-tex">((5< / annotation>< / semantics>< / com:Math>-methyl-2-<com:Math><semantics>(6<annotation encoding="application / x-tex">(6< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(trifluoromethyl)pyridin−3−yl)−<annotation encoding="application / x-tex">(trifluoromethyl)pyridin-3-yl)-< / annotation>< / semantics>< / com:Math> 1H-imidazol-1-yl)methyl)phenoxy)hexanoate: [Image disponible dans le document PDF, Image available in the PDF document] In a 100 mL round bottom flask, a stirred solution of 2-((5-methyl-2-(6- (trifluoromethyl)pyridin-3-yl)-1H-imidazol-1-yl)methyl)phenol (1.0 g, 3.0 mmol) in DMF (15 mL) was treated with <com:Math><semantics>K2CO3<annotation encoding="application / x-tex">K_2CO_3< / annotation>< / semantics>< / com:Math> (1.13 g, 4.5 mmol) and ethyl (S)-3-methyl-6- ((methylsulfonyl)oxy)hexanoate (1.24 g, 9.0 mmol) at RT under nitrogen atmosphere. The resulting reaction mixture was stirred at 80°C for 16 h. Upon completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT; solid was filtered and washed with ethyl acetate. The combined filtrate was concentrated under reduced pressure and residue obtained was diluted with cold water (50 mL), before extracting with ethyl acetate (50 mL). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (gradient elution, 15-30% EtOAc in hexanes) to afford the title compound (0.7 g, crude). LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 490.2 (M+H)<com:Sup>+< / com:Sup>. Step-5: Synthesis of <com:Math><semantics>(S)<annotation encoding="application / x-tex">(S)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2<annotation encoding="application / x-tex">(2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>((5<annotation encoding="application / x-tex">((5< / annotation>< / semantics>< / com:Math>-methyl-2-<com:Math><semantics>(6<annotation encoding="application / x-tex">(6< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(trifluoromethyl)pyridin−3−yl)−1H−<annotation encoding="application / x-tex">(trifluoromethyl)pyridin-3-yl)-1H-< / annotation>< / semantics>< / com:Math> imidazol-1-yl)methyl)phenoxy)hexanoic acid (Compound 2t): [Image disponible dans le document PDF, Image available in the PDF document] In a 50 mL round bottom flask, a stirred solution of ethyl (S)-3-methyl-6-(2-((5- methyl-2-(6-(trifluoromethyl)pyridin-3-yl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoate (0.4) g, 0.81 mmol) in THF (40 mL) and water (10 mL), was treated with lithium hydroxide monohydrate (60 mg, 2.4 mmol) at RT. The reaction mixture was stirred at RT for 12 h. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with water and washed with diethyl ether. The aqueous layer was neutralized with 1N HCl and solid obtained was filtered. The solid compound was washed with 50% diethyl ether-pentane to afford the title compound as a white solid (200 mg, 53.0 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 12.01 (brs, 1H), 8.81 (s, 1H), 8.06 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.91 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.26 (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>7.05−7.02<annotation encoding="application / x-tex">7.05 - 7.02< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>6.86<annotation encoding="application / x-tex">6.86< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>6.43<annotation encoding="application / x-tex">6.43< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.8<annotation encoding="application / x-tex">J = 6.8< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>5.22<annotation encoding="application / x-tex">5.22< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>3.99<annotation encoding="application / x-tex">3.99< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>2.22−2.14<annotation encoding="application / x-tex">2.22-2.14< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>2.14<annotation encoding="application / x-tex">2.14< / annotation>< / semantics>< / com:Math> (s, 3H), 2.01-1.86 (m, 1H), 1.86-1.81 (m, 1H), 1.72-1.66 (m, 2H), 1.43-1.37 (m, 1H), 1.28- 1.22 (m, 1H), 0.86 (d, <com:Math><semantics>J=6.8<annotation encoding="application / x-tex">J = 6.8< / annotation>< / semantics>< / com:Math> Hz, 3H). <com:Sup>19< / com:Sup>F NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> –66.77. LCMS (ESI+, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 463.1 (M+H)<com:Sup>+< / com:Sup>. HPLC: 97.23 % (210 nm). Example 2u Synthesis of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-3-methyl-6-<com:Math><semantics>(2−((5−(methyl−d3)−2−(6−(trifluoromethyl)pyridin−3−yl)−1<math>H<annotation encoding="application / x-tex">(2-((5-(methyl-d_3)-2-(6-(trifluoromethyl)pyridin-3-yl)-1H< / annotation>< / semantics>< / com:Math>- imidazol-1-yl) methyl)phenoxy)hexanoic acid (Compound 2u) [Image disponible dans le document PDF, Image available in the PDF document] Scheme: [Image disponible dans le document PDF, Image available in the PDF document] Step-1: Synthesis of 5-(4,5-dihydro-1H-imidazol-2-yl)-2-(trifluoromethyl)pyridine: [Image disponible dans le document PDF, Image available in the PDF document] In a 500 mL round bottom flask, a stirred solution 6-(trifluoromethyl)nicotinaldehyde (15.0 g, 85.71 mmol) and ethane-1,2-diamine (5.14 g, 85.71 mmol) in <com:Sup>t< / com:Sup>BuOH (150 mL) was stirred for 45 min at RT under nitrogen atmosphere. Iodine (25.8 g, 102.85 mmol) and K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (35.48 g, 257.13 mmol) was added and reaction mixture was heated at 85°C for 12 h under nitrogen atmosphere. Upon completion of reaction (monitored by TLC), the reaction mixture was quenched with saturated Na<com:Sub>2< / com:Sub>S<com:Sub>2< / com:Sub>O<com:Sub>3< / com:Sub> solution and extracted with ethyl acetate (100 mL X 3). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure to give desired product as a yellow solid, which was taken to next step without any purification (13.1 g, 71.1 %). <com:Sup>1< / com:Sup>H NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 9.05 (s, 1H), 8.28 (d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.74 (d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>4.10−3.50<annotation encoding="application / x-tex">4.10 - 3.50< / annotation>< / semantics>< / com:Math> (bs, 4H). (note: NH proton not observed in NMR) <com:Sup>19< / com:Sup>F NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>) : δ - 68.07 LCMS (ESI<com:Sup>+< / com:Sup>, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 216.2 (M+H)<com:Sup>+< / com:Sup>. Step-2: Synthesis of 5-(1H-imidazol-2-yl)-2-(trifluoromethyl)pyridine: [Image disponible dans le document PDF, Image available in the PDF document] In a 250 mL round bottom flask, a stirred solution 5-(4,5-dihydro-1H-imidazol-2-yl)- 2-(trifluoromethyl)pyridine (6.0 g, 27.9 mmol) in DMSO (50 mL) was treated with K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (4.62 g, 33.4 mmol) and (diacetoxyiodo)benzene (10.78 g, 33.4 mmol) at RT. The reaction mixture was stirred at RT for 18 h under nitrogen atmosphere. Upon completion of reaction (monitored by TLC), the reaction mixture was diluted with ice cold water and solid obtained was filtered. The solid was washed with water and n-hexane and dried under reduced pressure to get desired product as a yellow solid (4. 0 g, 67.7 %). <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 13.0 (s, 1H), 9.30 (s, 1H), 8.51 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 1H), 7.99 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> <com:Math><semantics>=8.1 Hz,1H,7.43 (s, 1H),7.16 (s, 1H).<annotation encoding="application / x-tex">= 8.1 \text{ Hz}, 1\text{H}, 7.43 \text{ (s, 1H)}, 7.16 \text{ (s, 1H)}.< / annotation>< / semantics>< / com:Math> LCMS (ESI<com:Sup>+< / com:Sup>, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 214.2 (M+H)<com:Sup>+< / com:Sup>. Step-3: Synthesis of 5-(1-(2-methoxybenzyl)-1H-imidazol-2-yl)-2-(trifluoromethyl) pyridine: [Image disponible dans le document PDF, Image available in the PDF document] In a 100 mL round bottom flask, a stirred solution 5-(1H-imidazol-2-yl)-2- (trifluoromethyl)pyridine (3 g, 14.0 mmol) in DMF (30 mL) was treated with NaH (60%) dispersion in oil, 1.12 g, 28.1 mmol) at 0°C and stirred for 30 min at same temperature under nitrogen atmosphere. 2-Methoxybenzyl bromide (3.68 g, 18.3 mmol) was added to the above mixture under nitrogen atmosphere. The reaction mixture was stirred for 12 h at RT under nitrogen atmosphere. Upon completion of reaction (monitored by TLC), the reaction mixture was quenched with saturated NH<com:Sub>4< / com:Sub>Cl solution and extracted with ethyl acetate (200 mL X 3). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was washed with n-hexane to afford the title compound as a white solid (3.5 g, 76.1 %) <com:Sup>1< / com:Sup>H NMR (300 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.96 (s, 1H), 8.25 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 1H), 7.98 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.1 Hz 1H), 7.39 (s, 1H), 7.28 (t, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.14 (s, 1H), 6.98 (d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.88 (t, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.88 (t, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.88 (t, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.88 (t, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.88 (t, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> H 7.2 Hz, 1H), 6.81 (d, <com:Math><semantics>J=7.5<annotation encoding="application / x-tex">J = 7.5< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.32 (s, 2H), 3.67 (s, 3H) <com:Sup>19< / com:Sup>F NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>) : δ - 66.43 LCMS (ESI<com:Sup>+< / com:Sup>, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 334.2 (M+H)<com:Sup>+< / com:Sup>. Step-4: Synthesis of 5-(5-bromo-1-(2-methoxybenzyl)-1H-imidazol-2-yl)-2- (trifluoromethyl)pyridine: [Image disponible dans le document PDF, Image available in the PDF document] In a 50 mL round bottom flask, a stirred solution of 5-(1-(2-methoxybenzyl)-1H- imidazol-2-yl)-2-(trifluoromethyl)pyridine (3 g, 9.00 mmol) in DMF (30 mL) was treated with a NBS (1.6 g, 9.00 mmol) at RT under nitrogen atmosphere. The reaction mixture was stirred at RT for 3 h. Upon completion of reaction (monitored by TLC), the reaction mixture was quenched with ice water and extracted with ethyl acetate (30 mL X 2). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (elution 5 % EtOAc in hexanes) to afford the title compound as a white solid (0.9 g, 24.3 %) and mixture (2 g) of 5-(4-bromo-1-(2-methoxybenzyl)-1H-imidazol-2-yl)-2-(trifluoromethyl) pyridine and 5-(4,5-dibromo-1-(2-methoxybenzyl)-1H-imidazol-2-yl)-2-(trifluoromethyl) pyridine. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>): <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> 8.87 (s, 1H), 8.15 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 1H), 7.98 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz 1H), 7.39 (s, 1H), 7.28 (t, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.02 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.87 (t, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>6.47<annotation encoding="application / x-tex">6.47< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.0<annotation encoding="application / x-tex">J = 6.0< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>5.30<annotation encoding="application / x-tex">5.30< / annotation>< / semantics>< / com:Math> (s, 2H), <com:Math><semantics>3.74<annotation encoding="application / x-tex">3.74< / annotation>< / semantics>< / com:Math> (s, 3H). <com:Sup>19< / com:Sup>F NMR (300 MHz, CDCl<com:Sub>3< / com:Sub>) : δ - 66.55 LCMS (ESI<com:Sup>+< / com:Sup>, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 412.2, 414.2 (M+H)<com:Sup>+< / com:Sup>. Step-5: Synthesis of 5-<com:Math><semantics>(1−(2−methoxybenzyl)−5−(methyl−d3)−1H−imidazol−2−yl)−2−<annotation encoding="application / x-tex">(1-(2-methoxybenzyl)-5-(methyl-d_3)-1H-imidazol-2-yl)-2-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)pyridine: [Image disponible dans le document PDF, Image available in the PDF document] In a 100 mL re-sealable reaction tube, a solution of ZnCl<com:Sub>2< / com:Sub> (0.5 M in THF, 20.0 mL, 40.0 mmol) was treated with CD<com:Sub>3< / com:Sub>MgI (1 M in diethyl ether, 12 mL, 12.0 mmol) dropwise at RT under nitrogen atmosphere. The mixture was stirred at RT for 1 h and treated with 5-(5- bromo-1-(2-methoxybenzyl)-1H-imidazol-2-yl)-2-(trifluoromethyl)pyridine (200 mg, 0.486 mmol) and Ni(PPh<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>Cl<com:Sub>2< / com:Sub> (26 mg, 0.0486 mmol) at same temperature under nitrogen atmosphere. The resulting reaction mixture was stirred at RT for 48h under nitrogen atmosphere. Upon completion of reaction (monitored by TLC), the reaction mixture was quenched with ice cold water and extracted with EtOAc (10 mL x 2). The combined organic extract was washed with brine, dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (elution 50) % EtOAc in hexanes) to afford the title compound (50 mg) contaminated with debrominated side product, 5-(1-(2-methoxybenzyl)-1H-imidazol-2-yl)-2-(trifluoromethyl) pyridine (as indicated by NMR (~ 1:1)) LCMS (ESI<com:Sup>+< / com:Sup>, <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>): 351.1 (M+H)<com:Sup>+< / com:Sup>. Step-6: Synthesis of 2-<com:Math><semantics>((5−(methyl−d3)−2−(6−(trifluoromethyl)pyridin−3−yl)−1H−imidazol−1−yl)<annotation encoding="application / x-tex">((5-(methyl-d_3)-2-(6-(trifluoromethyl) pyridin-3-yl)-1H-imidazol-1-yl)< / annotation>< / semantics>< / com:Math> methyl)phenol: [Image disponible dans le document PDF, Image available in the PDF document] In a 100 mL round bottom flask, a solution of 5-(1-(2-methoxybenzyl)-5-(methyl-d<com:Sub>3< / com:Sub>)- 1H-imidazol-2-yl)-2-(trifluoromethyl)pyridine (200 mg, 0.571 mmol) in DCM (5 mL) was treated with neat BBr<com:Sub>3< / com:Sub> (0.2 mL) dropwise at -78°C un...
Claims
1. A compound of Formula (I): [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is hydrogen, halogen, -C 1 -C 4 -alkyl, -C 1 -C 4 -haloalkyl, -CN, -C 1 -C 4 -alkoxy, -C 1 -C 4 -haloalkoxy, or -C 3 -C 6 -cycloalkyl; Q 1 Q^1 is CH or N; R 2 is halogen, -C 1 -C 4 -alkyl, -C 1 -C 4 -haloalkyl, -C 1 -C 4 -haloalkoxy, -S(C 1 -C 4 -alkyl), or furanyl, wherein the furanyl can be optionally substituted with C 1 -C 4 -alkyl; x is an integer having a value of 1 or 2; each R 20 is independently hydrogen, halogen, -C 1 -C 4 -alkyl, -CN, or -C 1 -C 4 -alkoxy; and R 3 R^3 is -CH 3 or -CD 3 .
2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R 3 is - C H 3 CH_3 .
3. The compound of claim 2, having the structure of Formula (Ia): [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt or stereoisomer thereof.
4. The compound of claim 3, having the structure of Formula (Iaa): [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof.
5. The compound of claim 2, having the structure of Formula (Ib): [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt or stereoisomer thereof.
6. The compound of claim 5, having the structure of Formula (Ibb): [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof.
7. The compound of any one of claims 1–6, or a pharmaceutically acceptable salt thereof, wherein R 2 is halogen, -CH 3 , -C 1 -haloalkyl, -C 1 -haloalkoxy, -SCH 3 , or furanyl, wherein the furanyl can be optionally substituted with CH 3 .
8. The compound of any one of claims 1 − 7 1-7 , or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen or halogen.
9. The compound of any one of claims 1–8, or a pharmaceutically acceptable salt thereof, wherein each R 20 R^{20} is independently hydrogen or halogen.
10. The compound of any one of claims 7–9, or a pharmaceutically acceptable salt thereof, wherein R 2 is chloro, unsubstituted furanyl, -CH 3 , -CF 3 , -OCF 3 , -OCHF 2 , or -SCH 3 .
11. The compound of any one of claims 1 − 10 1-10 , or a pharmaceutically acceptable salt thereof, wherein R 2 R^2 is -CF 3 or -OCF 3 .
12. The compound of any one of claims 1 − 11 1-11 , or a pharmaceutically acceptable salt thereof, wherein R 2 R^2 is -CF 3 .
13. The compound of any one of claims 8-12, or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen or fluoro.
14. The compound of any one of claims 9-13, or a pharmaceutically acceptable salt thereof, wherein R 20 R^{20} is hydrogen or fluoro.
15. The compound of claim 1, wherein the compound is (R)-6-(2-((2-(4-(furan-2-yl)phenyl)- 5-methyl-1H-imidazol-1-yl)methyl)-phenoxy)-3-methylhexanoic acid, or a pharmaceutically acceptable salt thereof.
16. The compound of claim 1, wherein the compound is (R)-3-methyl-6-(2-((5-methyl-2-(4- (trifluoromethyl)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid, or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1, wherein the compound is (R)-3-methyl-6-(2-((5-methyl-2-(4- (trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid, or a pharmaceutically acceptable salt thereof.
18. The compound of claim 1, wherein the compound is (R)-3-methyl-6-(2-((5-methyl-2-(6- (trifluoromethyl)pyridin-3-yl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and the compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof.
20. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 19, for use in the treatment of a PPAR δ \delta related disease or condition, wherein the PPAR δ \delta related disease is a muscle structure disorder, a neuronal activation disorder, a muscle fatigue disorder, a muscle mass disorder, a mitochondrial disease, a beta oxidation disease, a metabolic disease, a cancer, a vascular disease, an ocular vascular disease, a muscular eye disease, or a renal disease.
21. A compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19 for use in the treatment of acute kidney injury.
22. A compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19 for use in the treatment of a PPARδ related disease or condition, wherein the PPARδ related disease or condition is Alpers Disease, chronic progressive external ophthalmoplegia (CPEO), Kearns-Sayra Syndrome (KSS), Leber Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red fiber disease (MERRF), neurogenic muscle weakness-ataxia-retinitis pigmentosa (NARP), or Pearson Syndrome.
23. A compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19 for use in increasing endurance.
24. A compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19 for use in the treatment of adrenoleukodystrophy.
25. A compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19 for use in the treatment of Duchenne Muscular Dystrophy.
26. A compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19 for use in the treatment of chronic fatigue syndrome.
27. A compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19 for use in the treatment of a renal disease.
28. Use of the compound of any one of claims 1 − 18 1-18 , or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 19 in the manufacture of a medicament for treating a PPAR δ \delta related disease or condition, wherein the PPAR δ \delta related disease is a muscle structure disorder, a neuronal activation disorder, a muscle fatigue disorder, a muscle mass disorder, a mitochondrial disease, a beta oxidation disease, a metabolic disease, a cancer, a vascular disease, an ocular vascular disease, a muscular eye disease, or a renal disease.
29. Use of the compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 19 in the manufacture of a medicament for treating acute kidney injury.
30. Use of the compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 19 in the manufacture of a medicament for treating a PPAR δ \delta related disease or condition, wherein the PPAR δ \delta related disease or condition is Alpers Disease, chronic progressive external ophthalmoplegia (CPEO), Kearns-Sayra Syndrome (KSS), Leber Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red fiber disease (MERRF), neurogenic muscle weakness-ataxia-retinitis pigmentosa (NARP), or Pearson Syndrome.
31. Use of the compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 19 in the manufacture of a medicament for increasing endurance.
32. Use of the compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 19 in the manufacture of a medicament for treating adrenoleukodystrophy.
33. Use of the compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 19 in the manufacture of a medicament for treating Duchenne Muscular Dystrophy.
34. Use of the compound of any one of claims 1–18, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 19 in the manufacture of a medicament for treating chronic fatigue syndrome.
Citation Information
Patent Citations
PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
US62238629P0
PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
US62243263P0
Methods of treating acute kidney injury
US62404390P0
